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 I 
Abstract 
Halichlorine 1 is a marine spirocyclic alkaloid, which has shown to exhibit anti-
inflammatory properties.1  Due to the complexity of this structure, and the low 
abundance in nature, the development of total and partial syntheses of this 
compound have become of interest to the organic chemist. 
This project aimed to evaluate the therapeutic potential of this class of 
compounds by producing a library of simplified halichlorine derivatives by 
addition of Grignard reagents onto a key spironitrone that maps onto the core 
structure of halichlorine and thence to monitor potential bioactivity by 
conducting a series of biological assays to determine what effects these 
compounds have on human U937 cells. 
Addition of a wide range of Grignard reagents to spironitrone 128 was 
successful and generally proceed with high diastereoselectivity.  In addition, 
reductive cleavage of the resulting N-hydroxyspirocycles with Zn/AcOH 
provided a host of N-acetyl-C7-substiuted spirocyclic derivatives 167-172. 
Reduction with indium provided free amines 173-181.  
As additions to spironitrone 128 proceeded with undesired stereoselectivity 
attempts were made to access O-protected spironitrone 204 by oxidation of 
spiroamines such as 199. This strategy was unsuccessful. In order to explore 
alternative spirocyclic derivatives, synthetic studies were also directed in 
attempts to access un-substituted derivatives by ring closing metathesis (RCM) 
of diene precursors 222-224. While RCM substrates were accessed cyclisation 
of these did not proceed. 
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It was discovered that heating 6,5-spiroisoxazolidine 102 under pressure in a 
microwave reactor provided access to the corresponding 6,6-isomer 164 which 
maps onto the core structure of the amphibian toxin histrionicotoxin (HTX). 
Oxidation to 6,6-spironitrone 192, as followed by conversion to cycloadducts 
193-195, which represent new analogues of the HTX family of alkaloids. 
Grignard additions to this nitrone, did not proceed in general. 
Biological screenings using undifferentiated and LPS activated U937 cells helped 
to identify a number of biologically active derivatives, when tested in the NO 
and growth and viability assays.  The NO assay using LPS activated cells, 
identified that the adducts containing larger alkyl or aryl chains, particularly the 
pentyl, hexyl and benzyl adducts, expressed significant differences in NO 
inhibition at both 10-4 M and 10-5 M concentrations tested, compared to the 
untreated cells.  
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Chapter 1. Halichlorine, a natural product 
1.1 Introduction 
1.1.1 The history of natural products 
Nature is an ancient pharmacy.  For thousands of years, natural products have 
been the source of therapeutic medicines all over the world.  Plants have 
formed the basis of sophisticated traditional medicines, but natural remedies 
have also been sourced from microorganisms, marine organisms and animals.2 
In recent years, natural products have been the most successful source of 
potential drug leads.3  Bioactive natural products act as the inspiration for 
structural scaffolds to the medicinal chemist,4 because they are generally small 
molecules with drug-like properties.5  Thousands of extracts from plant sources 
have undergone extensive screenings, although it is estimated that thousands 
remain unexplored.5  As well as being the inspiration for drug development, 
plants have also been a rich source of directly isolated medicinal drugs, for 
instance, morphine; cocaine; codeine and quinine.6  
Microorganisms have yielded some of the most important products of the 
pharmaceutical industry,7 which started with the development of penicillin in 
the late 1930’s- early 1940’s.8  This expanded drug discovery from 
microorganisms, which has led to important modern day drugs including 
antibiotics, immunosuppressant’s and lipid-lowering statins.5  Interestingly, 
these drugs have all been produced from a small range of the world’s microbial 
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diversity, and it is thought that there are potentially millions of bacterial species 
yet to be discovered.5  
Marine natural products do not have an extensive history unlike the other 
sources, resulting from a previous lack of technology (mainly scuba diving).  This 
has rapidly improved in recent years, with more than 20,000 compounds having 
been discovered since the 1960’s.9  The earliest published work on marine 
organisms dates back to 1951 by the group of Werner Bergmann,10  which 
documents the discovery of nucleosides obtained from marine sponges, leading 
to the development of a successful anticancer drug.11  Systematic investigations 
into marine organisms only began properly during the mid 1970’s, during which 
time thousands of compounds were isolated.7  Marine organisms produce a 
unique and wide array of biologically diverse, fascinating molecular structures.12  
As many of the marine life are soft bodied,  they require the deadly yet 
intriguing ability to either synthesise toxic compounds or obtain them from 
microorganisms as a defensive mechanism, or a way to paralyse their prey.13 
The discovery of bioactive compounds is on-going from all natural resources.  
Halichlorine is one example of such an isolated compound, which was involved 
in a mass biological screening and showed potential biological properties.1 
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1.1.2 Halichlorine and Pinnaic acid 
Halichlorine 1 is a marine alkaloid isolated from marine sponge Halichondria 
Okadai, which was discovered whilst on a search for biologically active 
compounds.14  Sponges exhibit a high frequency of bioactive compounds for 
their chemical defences, it is also therefore reasonable to see that the highest 
concentrations of toxic or antioxidant properties are found in areas such as 
coral reefs, where there is feeding pressure from fish, and a constant 
competition for space.15  
The complex structure of halichlorine shares a 6-azaspiro[4.5]decane core with 
similar marine compounds, pinnaic acid 2 and tauropinnaic acid 3 (Fig. 1).1 
 
Figure 1. Halichlorine 1, Pinnaic acid 2 and Tauropinnaic acid 3, with the 6-azaspiro[4.5]decane 
core. 
 
Pinnaic acid and tauropinnaic acid have activity against expressed cytosolic 
phospholipase A2 (cPLA2) activity.14  The hydrolytic process catalysed by the 
cPLA2 enzyme forms products which are precursors to a wide array of pro-
inflammatory mediators,  which act as either intracellular messengers within 
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the cell, or interact with specific receptors on the cell surface of the parent cell 
or neighbouring cells.16  The therapeutic potential in controlling this enzyme 
make cPLA2 a drug target, thus, making pinnaic acid and tauropinnaic acid 
biologically interesting molecules. 
Halichlorine has been shown to inhibit lipopolysaccharide-induced nuclear 
factor-kappa beta (NF-κB). NF-κB results in the suppression of vascular cell 
adhesion molecule-1 (VCAM-1); intracellular adhesion molecule-1 (ICAM-1); E-
selectin gene expression and endothelial cells adhesion molecules (ECAM).17  It 
has been reported, however, that although halichlorine has shown inhibitory 
properties towards VCAM-1, the same can not be said for ICAM-1.  According 
to a review of bioactive alkaloids from the sea by the Uemura group,18 
halichlorine does not affect ICAM-1, the reason for this remains unknown, but 
it may lead to ideas on how the biological mechanism may work.  Drugs which 
block the expression of VCAM-1 may be useful in treating atherosclerosis, 
coronary heart disease, angina and non-cardiovascular inflammatory 
diseases.14   
Beyond this knowledge, the specific biological capabilities and biological 
mechanisms of halichlorine remain to be investigated in detail. 
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1.2 Biological Processes 
1.2.1 An introduction into Inflammation 
Inflammation is an essential response provided as a protective strategy against 
microbial infection, tissue injury and other noxious conditions.  What was once 
seen as a fairly straight-forward immune response, has now emerged to operate 
in a sophisticated manner.19  The ultimate goal of inflammation is to remove the 
cause as well as any injured cells or tissue from the organism.  The process 
simultaneously destroys, dilutes and defends against the unwanted agent, as 
well as healing the injured tissue with either native parenchymal cells (local 
cellular tissue) or with fibroblastic cells (scar tissue).20    Inflammation is 
considered an ‘adaptive response’, as it is closely connected to homeostasis, 
the system responsible for maintaining the stability of the body.19 
The inflammatory process is initiated by chemical mediators, or signals, 
expressed upon injury or injection. Figure 2 shows the release of chemical 
mediators from mass cells, causing the nearby blood vessels to dilate, becoming 
more permeable.  The chemical signals released from the macrophages 
increases the blood flow to the local area, visible by a reddening of the injured 
area.  The increased blood flow brings in phagocytes, which engulf the 
pathogens, dead cells and any cellular debris, which is recognised as pus from 
the wound, a fluid containing white blood cells with the engulfed debris and 
pathogens.  Finally, the platelets will move out of the capillary to seal the 
wounded area.21  
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Figure 2. The inflammatory Process21  Shows the stages of acute inflammation, lasting between 
a few hours to a few days. 
 
Once the potential danger to the body has subsided, the reversion of the 
inflammatory response to the homeostatic state should proceed quickly, failure 
to do so turns acute inflammation into the chronic stage. 
Acute inflammation is the initial response upon being injured (described above), 
and lasts for a relatively short period of time, usually between minutes to a few 
days.  Chronic inflammation on the other hand is a prolonged inflammatory 
response and can have damaging consequences to the host.  Chronic 
inflammation is believed to develop if the triggering stimuli isn’t eliminated, 
such as chronic cellular injury or a persistent infection.  Although it has been the 
subject of extensive studies, the underlying mechanism of the cause remains 
largely undetermined.  It is extremely problematic as the major damages done 
to the host are mediated by the host’s inflammatory response, not by the 
foreign pathogens.19, 20  Research into chronic inflammation has been unable to 
identify an inducer, which aids the continuation of the inflammatory response.  
Without this knowledge, an intervention is extremely difficult.  Further research 
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is required into the mechanisms which induce and sustain chronic inflammation 
to ensure any therapeutic designed will have minimal risk of damaging side 
effects for the host. 
It has recently been reported that inflammatory diseases can also play a role in 
promoting cancer, particularly tumorigenesis (tumour formation), as well as 
various inflammatory cells being present within tumours.22  It is also said that 
environmental factors, which promote inflammation are connected to an 
increased cancer risk, such as carcinogen exposure; inhalation of tobacco smoke 
or other pollutants and infectious microbes, particularly in lung 
tumorigenesis.19   
With inflammation being a vital defensive mechanism for the body, research 
into novel, potentially anti-inflammatory bio-active species could prove 
extremely important in the quest to control chronic inflammation. 
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1.2.2 NF-κB and Inflammation 
Upon its discovery in 1986 by Sen and Baltimore,23 NF-κB was identified as a 
nuclear factor that bound to an enhancer element of the immunoglobulin light-
chain gene and was believed to be specific to B cells.  Since then, research has 
discovered that NF-κB is actually a eukaryotic transcription factor 24 and serves 
as an important regulator of inducible inflammatory gene expression.  This 
includes regulation of ECAMs and pro-inflammatory cytokines, activating NF-κB 
dependent gene expression.25  
NF-κB exists in virtually all cell types in its inactive form, and is bound to 
inhibitory proteins (IκBs) residing in the cytoplasm.26  On activation, which is 
induced by agents including mitogens, chemical substances that encourage cell 
division, cytokines and inducible messengers that are generally produced and 
act for immune cells, NF-κB  is dissociated from IκB, allowing the free NF-κB to 
be transported into the nucleus, where it can regulate genes involved in 
immune and inflammatory responses.24   
As well as the usual activation pathways, researchers have suggested that 
reactive oxygen species, may also trigger the signalling process.  Studies 
involving peroxynitrite, (formed in vivo from a reaction of free radicals 
superoxide and nitric oxide (NO)), suggested the peroxynitrite amplifies 
signalling mechanisms under inflammatory conditions.  The amount of 
peroxynitrite synthesised increase in inflammation, with excessive amounts 
shown to have detrimental effects to the host, including DNA damage, cell 
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damage due to depletion of cellular energies, apoptosis leading to cell/ tissue 
damage.27  
NF-κB exist as hetero- or homogeneous dimers, in a combination of NF-κB and 
Rel proteins, which can bind to DNA through a terminal amino acid, this region 
is also responsible for the dimerisation.  There are various dimer combinations 
possible, most of which have shown to be transcriptionally active, although 
there are some homodimer exceptions, which have shown to be 
transcriptionally repressive.24 
NF-κB regulates pro-inflammatory cytokines, adhesion molecules and growth 
factors, but it also regulates genes encoding cyclooxygenase 2 (COX2) and 
inducible nitric oxide synthase (iNOS).28  The onset of inflammation is associated 
with the expression of COX-2 and iNOS, with COX-2 being induced by 
inflammatory stimuli hormones, which is said to be the dominant source of 
prostaglandin formation in inflammation.29  iNOS is responsible for the 
overproduction of NO, which is often observed during inflammation. 
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1.2.3 Nitric Oxide and Inflammation 
Since the discovery that mammalian cells have the ability to synthesise free 
radical nitric oxide in 1987, it has been the focus for many research groups.  NO 
is a gaseous molecule, produced, in vivo, in a reaction catalysed by NOS 
enzymes and has emerged to be a fundamental signalling device, responsible 
for regulating a variety of physiological and pathophysiological responses.  The 
NOS family currently consists of three isoforms.  All of the NOS family have the 
ability to produce NO, although eNOS and nNOS only produce relatively low 
amounts compared to iNOS.25  Exposing the enzyme to microbial molecules 
such as lipopolysaccharide (LPS) induces the expression of the iNOS gene in 
various inflammatory cells.27 
The role of NO seems to be dependent on the quantity released at a particular 
site, for example, low concentrations of NO has shown to be protective and 
anti-inflammatory, whereas much larger quantities of NO released by cells have 
shown to destroy tissue and impair discrete cellular responses,30 and may cause 
injury to the host during prolonged inflammation.  The concentration of NO is 
also an important factor in respects of cytotoxicity.  Low quantities of NO act as 
a defensive mechanism against invading microbial organisms for example, 
bacteria, viruses or parasites, an anti-inflammatory effect, whereas an inflated 
amount of NO can also start destroying cells and tissue, causing it to have a pro-
inflammatory effect,30 making it an important modulator in the inflammatory 
process. 
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Studies have reported a close link between NO and NF-κB, with NO causing an 
inhibitory effects on NF-κB activation and subsequent gene expression, as well 
as inhibiting NF-κB’s interaction with DNA.  The inhibitory effect of NO is not 
restricted to NF-κB though, as it is thought to inhibit the expression of many 
genes involved in inflammatory diseases. Studies also suggest that NO can 
effect both acute and chronic inflammation through influencing many 
pathophysiological processes, including leucocyte-endothelial interaction; 
ECAM expression and infiltration of activated leucocytes at inflammation 
sites.25, 27         
Research has shown that NO plays a vital role within the inflammatory process, 
therefore inhibition of an NO expression could provide a method to control 
inflammation.         
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Chapter 2.  Previous Syntheses of Halichlorine 
2.1 Literature Studies   
Since the discovery of the bioactive alkaloids, halichlorine 1 and pinnaic acid 2 
have interested many research groups with their unique structure and 
expressed bioactivity.  Many groups have used similar strategies to access both 
core structures/natural products, due to the structural similarities.31-37 Those up 
to 2005 have been comprehensively reviewed by the group of Clive. 38 
Owing to the volume of work in this area only a select number of routes to 
halichlorine will be reviewed here.  There are a number of total syntheses, some 
of which are similar to the first total synthesis by the Danishefsky group, all of 
which will be covered here.  Only those partial syntheses utilising nitrone 
chemistry, of particular relevance to this thesis, will be reviewed here. 
This section will also cover some synthetic approaches to the terrestrial-sourced 
spiroalkaloid histrionicotoxin. While this compound is exclusively isolated from 
frogs of the Dendrobates species, surprisingly, it exhibits a similar structure to 
the marine alkaloids halichlorine and pinnaic acid and thus synthesis of the core 
structure of this potentially useful neuroactive compound has also been the 
subject of this thesis.  
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2.1.1  The Danishefsky’s Lab 
Danishefsky’s lab were the first to achieve the total synthesis of halichlorine.39   
Retrosynthesis focuses on bisecting the target compound into a 
spiroquinolizidine core 4 and a highly functionalised fragment 5 (Scheme 1).40   
 
Scheme 1.  Shows the disconnection of Halichlorine to the spiroquinolizidine core.40 
 
The protected spiroquinolizidine core 14 was synthesised from known 
compound, `Meyers-lactam’ 6 in 12 steps.40 The last step involved a selective 
deprotection tried in two ways, one removed the silyl ester to afford a primary 
alcohol, and the other removed the tert-butyl group, releasing the 
corresponding acid.  The deprotected alcohol 15 was reacted further.38 
 
 
 
 
 14 
 
Scheme 2. The route from Meyers Lactam towards the spiroquinolizidine core.  a) 
allyltrimethylsilane, TiCl4, CH2Cl2, -78°C to r.t; b) Na, NH3, THF, EtOH, -78°C; c) Boc2O, DMAP, 
THF; d) (i) LiHMDS, THF, -40°C; (ii) Mel, -78°C to 0°C; e) LiOH, THF, H2O; f) (i) EtOCOCl, Et3N, THF; 
(ii) NaBH4, MeOH; g) TBDPSCl, Et3N, DMAP, CH2Cl2; h) (i) 9-BBN, THF; (ii) Pd(dppf)Cl2, Ph3As, 
Cs2CO3, DMF, H2O; i) (i) TFA, CH2Cl2; (ii) H2O, K2CO3; j) t-BuOAc, LiHMDS, THF, -50°C to r.t.; k) i) 
CH2O, EtOH, (Me3Si)2NLi, THF, 0 ii) CP2Zr(H)Cl, r.t., HF.pyridine, THF.40 
 
The challenging oxidation of 15 finally produced the corresponding aldehyde 
16, when reacted crude, followed by a Serferth-Gilbert homologation to 
produce a terminal alkyne 17.  This was converted to a vinyl zinc species 18, by 
hydrozirconation and transmetallation.  Addition of 19 produced 20 in a 4:1 
ratio of desired (17R)-diastereomer, which was taken forward without 
 15 
separation.  Protecting group manipulation followed, by replacement of the 
tert-butyl ester with a silyl group, which consequently protected the hydroxyl 
group in the process.  The two primary silyl groups were then removed, leaving 
the secondary silyl ester on 22 intact (Scheme 3).40  
 
Scheme 3.  Synthetic route from the spiroquinolizidine core to the deprotected derivative.  a) 
TPAP, NMO, MeCN, r.t.; b) N2CHP(O)(OMe)2, KOtBu, THF, -78°C; c) (i) [Cp2Zr(H)Cl], CH2Cl2; (ii) 
Zn2Me, heptane, -65°C; d) 19, DIBAL, PhMe, CH2Cl2, -78°C; e) TBSOTf, 2,6 Lutidine, CH2Cl2, -78°C 
to r.t.; f) NH4F, MeOH, H2O.39  
 
The ring closing step consisted of a Fischer esterification reaction under Keck 
macrolactonisation conditions,41 which involved the transfer of a proton from 
 16 
DMAP.HCl to the acid.  The result is a charged species, which can delocalise 
around the carbonyl carbon and hydroxyl group of the acid 22a.  The primary 
alcohol then attacks the carbonyl carbon and attaches forming 22b, followed by 
a proton transfer generating a leaving group, 22c.  The carbonyl is reformed 
during dehydration 23, after which the final silyl protecting group is removed to 
achieve 1.39 
 
 
Scheme 4.  The final steps in the first total synthesis of halichlorine.  a) EDCI, DMAP, DMAPHCl, 
CHCl3, THF, Δ; b) HF-pyridine, pyridine, THF.39 
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2.1.2 The Uemura Group 
2.1.2.1 Synthesis of a Tricyclic Halichlorine Core 
Halichlorine was discovered by the Uemura group, whilst on their quest for 
biologically active substances from marine organisms.1 The isolated yield was 
3.5x10-7% (70.8 mg from 200 kg of wet sponge), with which they determined 
the structure and absolute stereochemistry of the compound.42  They were also 
the group who discovered its biological potential, including its ability to inhibit 
the induction of VCAM-1.1 
In 2004, the Uemura group published the synthesis of the halichlorine tricyclic 
core via an ene-yne metathesis-based strategy.  They began with a 
cyclopentane derivative 24, constructed during the synthesis of pinnaic acid,43 
which already contained functionality in the correct positions, oxidative 
cleavage of this terminal alkene to an aldehyde was followed by a Horner-
Wadworth-Emmons reaction with phosphonate 25, yielding 26.  Hydrogenation 
of 26 effected a series of reactions, including saturation of the double bond, 
removal of the carboxybenzyl protecting group and stereo-selective reduction 
of the cyclic imine intermediate.  Reproducible results of the desired product 
were achieved by using a large amount of catalyst without the presence of acid.  
Introduction of a propargyl substituent to the sterically hindered nitrogen atom 
also proved challenging, this was finally successful when Proton Sponge™ was 
used, followed by the removal of the methoxyethoxymethyl (MEM) group to 
afford 28. A 2-nitrophenylselenyl group was added onto the primary alcohol, 
followed by the oxidation and elimination of the selenium group to give the 
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terminal alkene on 29.  The ring closing ene-yne metathesis reaction was 
performed using 2nd generation Grubbs’s Ru-catalyst under an ethylene 
atmosphere forming 30 in a good yield.  Sharpless dihydroxylation of the 
terminal alkene in 30 afforded 31, and the diol was finally oxidatively cleaved 
yielding the desired aldehyde and tricyclic halichlorine core 32.44 
 
Scheme 5 a) i. O3, MeOH, ii. Me2S; b) LiCl, Et3N, THF, phosphate 25; c) H2, Pd(OH)2/C, EtOH, 94%; 
d) propargyl bromide, proton sponge, MeCN, 60°C, 60%; e) PPTS, t-BuOH, reflux, 77%; f) 2-
nitrophenyl selenocyanate, (n-Bu)3P, THF, r.t., 98%; g) mCPBA, THF, r.t., 87%, h) 2nd generation 
Grubbs Ru-catalyst (11.7 mol %), ethylene atmosphere, toluene, 80°C, 72%; i) K2OsO4-H2O, 
(DHQD)2PHAL, NaHCO3, K3[Fe(CN)6], aq. t-BuOH, r.t., 52%; j) NaIO4, MeOH, 0°C-r.t., 81%.44 
 2.1.2.2 Enantioselective Total Synthesis of Halichlorine 
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In 2014, 10 years after the publication of the tricyclic core,44 the Uemura group  
reported an enantioselective total synthesis of halichlorine and pinnaic acid.45  
Interestingly, they did not build on previous work towards halichlorine 
described above.    
As pinnaic acid and halichlorine share the same structural backbone, the 
synthesis was designed to produce a common intermediate, in which both could 
be synthesised from.  They combined efforts from the previous total syntheses 
of pinnaic acid and the early steps in the synthesis of the halichlorine core.43, 44, 
46, 47   
As with the 2007 asymmetric total synthesis of pinnaic acid, they began their 
efforts with commercially available (R)-(+)-pulegone 33, with the first key 
intermediate being synthesised in 5 steps.  With quantities of the key chiral 
cyclopentenone 34 in hand, a palladium catalysed [3+2] cyclisation with 35 gave 
the fused bicyclic compound 36.  Installation of the nitrogen atom proved 
challenging, after trying the Schmidt reaction and the Beckmann 
rearrangement, the hindered nitrogen reagent o-
mesitylenesulphonylhydroxylamine (MSH) proved to be more successful, 
achieving 37 with a reproducible 85% yield.  A one-pot ozonolysis-Clemmensen 
reduction gave 38, which was followed by the protection of the nitrogen atom 
before the reductive ring opening with LiBH4, giving 39.  Further protecting 
group manipulation gave 40.  Oxidation of the free hydroxyl group was followed 
by a Horner-Wadsworth Emmons reaction with 41 to afford spiro-cyclic 
precursor 42 as the single trans isomer (Scheme 6).45  
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Scheme 6.  Steps towards the spirocyclic core shared with pinnaic acid and halichlorine.  a) O3, 
0°C, HOAc, H2O, EtOAc; b) AllylOH, H2SO4 (cat.), Dean-Stark, reflux, 89% (2 steps); c) K, AllylOH, 
PhMe, reflux, p-2-(iodoethyl)-methoxylphenyl, reflux; d) HCl, acetone, r.t; e) Pd(OAc)2 (5 mol 
%), MeCN, 90°C, 49% (3 steps); f) 35, Pd(OAc)2, (iPrO)3P, THF, reflux, 80%; g) MSH, CH2Cl2, r.t., 
silica gel, 85%; h) O3, iPrOH, CH2Cl2, -78°C then, Zn, TMSCl, -78°C - 0°C, (one pot) 72%; i) NaH, 
CBzCl, THF, reflux, 87%; NaBH4, LiBr, THF, 50°C; j) TBDPSCl, DMAP, Et3N, CH2Cl2, r.t; k) CAN, 
MeCN, H2O, 0°C, 79% (2 steps); l) SO3py, Et3N, DMSO, r.t; m) 41, Et3N, LiCl, THF, 30°C, quant. 
(2 steps).45 
 
Compound 42 undergoes an impressive one pot four step cyclisation, triggered 
by hydrogenation, proving to be a very efficient and powerful way to produce 
the piperidine ring present in both 1 and 2. It consists of four consecutive 
transformations: 1) saturation of the alkene, 2) removal of the CBz protecting 
group, 3) intramolecular cyclisation of the imine/enamine formation, 4) 
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stereoselective reduction of the imine/enamine intermediate.  The amino 
group in the spirocycle was protected to give 43, followed by the selective 
deprotection of the TBDPS group and a Grieco elimination, after which the 
MOM group was removed yielding the terminal alkene in 43.  Cross metathesis 
of 44 with 45 proceeded smoothly achieving 46.  Grieco elimination of the 
remaining hydroxyl group gave the corresponding terminal alkene, followed by 
the removal of the TFA group, and addition of 47.  This provided 48 with the 
ability to undergo ring closing metathesis using second generation Grubb’s 
catalyst.  Deprotection of the TBDPS groups on 49, and hydrolysis of the methyl 
ester allowed Shiina macrolactonisation of 50 to complete the total synthesis of 
1.45             
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Scheme 7.  The final steps towards the enantioselective total synthesis of halichlorine.  a) H2, 
Pd(OH)2/C (20 mol %), HOAc, EtOH, r.t.; b) TFAA, iPr2Net, CH2Cl2, 0°C, 80% (2 steps); c) TBAF, 
THF, 0°C; d) o-NO2PhSeCN, nBu3P, THF, r.t., then mCPBA, r.t., (99%); e)PPTS, tBuOH, 90°C, 86%; 
f) 45, Hoveyda-Grubb’s II catalyst (28 mol %), PhMe, static vacuum, 60°C, 72%; g) o-NO2PhSeCN, 
nBu3P, THF, r.t., then H2O2, r.t., 84% (2 steps); h) NaBH4, EtOH, 30°C; i) 47, K2CO3, MeCN, 60°C, 
84% (2 steps); j) Grubb’s II catalyst (10 mol %), CH2Cl2, reflux; k) HFpy, r.t., 93%; l) NaOH, THF, 
MeOH, H2O, 50°C; m) MNBA, DMAP, THF, r.t., 56% (2 steps).45 
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2.1.3 The Clive Group 
 2.1.3 Synthesis of Spirobicyclic core Structures 
The Clive group began their studies by focusing on the spirobicyclic core of 1 
and 2.  In 1999 and 2004, the Clive group reported two methods in producing 
very similar cyclic core structures, using radical cyclisation.48, 49  
The earlier paper comprised of two segments being synthesised from D-
Glutamic acid 51 and valerolacetone 53 (scheme 8a).  Deprotonation of 52 
followed by the slow addition of aldehyde 54 produced a diastereoisomeric 
mixture of 55.   Oxidation of the hydroxyl group, followed by the removal of the 
allyloxycarbonyl group allowed the formation of the enamine. The benzyl 
protecting group was removed, allowing the replacement of the proton with a 
bromide, this then radically cyclised and finalised with a desulphonylation to 
achieve 57.48  
 
Scheme 8a. The two segments synthesised for Clive’s route to a spirocyclic core. 
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Scheme 8b.  Clive’s first synthesis of a spirocyclic core of 1 and 2. a) Dess-Martin reagent, CH2Cl2, 
90%; b) (PH3P)4Pd, dimedone, THF, 88%; c) Pd-C, H2, MeOH-EtOAc, 90% d) Ph3P, 2,6-lutidine, 
CBr4, MeCN, 82%; e) Bu3SnH, AlBN, PhMe, 75°C, 57%; f) Na(Hg), MeOH, Na2HPO4, 75%. 
In 2004, the Clive group published a second paper showing an alternative 
method to synthesise a very similar azaspiro[4.5]decane core .  This time they 
began with pyridine 2,6 dicarboxylic acid 58 and produced intermediate 59 in a 
lengthy 18 step synthesis.  After experiencing some difficulties in the radical 
cyclisation of 59, the enone was reduced which allowed the cyclisation to 
proceed giving 60, followed by the removal of the acetoxy group. After 
installation of the required methyl group, the lactam was opened with 
Meerwein’s reagent affording 63.49 
 25 
 
Scheme 9.  Clive’s second syntheses towards a spirocyclic core.  a) NaBH4, CeCl3.7H2O, MeOH, -
45°C, 40 min, 85%; b) Ac2O, pyridine, 12 h, 99%; c) Bu3SnH (addition over 10 h), AIBN, PhH, 80°C, 
reflux further 3 h, 67%; d) MeONa, MeOH, 4 h; e) MeSO2Cl, Et3N, THF; f) DBU, PhMe, reflux, 48 
h, 69% over 2 steps; g) Me2CuLi, Me3SiCl, Et3N, THF, -78°C (2 h) to 25°C (1 h), 81%; h) Me3OBF4, 
2,6-di-tert-butylpyridine, CH2Cl2, 4.5 h, aq. Na2CO3, 71%.50 
 
This core structure was followed soon after with another spirocyclic amine.  
Further reading into Clive’s partial syntheses can be found here.32, 38, 50, 51  
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2.1.4 Clive’s Total Synthesis of Halichlorine 
Following the several partial syntheses of 1 and 2, the Clive group focussed their 
efforts on a total synthesis of 1.  They looked to employ a completely new route 
to the one’s previously published, who’s syntheses relate to Danishefsky’s 
routes. After extensive exploratory studies, they constructed their synthesis to 
form an asymmetric spiro-centre early, and built around it.52   
 They began with the diester 64, allylation and reduction of the diesters 
afforded 65.  Selective protections of the hydroxyl groups 66 allowed 
hydroboration of the allyl 67.  Protecting group manipulation of the 
corresponding hydroxyl group and removal of the pivaloyl group allowed the 
formation of an aldehyde 68 by Swern oxidation.  Aldol condensation of 68, was 
followed by the removal of the benzyl group yielding 69 in a diastereoisomeric 
mixture.  Heating in PhMe formed the rigid bicyclic lactam 70.  Dehydration of 
the hydroxyl group, followed by removal and replacement of the silyl group with 
first a bromide, which was proved to provide the wrong stereochemistry for the 
vital pendent methyl group on 1, when radical cyclisation occurred, was later 
changed for a phenylseleno group 71.52  
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Scheme 10. The first steps towards Clive’s total synthesis of halichlorine.  a) chiral base, BuLi, 
THF, allyl bromide, 65%; b) LiAlH4, THF, 0°C to r.t., 71%; c) t-BuCOCl, i-Pr2NEt, DMAP, CH2Cl2, -
10°C , 67%; d) MOMCl, i-Pr2NEt, DMAP, CH2Cl2, 0°C to r.t, 95%; e) 9-BBN, THF, 0°C to r.t.; 30% 
H2O2, MeOH, NaOH, 0°C to r.t., 99%; f) i-Pr3SiOSO2CF3, i-Pr2Net, CH2Cl2, 0°C, 99%; g) DIBAL-H, 
CH2Cl2, Et2O, -78, 89%; h) Swern, 93%; i) LDA, MeO2CCH2CH3, THF, -78°C; j) 10% Pd-C, 1,4-
cyclohexadiene, EtOAc, 58°C, 94%; k) PhMe, reflux, 48 h, 89%; l) MsCl, Et3N, THF, 0°C to r.t.; 
DBU, reflux, 88%; m) Bu4NF, THF, 93%; n) PhSeCN, Bu3P, THF, 97%.52 
 
Ozonolysis of 71 opened up the bicyclic ring.  Upon treatment with DBU, 72 
underwent consecutive intramolecular aldol condensation and dehydration to 
afford 73.  The enone was reduced before radical cyclisation of the selenium 
protected pendent.  This produced a number of compounds including the 
corresponding acetate in both diastereoisomers, as well as an enone 74.  All the 
acetate was converted to 74, before the introduction of the methyl group 75.52 
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Installation of the final ring proceeded by removal of the MOM group, oxidation 
to the corresponding aldehyde followed by Wittig olefination and acid 
hydrolysis to afford 76.  76 was subjected to a Baylis-Hillman reaction, to give 
an alcohol, which was immediately converted to the acetate 77.   These 
previously formed lactam was opened to give a methyl ester, and also 
experienced spontaneous intramolecular cyclisation yielding 78. 
 
Scheme 11.  Installation of the spirocyclic rings.  a) O3, CH2Cl2, -78°C; (MeO)3P, -78°C to r.t., 84%; 
b) DBU, THF, 0°C to r.t, 80%; NaBH4, CeCl37H2O, MeOH, -45°C, 90%; Ac2O, pyridine, 98%; d) 
Bu3SnH, AIBN, PhH, 80°C, e) Bu3P, o-O2NC6H4SeCN, THF, H2O2, 96%; f) Me2CuLi, Me3SiCl, HMPA, 
THF, -78°C to r.t., 96%; g) Me3SiBr, CH2Cl2, -10°C, 86%; h) Pr4NRuO4, NMO, CH2Cl2, 84%; i) 
MeOCH2PPh3Cl, t-BuOK, THF, 0°C; j) CSA, MeCN-water, 92%; k) acrylonitrile, DABCO, Sc(OTf)3, 5 
days; l) AcCl, pyridine, CH2Cl2, 0°C to r.t., 89%; m) Me3OBF4, CH2Cl2; aq. Na2CO3, MeCN.52 
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Now that the spiro-bicyclic system was in place, the side chain was extended in 
preparation for macrocyclisation.  The nitrile was reduced to an aldehyde 
before being protected.  This allowed for selective oxidation of the alcohol 79, 
which was quickly converted to selenides 80, before addition of the known 
chloro- aldehyde 81. The selenium was removed forming a double bond, before 
protecting group manipulation of 82 protected the hydroxyl group and released 
the aldehyde, which was oxidised to the corresponding acid.  Selective 
deprotection of the primary silyloxy group released the hydroxyl group 83, 
which underwent macrocyclisation to achieve 84, as shown in Danishefsky’s 
synthesis.40  Finally, the remaining silyl group was removed affording 1 (Scheme 
12).52  
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Scheme 12.  The final steps towards the total synthesis of halichlorine.  a) DIBAL-H, CH2Cl2, THF, 
PhMe, -78°C, 72%; b) Me3SiOSO2CF3, 1’2-bis(trimethylsiloxy)ethane, CH2Cl2, 76%; c) Pr4NRuO4, 
NMO, CH2Cl2, 88%; d) Bu3SnLi, THF, -78°C; then Bu3PPhSeCN, THF, pyr, 61%; e) 81, BuLi, THF, -
78°C; f) NaHCO3, NaIO4, MeOH; g) t-BuMe2SiCl, ImH, DMF, 36%; h) Me3SiOTf, 2,6-lutidine, 
CH2Cl2, 81%; i) Pinnick oxidation, 75%; j) NH4F, water-MeOH, 40°C, 20 h, 81%; k) DMAP, 
DMAPHCl, EDCl, CHCl3, reflux, 58%; l) HF-Pyr, THF, 54%.52  
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2.2 Partial Syntheses of Halichlorine using Nitrone Chemistry 
 2.2.1 The White Group 
The White group based their efforts towards the core of 1 and 2 using a 
transannular nitrone cycloaddition.  This unique class of intramolecular reaction 
differs by containing both the dipole and the alkene within a ring, allowing a 
high degree of stereocontrol.  One requirement of this reaction is that the 
macrocycle must be large enough to permit flexibility to allow the functional 
groups to meet, but not too large that the N-oxide passes through the plane of 
the ring.  Upon meeting these conditions, the reaction will proceed yielding a 
single stereocentre.53  
The synthesis began by formation of the macrocycle.  Using a keto aldehyde 85, 
an oxaziridine 86 was formed in 4 steps.  Treatment of 87 with p-toluenesulfonic 
acid resulted in simultaneous hydrolysis of the ketal forming the hydroxylamine 
intermediates, which spontaneously cyclised forming the nitrone 88.  Upon 
heating a single crystalline product was afforded 89, before methanolysis gave 
90 and reductive cleavage of the isoxazolidine afforded the spirocyclic amine 
91.38, 53 
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Scheme 13.  White’s partial synthesis of halichlorine. a) Ph3CHCO2CH2CHCH2, CH2Cl2; b) HN3, 
Et3N, PhH, reflux; c) (CH2OSiMe3)2, Me3SiOTf, CH2Cl2, -78°C; d) Grubbs I, CH2Cl2; e) Ph3P, p-
MeOC6H4CHO, relfux; f) mCPBA, -78°C to r.t.; g) TsOH, MeOH; h) PhMe, reflux; i) K2CO3, MeOH, 
reflux; j) SmI2, THF.53  
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2.2.2 The Zhao Group 
The Zhao Group used intramolecular cycloaddition reactions of nitrones 
previously developed by Grigg and co-workers, as they are usually regio- and 
stereospecific.54, 55  Employing this method, they managed to produce a 
spirocyclic structure, and unlike the White group, with the alkene already 
situated within the macrocycle, the Zhao nitrone was only connected to the 
alkene at one terminus. 
They began their synthesis with sequential alkylation of 1,3-dithiane 92 to yield 
a dialkylated dithiane.  Hydrolysis released the ketonic carbonyl, which was 
treated with hydroxylamine hydrochloride to afford oxime 93.  Upon heating 
with benzyl acrylate 94, nitrone intermediate 95 was formed, before cyclisation 
to 96.  Removal of the THP protecting group, followed by Swern oxidation and 
Wittig homologation gave the corresponding enonate 97.   Cleavage of the N-O 
bond yielded 98, which upon heating cyclised intramolecularly to achieve the 
desired product 99 (scheme 14).38, 54 
 34 
 
Scheme 14.  Zhao’s partial synthesis utilising nitrone chemistry.  a) Cl(CH2)4OTHP, BuLi, THF, 
85%; b) CH3CH(CH2)3I, BuLi, THF, HMPA, 87%; c) NCS, AgNO3, MeCN-water, 97%; d) H2NOHHCl, 
AcONa, MeCN, 99%; e) benzyl acrylate 94, xylene, 140°C, 92%; f) TsOHH2O, MeOH 93%; g) 
Swern, 97%; h)PH3PCHCO2Me, CH2Cl2, 93%; i) zn, AcOH-water, 55°C, 94%; j) o-Cl2C6H4, reflux, 
84%.38  
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2.3 Synthetic Studies towards Histrionicotoxin 
The histrionicotoxins (HTX) are a family of alkaloids, members of which were 
first isolated in 1971 by the Daly group.56  Since that time, other members have 
been discovered, taking the HTX family to 15 plus derivatives.57   Table 1 shows 
the HTX core structure, with the HTX substrates shown in the first entry.  The 
following entries the various combinations isolated.  The review by Stockman 
shows a extensive research on the HTX derivatives.57  
Table 1. The histrionicotoxin family of alkaloids. 
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 HTX can be isolated from the skin of Dendrobatidae, poisonous dart frogs, 
which have shown to store the poison, which is secreted onto the surface of the 
skin as a defence mechanism.  Studies have shown that frogs raised in captivity 
they do not produce such alkaloids, indicating the source to be dietary.58    
HTX are of synthetic interest due to their biological activity and unique 
structure.  They have shown to have various effects on both mammalian and 
amphibian nerve-muscle preparations by selectively binding to the 
acetylcholine receptors, which interrupt the transmission neuromuscular 
impulses.59   
There have been many synthetic approaches adopted in the total syntheses of 
HTX variants,57 comprehensively reviewed by Stockman.  This review will only 
look at those syntheses of relevance to the nitrone-based approach studied in 
this thesis.   
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2.3.1 The Gossinger Group  
 In 1975, the Gossinger group reported their efforts towards HTX utilising 
nitrone chemistry.  They began with piperidinol 115, which was synthesised 
from 1,5-dibromopentane in a double SN2 cyclisation.  Oxidation to nitrone 116 
was achieved using HgO, followed by a nucleophilic addition of 4-
pentenylmagnesium bromide to 116.  Oxidation of 117 with HgO gave the 
nitrone 118, which in refluxing toluene underwent intramolecular 1,3-dipolar 
cyclisation to give the kinetic cyclo-adduct 119.  This was converted to the 
thermodynamic product 120, by heating to 195°C in a sealed tube.  Raney nickel 
hydrogenation opened up the ring to yield HTX 121 (scheme 15).57, 60 
 
Scheme 15.  Synthesis of HTX core structure by the Gossinger group.  a) HgO, CHCl3, 0°C to r.t.; 
b) BrMg(CH2)3CH=CH2, Et2O, reflux; c) HgO, Et2O, 0°C to r.t.; d) toluene, reflux; e) toluene, 195°C; 
f) H2, Raney Ni, EtOH. 
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With 121 successfully synthesised, The Gossinger group then tried to produce a 
more substituted member of the HTX family using the same methodology, the 
nucleophilic addition was performed using non-4-enylmagnesium bromide to 
give 122.  Oxidation formed the corresponding nitrone 123, followed by the 
intramolecular cyclisation which resulted in a 6,5,5-kinetic adduct 124, with a 
butyl chain.  Unfortunately, this compound could not be converted to the 
desired thermodynamic product 125, which maybe a result of the steric 
hindrance caused by the butyl chain.60 
 
Scheme 16.  Synthetic efforts towards a HTX structure.  a) BrMg(CH2)3CH=CH(CH2)3CH3, Et2O, 
reflux; b) HgO, Et2O, 0°C to r.t.; c) toluene, sealed tube, reflux.  
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 2.3.2 The Holmes Group 
In 1999, the Holmes Group reported their route to an enantioselective total 
synthesis of (-)-HTX283A, also utilising the functionality of the nitrone.61  They 
began their efforts with a known acetylenic diol 126.  Debenzylation allowed 
oxidation to the acid 127, followed by the addition of (1R)-(+)-2,10-
camphorsultam 128, which was used as a chiral auxiliary to achieve the desired 
stereoselectivity.  Installation of the hydroxylamine 129 was therefore achieved 
diastereoselectively.  Intramolecular cyclisation between the hydroxylamine 
and the alkyne gave nitrone 130, which was swiftly followed by  an 
intermolecular cyclisation with styrene to yield isoxazolidine 131 as a single 
regio- and stereoisomer.  The chiral auxiliary was removed, followed by 
protecting group manipulation, oxidation of the hydroxyl group to an aldehyde 
and conversion to a nitrile 132.  Heating in a sealed vessel at 190°C, caused a 
retro-[3+2] cycloaddition, decomposition of the five membered heterocycle, 
releasing the styrene moiety, and forming a key nitrone intermediate 133, 
before intramolecular cyclisation to the thermodynamic tricyclic adduct 134.  
With the ring structure to the HTX core now in place, the Holme’s group 
converted the benzyl ester pendant to a nitrile, followed by reduction of both 
nitriles to bis-aldehyde 135.  The aldehyde groups were converted to enyne 
chains through a modified Stork-Wittig procedure, which involves an enamine 
alkylation before the installation of the alkyne.  The final stages include the 
reductive ring opening and removal of the TMS groups to yield HTX 137.57, 61 
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Scheme 17.  Holme’s enantioselective total synthesis of (-)-HTX283A.  a) BCl3DMS, CH2Cl2, 97%; 
b) Jones’ reagent, acetone, 98%; c) NEt3, pivaloyl chloride, 0°C then (1R)-(+)-10,2-
camphorsultam 128, n-BuLi, THF, -78°C, 84%; d) NaN(TMS)2, 1-chloro-1-nitrosocyclohexane, 
THF, then HCl (aq), 70%; e) toluene, 80°C, 6 h; f) styrene, 75°C, 85% (2 steps); g) LiAlH4, THF, 0°C; 
h) NaH, BnBr, THF 90% (2 steps); i) HF, CH3CN, 91%; j) TPAP, NMO, 4 Å sieves, 98%; k) 
Me3SiCH2CN, n-BuLi, THF, -78°C, B(OiPr)3, 87% (E:Z 10:90 increasing to 8:92 with HMPA); l) 
toluene, sealed tube, 190°C, 3.5 h, 80%; m) BCl3DMS, CH2Cl2, 99%; n) methanesulfonyl 
chloride, NEt3, DMAP, CH2Cl2, 100%; o) NaCN, DMSO, 4 Å sieves, 55°C, 85%; p) DIBAL-H, toluene, 
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-78°C, 100%; q) KN(TMS)2, [Ph3PCH2I]+I-, THF, -78°C, 95%; r) Pd(PPh3)4, CuI, Et2NH, MeSi-CCH, 
92%; s) Zn, AcOH, 30 min, 98%; t) K2CO3, MeOH, 94%. 
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2.3.3 The Brossi Group 
In 1985, the Brossi group reported an efficient route to a 6,6-spirocyclic core 
structure, through the use of lactams.  While this approach does not utilise 
nitrone chemistry it is of some relevance to the work towards the HTX core 
structure described in this thesis, which focuses on C-2 functionalised 
analogues.  The synthesis began with addition of pent-4-enylmagnesium 
bromide onto glutarimide 139, providing a cyclic iminium species which 
underwent intramolecular cyclisation with the alkene portion of the introduced 
pentenyl side chain forming isomeric spirocyclic mixtures 140a, 140b, which 
could be separated, after many synthetic investigations the Brossi group found 
that after further reactions on 140a and 140b the diastereoisomers could no 
longer be separated, they therefore resorted back to 140a.  They first reduced 
the aldehyde to 141, before functional group manipulation, firstly through a 
thiolactam 142, to a methylthio group 143 to a ketimine 144, which was 
reduced to give diastereoisomeric mixture 145a and 145b.  Reduction of the 
terminal alkene yielded pentyl derivatives 146a and 146b.62 
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Scheme 18. Brossi’s route to a HTX derivative.62 a) CH2=CH(CH2)3MgBr, THF, 40-60°C; b) HCOOH, 
25°C; c) KOH/EtOH/H2O; d) Ac2O, PyH, 25°C; e) P2S5, benzene, reflux; f) MeONa, EtOH, reflux; g) 
Mel, CH2Cl2, 25°C; h) CH2=CH(CH2)3MgBr, MgCl2, CH2Cl2, reflux; i)NaBH4, MeOH, -70°C; j) H2, 
Pd/C, EtOH, 25°C.  
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2.3 Previous Syntheses by the Caprio group 
The Caprio group have concentrated their efforts on the core structure of both 
1 and 2 utilising nitrone chemistry.  Based on the synthetic route of Gössinger 
et al. (Scheme 15),60 who produced the tricyclic compound from piperidinol, a 
spironitrone core structure was synthesised (Scheme 19).  In this strategy 
spironitrone 147 is retroanalysed back to tricyclic isoxazolidine 119, which in 
turn is obtained by intramolecular cycloaddition of alkene tethered nitrone 118.  
The alkene tether is introduced by Grignard addition onto nitrone 116. 
 
 
Scheme 19.  Retrosynthetic analysis of spironitrone 147. 
 
Using 147, a study of 1,3-dipolar cycloadditions was performed, using both 
electron rich and electron deficient alkene substrates, which gave a range of 
isoxazolidines 148 as single stereoisomers.  Reductive ring opening conditions 
were then optimised which produced a small range of spiro-amines 149.  As the 
undesired stereoisomer was achieved, the reduced adducts were transformed 
to the desired stereoisomers by an oxidation/reduction sequence 152 (Scheme 
20). 
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Scheme 20. Caprio’s 1,3-dipolar cycloaddition, reductive ring opening studies. a) 147, 
dipolarophile, electron deficient dipolarophiles were heated, PhMe/ EtOH/CH2Cl2, 64-94%; b) 
Zinc dust, AcOH-water 1:1, reflux, 3 h, 76-81%; c) mCPBA, CH2Cl2, 0°C, 1 h, 85%; d) NaBH4, 
MeOH, 0°C, 20 min, 90%; e) 20% TiCl3(aq), H2O, MeOH, r.t., 3 h, 92%.63 
 
Following the preliminary stereoisomeric and optimisation studies, they next 
constructed the core structures of both pinnaic acid and halichlorine.  Synthesis 
of the halichlorine core began using the nitrone intermediate 147.  1,3-dipolar 
cycloadditon with dipolarophile 153, gave 154 as an inseparable 
diasteroisomeric mixture.  Selective silyl protection yielded 155, before 156 was 
achieved through oxidative ring opening and reduction as previously optimised.  
Cyclisation with mesyl chloride gave a mixture of diastereoisomers 158, which 
was followed by removal of the benzyl protecting group allowing oxidation to 
the corresponding aldehyde to proceed.  Further oxidation and esterification 
gave 160.  Finally, removal of the silyl group gave the target core structure 161 
Scheme 21. 
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Scheme 21.  Synthetic route towards a halichlorine core structure.  a) 153, PhMe, 210°C, MW, 
2 h, 78%; b) TBDPSCl, DMAP, Et3N, CH2Cl2, 0°C to r.t., 1 h, 93%; c) mCPBA, CH2Cl2, 0°C to r.t., 1 
h, 93%; d) NaBH4, MeOH, 0°C to r.t, 30 min, 89%; e) cat. In, Zn, EtOH-NH4Cl(aq) (2:1), reflux, 4 h, 
100%; f) 2 equiv. MsCl, Et3N, CH2Cl2, 0°C to reflux, 6 h, 99%; g)LiDBB, THF, 0°C to r.t., 89%; h) 
Dess-Martin periodinane, 0°C to r.t., 1 h, 80%; i) 1. NaClO2, NaH2PO4, 2-methyl-2-butene, tBuOH, 
0°C, 24 h, 74%; 2. DCC, EtOH, DMAP, CH2Cl2, 0°C to r.t., 24 h, 65%; j) TREATHF, Et3N, MeCN, 
reflux, 4 h, 94%. 
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Chapter 3. Synthetic Studies  
3.1 The History of Nitrones 
Nitrones have the general formula of X-CH=NO-Y.64  The unique functionality of 
nitrones makes them extraordinarily useful substrates and one of the most 
efficient multifunctional compounds, therefore making them the centre of 
extensive research into their actions as both radical spin traps and 1,3-dipoles. 
The use of nitrones as radical spin traps was first reported in 1969, by Janzen 
and Gerlock.  Spin traps are used to detect and identify short-lived free radicals 
by forming a more stable adduct which can be detected by electron 
paramagnetic resonance (EPR).65  α-Phenyl N-tertiary-butyl nitrone (PBN, 162) 
was used in Janzen and Gerlock’s study, and is still one of the most popular 
radical spin traps, along side 5,5-dimethyl-1-pyrroline-N-oxide 163 (figure 3). 
 
Figure 3.  The structures of the most studied and widely used nitrone spin traps. 
 
Early research implicated that nitrones were useful for trapping free radicals in 
chemical systems, which later led to their application as spin trap reagents in 
biochemical systems, consequently leading to the thought that they play an 
active role in anti-ageing.64, 66, 67  The free radical process in biological systems 
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has shown to be much more complex than originally conceived.  By trapping the 
free radicals, oxidative damage to the brain is reduced, thus exhibiting neuro-
protective activity.68  PBN has shown to have general anti-inflammatory 
properties, with a PBN derivative making it to clinical trials as a potential 
protective drug for strokes.69 
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3.2 Preparation of Nitrones 
There are a number of methods employed in the synthesis of both acyclic and 
cyclic nitrones, with most reactions centring on the oxidation of imines, amines 
and hydroxylamines. 
A common route to acyclic nitrones involves the condensation reaction of a 
hydroxylamine with an aldehyde or ketone, which forms a nitrone through an 
iminium ion intermediate (Scheme 22).70  N,N-disubstituted hydroxylamines 
also form nitrones by utilising a wide range of reagents including metallic 
compounds and organic oxidants.   
 
Scheme 22.  The mechanism of action for a condensation reaction, forming a nitrone. 
 
Acyclic and cyclic nitrones can be synthesised from simple tertiary amines.  
Oxidation and elimination forms a hydroxylamine, followed by further oxidation 
with oxidants such as mercuric oxide to produce the corresponding nitrone 
(Scheme 23).70 
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Scheme 23.  A mechanism for a common way to synthesise cyclic nitrones. 
 
Indeed, there are a range of reagents useful in the oxidation of hydroxylamines 
or amines to nitrones. The former transformation can be achieved with 
mercuric oxide,60 manganese dioxide,71 gold nanoparticles,72 triphenylbismuth 
carbonate,73 sodium hypochlorite,74 iodine, tert-butyl hydroperoxide, ceric 
ammonium nitrate,75 hypervalent iodine compounds76 and even by 
electrochemical oxidation.77 A wide range of methods have been developed for 
the conversion of secondary amines to nitrones including alkyl hydroperoxide 
in the presence of titanium catalysts,78 sodium tungstate/hydrogen peroxide,79 
oxone,80 methyltrioxorhenium/hydrogen peroxide,81 urea-hydrogen peroxide 
complex,82 molecular oxygen in the presence of picryl hydrazide with tungsten 
oxide/alumina,83 and  trichloroacetonitrile/hydrogen peroxide.84  
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There have been reported efforts in the synthesis of cyclic nitrones from 
alkylation of oximes and bromocyclisation of oximes for example 164-165, 
although reported yields are low (scheme 24).85 
 
Scheme 24.  A bromocyclisation to achieve a cyclic nitrone.  a) Br2, NaHCO3, 0°C to r.t, 23%.85  
 52 
3.3 Reactions of Nitrones 
The nitrone structure consists of a four electron system, which is shared across 
three atoms, with two π electrons coming from the double bond and two 
coming from a lone pair off the oxygen.   Although it is implied that the positive 
charge resides on the nitrogen, delocalisation between the nitrone and α–
carbon results in a 1,3 dipolar structure (figure 4).86 
 
Figure 4.  The delocalisation of electrons in the 1,3 dipole of a nitrone. 
 
Studies performed on the nitrone models have reported some interesting 
properties.  Of the nitrone 166 and oxime 167 studied (Figure 4), the study 
showed that the nitrone has a shorter N-O bond, 1.284Å, in comparison to 
1.408Å of the oxime.  It also exhibits a longer C=N bond length of 1.309Å verses 
the 1.260Å in the oxime.86  This indicates partial double bond characteristics in 
the nitrone and also supports the delocalisation theory show in figure 5. 
 
Figure 5.  The nitrone 166 and oxime 167 studied.86 
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Since the discovery of the nitrone, many research groups have investigated the 
capabilities of this functional group, some of which will be highlight below.  For 
a more in depth review please refer to the review by Eli Breuer.86  
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3.3.1 Oxidation of Nitrones 
The influence of varying oxidising agents on nitrones has been examined.  
Oxidants such as lead tetraacetate (LTA); Iron (III) salts; periodates; ozone; and 
selenium dioxide are just a few which have been reported to successfully oxidise 
various acyclic and cyclic nitrones. 
LTA has shown to oxidise nitrones with various groups attached including 
ketonitrones, arylaldonitrones and triphenyl nitrone.  The example below 
shows the formation of N-acetoxy-N-acylamine 169 from an arylaldonitrone 
168 through a pentocoordinated lead derivative intermediate Scheme 25. 
 
Scheme 25.  Oxidation of an arylaldonitrone using LTA. 
 
Iron complexes such as ferric chloride and potassium ferricyanide have been 
reported as successful oxidising agents of aldo- and ketonitrones.  The 
aldonitrones produced hydroxamic acids, whereas the ketonitrones such as 170 
can be oxidised first to nitrosoketones 171 then to acids devoid of the nitrogen 
172 Scheme 26. 
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Scheme 26.  An example of oxidising a ketonitrone. 
 
 Selenium dioxide oxidises a methyl or methylene group to the α-position of the 
nitrone.  It has also been reported that oxidation of a pyrroline N-oxide 173 
leads to a six membered ketonitrone 175 by rearrangement of the initially 
formed aldehyde 174 Scheme 27.87 
 
Scheme 27.  Oxidation and rearrangement of a ketonitrone. 
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3.3.2 Reductions of Nitrones 
Reduction of a nitrone can either form an imine or a hydroxylamine, depending 
on the reducing agent used.   
Hydride reducing agents such as sodium borohydride or lithium aluminium 
hydride reduce nitrones to the hydroxylamines as shown in scheme 28.  The 
reaction proceeds by attack of a hydride at the electrophilic α-carbon, followed 
by hydrolysis.  It has been reported that even under vigorous conditions, it 
doesn’t reduce any further. 
 
Scheme 28.  Reduction using sodium borohydride to produce a hydroxylamine. 
 
Zinc dust in acetic acid is just one of many methods employed to remove the 
oxygen.  It occurs through a single electron transfer, and utilises fairly mild 
conditions, although this method is not compatible with acid-sensitive 
compounds.  
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3.3.3  The 1,3 Dipolar Cycloaddition 
The four π-electron component of the nitrone allows the formation of five 
membered rings through a single-step concerted cycloaddition reaction.  The 
[4+2] cycloaddition occurs in the presence of a two-electron component, the 
dipolarophile, such as a simple alkene.   
 
Scheme 29. The mechanism for the [4+2] cycloaddition. 
 
The 1,3 dipolar cycloaddition can be described by frontier molecular orbitals 
(FMO) theory, and the orbital interactions can be classified into 3 different types 
depending on their relative FMO energies between the dipole and the 
dipolarophile.  Type I focuses on an interaction between the HOMOdipole and 
LUMOalkene, implying that an electron withdrawing group is present on the 
dipolarophile; in type II the dipole and alkene have similar FMO energies, which 
makes both interactions important; type III are controlled by interactions 
between the LUMOdipole and HOMOalkene, which would be indicative of an 
electron donating group present on the dipolarophile.   
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The unique functionality of the nitrone means it is both electrophilic and 
nucleophilic, meaning both its HOMO and LUMO interactions are important, it 
is therefore characterised as a type II interaction (figure 6). 
  
Figure 6.  A frontier molecular orbital diagram showing the various types of HOMO-LUMO 
interaction in the 1,3-dipolar cycloaddition. 
 
The FMO approach helps us to visualise the possible outcomes for the p-orbital 
interactions, and can also be useful in predicting the relative reactivity of 
dipole/dipolarophile pairs.  Figure 7 shows the FMO for a typical 1,3 dipolar 
cycloaddition.  It can be seen, following the explanation of the type II 
interaction, that both the HOMOdipole- LUMOalkene and HOMOalkene- LUMOdipole 
give rise to abonding overlap of orbitals and are thus symmetry allowed.  
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Figure 7.  Shows the FMO for the dipole and dipolarophile, leading to two possible transition 
states, depending on the electronegativity of the dipolarophile. 
  
 60 
3.3.3.1 Stereochemistry of the cycloaddition. 
The stereochemistry of cycloadditions, including the Diels-Alder reaction and 
1,3-dipolar cycloadditions can be readily predicted from a knowledge of the 
geometrical isomerism of diene/dipole and alkene partners which makes these 
reactions especially powerful in the preparation of products with multiple chiral 
centres.  
A Diels Alder cycloaddition is stereospecific, meaning that the geometrical 
isomerism of substrates is “locked” into the relative stereochemistry of the 
products.  For instance, reaction of the diene and ethene below gives rise to one 
of two products: 
 
Figure 8.  Showing the differences in the endo and exo reaction, which illustrates why the exo 
product is favoured. 
 The cis-relationship between R3 and R4 arises from the cis-stereochemistry of 
the dienophile substrate. Similiarly, the relative stereochemistry between R1 
and R2 is predetermined by the stereochemistry of the diene. The relative 
steroechemitry between R1/R2 and R3/R4 can also be predicted by the 
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favourability of an endo over and exo transition state in this reaction. In an endo 
approach (the R3/R4 approach), from “underneath” the diene, the approach is 
favoured by secondary π-orbital interactions between R3/R4 and π-orbitals of 
the diene (figure 9).   
 
Figure 9. A representation of an endo orbital interaction in a Diels Alder cycloaddition. 
The alternate, exo-approach is favoured by a reduction in steric effects seen in 
the endo-mode of approach but the secondary orbital effect dominates in the 
Diels-Alder process. 
The 1,3 dipolar cycloaddition is also stereoselective. Specifically with the 
nitrone as the dipolarophile, which contains no secondary π orbitals for 
stabilisation, exo-products predominate. However, the stereochemistry of the 
dipolarophile is retained on conversion to products as in the Diels-Alder 
reaction (figure 10). 
 
Figure 10.  The stereoselective bond formation in a 1,3 dipolar cycloaddition. 
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3.3.4 Nucleophilic Addition to Nitrones 
Nitrones react readily with nucleophiles to give N,N-disubstituted 
hydroxylamines.  A wide variety of nucleophilic reagents have shown to add 
successfully to a number of nitrone structures, including Grignard reagents; 
metalated oximes; sulfones; pyrroles; silylketene acetals etc, although 
organometallic additions are the most widely reported.88   
The addition to nitrone 188, impressively, also proceeds with enolates 189, 
although in this case it is common for the hydroxylamine product 190, to 
undergo a spontaneous intramolecular cyclisation resulting in a substituted 
isoxazolidine 191 (scheme 30).89 
 
Scheme 30. Shows the nucleophilic addition of a lithium enolate, before the spontaneous 
intramolecular cyclisation.  a) THF, -78°C (10 min) then -40°C; b) TMSCl, TEA, -40°C ,19% over 
two steps.89 
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Stereocontrolled reactions can be achieved using chiral additives, this had also 
been explored with regards to addition to nitrones.  Using silylketene acetal 
193, a stereochemically pure pentonalide 195 was achieved.88, 90 
 
Scheme 31.  Shows the stereocontrolled addition of a chiral nucleophile.90 a) ZnI2 (cat.), CH2Cl2, 
-70°C, 0.5 h b) Zn, AcOH, 60°C, 0.5 h. 
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3.4 Project Aim’s 
The ultimate aim of the project was to synthesise a biologically active derivative 
of halichlorine, based on pinnaic acid and halichlorine’s shared 6-
azaspiro[4.5]decane core.  In order to achieve this goal, it was planned to exploit 
nitrone chemistry, using a key nitrone intermediate previously designed by the 
Caprio group, and apply novel synthetic methodology to produce a library of 
compounds.  Biological assays will be performed on each derivative to 
determine if they exhibit any biological activity.  
Due to the complexity of halichlorine, it is a challenge to produce quantitative 
amounts for pharmacological evaluation.  Therefore, it is hoped that the more 
simple derivatives, which are far more accessible will possess some of the 
biological properties of its parent compound.   
The results of these biological screenings may provide an insight as to which 
functional groups are involved in the bio-interaction, which would allow for a 
more specific library of derivatives to be produced in the future. 
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Chapter 4 Additions to [6,5,5]-Spironitrone  
4.1 Synthesis of the Sprionitrone 
To begin this project, quantities of the spironitrone 147 were produced. The 
synthetic route utilised studies by the Gossinger group (Section 2.3.1),60 to 
prepare tricycle 119.  An oxidative ring opening of this isoxazolidine, previously 
developed by the Caprio group, then provides spironitrone 147, (scheme 32).  
 
Scheme 32. The synthetic route used to produce quantities of the spironitrone 147.   
 
The route to tricyclic isoxalidine 119 proceeds from tetrahydropyridine N-oxide 
116.  Thus, addition of a pentenyl fragment followed by oxidation to nitrone 118 
is followed by an intramolecular 1,3-dipolar cycloaddition provides 119 as a 
single diastereomer with the desired relative stereochemistry for the synthesis 
of halichlorine/pinnaic acid. 
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Once produced, the Caprio group functionalised spironitrone 147, via 1,3 
dipolar cycloadditions, with success, though in no systematic manner, as 
discussed in section 2.3. 
This current project aimed to bio-evaluate a range of easily accessible 
spirocyclic scaffolds, based on the structures of pinnaic acid and halichlorine.  
To date, only a very limited study into the addition of Grignard reagents to 147 
have been examined, thus we decided to focus our studies in this area to 
generate a wide range of simple spirocyclic analogues using Grignard reagents.  
It was planned to add a range of ever bulkier alkyl Grignard species from methyl 
to hexylmagnesium bromide and including phenyl, benzyl, pentenyl and allyl 
derivatives. 
The synthesis of nitrogen 147 began with a double SN2 on dibromide 196 using 
hydroxylamine hydrochloride, which neatly cyclised to 115 obtained as a clear 
oil after column chromatography, which solidified upon cooling.  Oxidation of 
115 followed, using mercuric oxide in CH2Cl2.  This reaction was monitored by 
TLC until all the starting material shifted to the baseline in ethyl 
acetate:methanol (9.5:0.5), indicating oxidation to a much more polar species.   
After filtration and concentration, the nitrone was taken further without 
purification, owing to the known instability of this compound.  Using freshly 
prepared pentenylmagnesium bromide under inert conditions, which was 
added via cannula to a cooled solution of 116 in THF provided pentenyl adduct 
117. To maximise product yield it was found important to quench the reaction 
with a small amount of aqueous ammonium chloride and remove the THF prior 
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to further work-up.  Analysis of the 1H-NMR spectrum of product clearly 
confirmed formation of the desired product by the absence of an -proton at 
approximately 7.3 ppm present in a nitrone and two peaks at 4.8-4.9 and 5.7-
5.8 ppm assigned to the alkene functional group of the pentenyl chain. 
Purified 117 then underwent the same oxidation conditions to a second nitrone 
118, which was also used crude.  In this oxidation, two nitrones can be produced 
but the desired, more substituted target predominates.  This is again taken 
through without purification owing to instability issues.   
Formation of 119 proceeds through an intramolecular 1,3 dipolar cycloaddition, 
which was achieved by heating under reflux in toluene, yielding a kinetic [6,5,5] 
cyclo-adduct product (scheme 33). 
 
Scheme 33.  Mechanism of action for the formation of the kinetic [6,5,5] cyclo-adduct 119. 
 
Analysis of the 1H-NMR spectrum clearly shows no peak for the -proton, as 
well as the loss of the two alkene peaks.  The peaks furthest downfield belong 
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to -protons to the oxygen, at 4.2 and 3.4 ppm, indicating the desired product 
was formed. 
The thermodynamic [6,6,5] cyclo-adduct can be formed by applying more heat 
and increased pressure.  We have developed a convenient procedure for this 
transformation using a microwave reactor.  This strategy provides a basis for 
the synthesis of the core structure of histrionicotoxin and will form the basis of 
discussion in chapter 5. 
 
Scheme 34.  Thermodynamic product in the 1,3 dipolar cycloaddition of 118. 
 
The final step towards spironitrone 147 involved a challenging oxidative 
cleavage of the weak N-O bond using meta-chloroperbenzoic acid (mCPBA) 199.  
Nucleophilic attack of the hydroxyl group on mCPBA occurs to give N-hydroxy 
derivative.  Removal of a proton followed by opening of the isoxazolidine ring 
allows the formation of a nitrosonium species.  Deprotonation then forms the 
nitrone functionality in 147.   
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Scheme 35.  Mechanism for the oxidative ring opening of 119. 
 
The reaction is very sensitive to the rate of addition of oxidant and reaction 
concentration.  If this rate is too high then a number of other, possibly partially 
oxidised products are formed.  Thus, success was only achieved using a 7 hour 
drop-wise addition of oxidant as a solution in dichloromethane at 0°C and the 
procedure was thus only successful, and reproducible, on a large scale (above 
3g) when such a rate of addition can be easily maintained to low concentration 
of tricycle 119.  The spironitrone, however, is stable to column chromatography, 
presumably owing to its bulk, and was purified using CH2Cl2:methanol (9.5:0.5) 
as the eluent without much difficulty.   
From the 1H-NMR spectrum it was easily determined that the nitrone was 
present due to a triplet pertaining to -proton 7.  The protons on ‘1, adjacent 
to the oxygen, have also shifted together to form a multiplet at 3.6 ppm 
integrating to two protons, whereas in isoxazolidine 119 they are split, and 
appear as a triplet and a multiplet at 4.2 and 3.4 ppm respectively.  
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Figure 11.  Spironitrone 147. 
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4.2 Nucleophilic Additions to the Spironitrone 
Whilst challenging, the oxidation of 119 to 147 could be routinely performed on 
a 3-4g scale, and indeed performs better on a large scale. With quantities of the 
spironitrone in hand, the next step was the addition of the Grignard species to 
create a library of spirocyclic analogues.  Some of the Grignard reagents were 
commercially available, and the rest were prepared freshly when required.  The 
reaction conditions remained the same throughout, irrespective of the Grignard 
species employed, using inert conditions and addition at 0°C, with the only 
difference being a change in solvent (either diethyl ether or THF) when solubility 
of the resulting magnesium alkoxide salt initially transferred became an issue 
(scheme 36).  
 
Scheme 36.  The mechanism of action for the nucleophilic additions to spironitrone 147. 
 
Upon addition of the Grignard reagent, (RMgBr = Me, Et, Pr, Pentyl, Ph, Bn) 
analysis using thin layer chromatography of the reaction mixture quenched with 
saturated aqueous NH4Cl, displayed new bright permanganate-active product 
spots, with an RF much higher than the RF of the nitrone, which indicated 
conversion of a nitrone to a less polar hydroxylamine.  Unfortunately, upon 
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purification by flash column chromatography, separation of these spots proved 
challenging.  This is possibly due to the presence of adduct diastereoisomers 
eluting directly after one another, although only single diastereoisomers have 
been isolated in these studies.  In order to resolve this issue, the substituted 
hydroxylamines were instead reduced without isolation.  Purification of these 
compounds by column chromatography was significantly easier than the free 
amine using CH2Cl2: methanol (9:1) as the eluent, and only one spot was evident 
on TLC.   
 
NMR studies were then carried out on each of the substrates to confirm the 
desired product had been formed, and to determine stereochemistry.  Analysis 
of the methyl-adduct 205 displayed the characteristic peaks you would expect 
to find on a 1H-NMR of these adducts.  For instance, the spectrum of the methyl 
adduct displayed a doublet at 1.2 ppm integrating for three protons indicative 
of a methyl group to the desired position on the spirocyclic ring.  Additionally a 
proton, -to the nitrogen atom was observed to resonate at 3.42-3.5 ppm, as 
well as the protons on C1 split at 3.5-3.6 ppm and 3.7-3.8 ppm, (figure 12). 
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Figure 12. 1H-NMR of the N-acetylated methyl adduct 205. 
The spectra of other alkylated products (R= Et, Pr etc) all displayed a 
characteristic triplet at 0.8-0.9 ppm, indicating incorporation of an alkyl chain. 
Intriguingly, on closer inspection of all NMR spectra of these adducts, a singlet, 
integrating for three protons, was observed at 1.9 ppm. This peak was not 
always easily discernable as it often appeared overlaid onto the envelope of 
hydrocarbon-like proton resonances between 1.1 and 2.0 ppm. This 
observation led us to postulate that N-acetylation has occurred in-situ – a 
theory that was backed up by high resolution mass spectral analysis of each 
adduct- to provide a range of N-protected substrates (figure 13).  
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Figure 13.  Structures of N-acetylated reduced compounds 205-210. 
 
Although unexpected and not the desired derivatives of choice, these six 
compounds may still be of biological interest.  The additional N-acetyl group, 
may merely act as a prodrug, by aiding with the administration/solubility of the 
compound, as well as potentially reducing drug toxicity, or facilitate in 
delivering the drug to a specific area.  These compounds were also far easier to 
purify, making them more manageable to reproduce. 
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4.2.1 Stereochemistry of the acetylated cycloadducts 
The relative stereochemistry of addition was determined by analysis of the 2D-
NOESY spectra obtained for each adduct. The adduct can adapt either of two 
conformers with the newly introduced R-group in an axial or equatorial 
position. Examination of the structure of each possible conformer, arising from 
attack of a Gringard reagent on the opposite face as the hydroxymethyl group 
(a, a) (figure 14), indicates that equatorial oriented conformer (a) is most likely 
lower in energy owing to steric hindrance likely to occur in conformer (a) 
between the alkyl chain and protons on C4.  Introduction of the R-group on the 
same side as the hydroxymethyl group gives rise to two additional conformers 
(b, b).  Here, b is most likely lower in energy due to steric hindrance between 
R/ CH2OH in conformer b.  
 
Figure 14.  Possible conformers generated from a nucleophilic addition of a Grignard species to 
nitrone 147. 
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Comparison of the two preferred conformers above indicates that observation 
of NOESY cross peaks between the proton -to the nitrogen at C7 and the 
hydroxymethyl protons (C1), indicates attack from the opposite face the 
hydroxymethyl moiety, while cross peaks between protons on C4 and C7 
indicate attack on the same face as the hydroxymethyl (figure 15). 
 
Figure 15.  The different sides of attack leading to conformers a, a; and b, b. 
 
Analysis of the NOESY spectra of N-acetylated methyl adduct 205 clearly 
indicated a correlation between H7 and H1 strongly suggesting the formation 
of comformer a.  This coincides with the stereochemistry gained from previous 
work published by the Caprio group throughout the series of cycloadditions.63  
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Table 2.  Reductions of the spirocyclic adducts with zinc powder, with the addition of an acetate 
group. 
Entry R group Acetate adducts Yield (%)1 
1 Methyl 205 44 
2 Ethyl 206 38 
3 Propyl 207 47 
4 Pentyl 208 40 
5 Benzyl 209 61 
6 Phenyl 210 42 
1Yield over 3 steps.  
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4.3 Indium-Mediated Reductive Method 
In order to resolve the issue of the addition of an acetate during reduction of 
hydroxylamines yielded via Grignard addition to nitrone 147, an alternative 
reductive method was proposed.  Indium powder as the reductant was chosen 
as literature shows this reagent conveniently reducing hydroxylamines to 
amines under mild conditions.63 91 
Following the method developed by the Goti group,91 a convenient nucleophilic 
addition of the Grignard species, followed by an indium-mediated reduction in 
a one pot process was carried out.  Under inert conditions, the Grignard species 
were added via syringe to the cooled solution of either diethyl ether or THF.  
Again, a range of alkyl, aryl and alkenyl Grignard reagents were examined.  After 
warming to room temperature and allowing to stir for 12 hours, the reaction 
mixture was quenched with saturated aqueous NH4Cl: ethanol (1:2) and 
stoichiometric amounts of indium powder, this was heated under reflux for 5 
hours.   Upon completion quantities of saturated aqueous NH4Cl were added 
before extraction with diethyl ether.  The reduced products formed very streaky 
spots on TLC, owing to the formation of a free amine.  Nevertheless, the 
compounds were purified by flash column chromatography using CH2Cl2: 
methanol (9:1) as the eluent.  The adducts were difficult to fully purify, probably 
due to how much they streaked down the column, but a range of adducts that 
was aimed for was achieved, (figure 16).  With these results in hand, NMR 
spectral analysis was conducted to confirm structure and stereochemistry. 
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Figure 16. Spirocyclic amines synthesised via Grignard addition/ indium reduction one pot 
method. 
As per the previous adducts, formed via Grignard addition using Zn/AcOH 
methodology. NMR spectra readily confirmed the formation of the desired 
adducts. A doublet at 1.4 ppm, revealed addition of a methyl group to give 
adduct 211 while the presence of easily discernable triplets at 0.85 ppm 
indicated addition of increasingly sizeable alkyl chains to yield adducts 212-216. 
The presence of absorbance’s in the aromatic region between 7.2 and 7.4 ppm 
confirmed the addition of phenyl rings to give 217/218 while two peaks in the 
NMR spectrum of compound 219 at 5.0 and 5.7 ppm confirmed addition of an 
allyl moiety. 
The use of NOESY spectra to determine relative stereochemistry here was 
complicated as the important proton resonances for C7/C1/C1’ often 
overlapped. In contrast to the N-acetyl adducts the two hydroxymethyl protons 
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at C1’ split into two signals at around 3.5 and 4.0 ppm with the later overlapping 
with the C7 proton resonance, which also signals at 3.5 ppm (figure 17a).  Thus 
NOESY cross peaks between either C7/C1  or C1’/C1 (both resonating at 3.5 
ppm/ 2.45 ppm) could not be unambiguously identified.  
 
Figure 17a.  1H-NMR spectrum of the propyl adduct 213. 
 
Figure 17b.  NOESY spectrum of the propyl adduct 213, showing the cross peaks for overlapping 
peaks C1’/C7. 
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Taking into consideration the stereochemistry of compounds of a similar 
structure, where the orientation of the R-group on C7 prefers attaching on the 
opposite face to the hydroxymethyl group, it is logical to assume that these have 
adopted the same orientation.  
 
Table 3. Grignard addition/ indium reduction onto nitrone 147. 
 
1Yield over 2 steps; 2NMR contained impurities; 3 Mixture of diastereoisomers. 
 
Entry R group Cycloadducts Yield1 (%) 
1 Methyl 211 42 
2 Ethyl 212 272 
3 Propyl 213 29 
4 Butyl 214 43 
5 Pentyl 215 44 
6 Hexyl 216 34 
7 Benzyl 217 32 
8 Phenyl 218 67 
9 Allyl 219 553 
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The results of the additions are summarised in Table 3. In general yields are 
slightly lower than those obtained for addition/reduction/acetylation probably 
owing to the difficulty in purifying these polar amines. However, it should be 
borne in mind that three transformations are achieved in one pot and all 
products are obtained as single diastereomers with three chiral centres. 
Furthermore, sufficient quantities were obtained for some detailed biological 
evaluations described in chapter 7. 
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4.4 Further studies into the allyl-adduct 
The allyl adduct 220, with its useful terminal alkene group, potentially provides 
access to a host of useful analogues. In particular, analogues closely matching 
the core structure of pinnaic acid/halichlorine could be accessed by RCM of 
compounds 221 and 222, readily derived from this compound. 
 
Scheme 37. Proposed synthesis of the Pinnaic acid core strcture from allyl adduct 220. 
 
Indeed, a similar strategy has been previously adopted to access these core 
structures. For instance, diene 224 underwent RCM to provide tricycle 225 in 
near quantitative yield.92 
 
 
 
 84 
 
Scheme 38. RCM-based synthesis of the Halichlorine core structure.93  
 
Additionally, the core of pinnaic acid 227 was accessed by cross metathesis of 
N-protected, allylated spirocycle 226.94 
 
Scheme 39.  RCM-based synthesis of the Pinnaic acid core structure.93 
 
Unfortunately, while all other Grignard adducts were isolated as single 
diastereomers, the allyl adduct was obtained as a diastereomeric mixture which 
could not be separated on column chromatography. These were separated as 
the N-hydroxy derivatives obtained by omitting the reduction step after 
addition of the Grignard reagent. This was achieved albeit with great difficulty, 
as the spots sat  directly above one another,    (RF values of 0.67 and  
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0.73. A single diastereomer was obtained cleanly in 3% yield. NOESY studies 
indicated that this exhibited undesired relative stereochemistry arising from 
addition of the allyl group from the “bottom” face as seen during addition of 
other Grignard reagents. Unfortunately, the other diastereomer could not be 
obtained cleanly. It was attempted to protect this compound as a silyl ether 228, 
as a prelude to functionalising towards the pinnaic acid/halichlorine core as 
outlined above. Unfortunately, this proved unsuccessful, with analysis of 1H and 
13C NMR spectra exhibiting evidence of the protecting group, but additional 
peaks were also present.  Accurate mass of this sample did not detect the 
desired mass. 
 
Scheme 40. Studies into protection of the hydroxyl group. 
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Chapter 5 Additions to 6,6-Spironitrone 
This chapter focuses on investigations into the synthesis of the histrionicotoxin 
core structure and analogues. As outlined in section 2.3, this natural product is 
isolated from the skin of poisonous tropical frogs of the Dendrobates species. 
Histrionicotoxins are known to be noncompetitive inhibitors of neuromuscular, 
ganglionic and nicotinic acetylocholine receptors.57  Inhibitors of such neuron 
receptor proteins will inhibit the main function of the receptors, being 
transmission of signals at neuromuscular junctions and in the central and 
peripheral nervous systems.95 
The unusual neurological effects these compounds possess makes them of 
interest to the biochemist, with various research groups exploring the biological 
capabilities and structural variations such as the Holmes group and the group 
of Stockman.57, 61 
Despite this interest, the HTX core structure has proven quite resistant to the 
development of suitably flexible synthetic approaches that can generate 
libraries of analogues. For instance there are very few analogues at the C2 
position of this molecule.  Given the obvious structural similarity between the 
6,5-azaspirodecane core of pinnaic acids/halichlorine and histrionicotoxins, we 
envisioned application of our approach to the former to access HTX-like 
molecules with a variety of substituents at the C2 position. The group of 
Gossinger discovered that cycloadduct 119 utilised by us towards halichlorine 
could be converted to the isomeric 6,6-isoxazolidine by heating in toluene in a 
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sealed tube at 220C. Indeed, the 6,5-adduct 119 is the kinetic product of this 
internal cycloaddition while the 6,6-adduct 198 is the thermodynamic adduct 
(scheme 41).  
 
Scheme 41. Conversion of kinetic product 119 to thermodynamic product 198.   
 
Unfortunately, in order to access the thermodynamic adduct, the reactions 
conditions have to be quite forceful, and conversions of substituted 
cycloadducts such as the attempted conversion of 229 to 230, which does not 
proceed (scheme 42).60  
 
Scheme 42.  The attempted conversion of kinetic product 229 to thermodynamic product 230. 
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The relatively high activation energy towards the [6.6.5]-tricyclic can be 
attributed to destabilising 1,3-diaxial interactions in the transition state, 
scheme 43.  This has been further investigated further by Holmes et al., who 
applied computer modelling to this problem, which revealed that there is a 
relatively poor overlap between the requisite dipole/ alkene orbitals involved 
in the reaction due to poor alignment of the reacting groups.   
 
Scheme 43.  A predicted transition state during the formation of the [6,6,5]-tricycle 198, 
showing the destabilising 1,3-diaxial interactions. 
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5.1 Synthesis of the 6,6-Spironitrone 
Using the methodology previously outlined by the Gossinger group,60 and the 
information by Holmes,61 we postulated that we could access quantities of the 
[6,6,5]-tricyclic adduct through applying more energy to achieve the more 
stable thermodynamic product.   
We envisioned that the potentially hazardous thermodynamic cycloaddition, 
affected in a sealed tube, could be more conveniently, and much more safely, 
achieved with a microwave reactor which utilises thick glass walled, pressure-
capped, reaction vessels. Here the reaction is performed within the 
instrumentation, which protects the experimentalist from any hazards due to 
the development of high pressures and reaction can be routinely performed at 
pressures up to 30 bar.  Indeed, heating a toluene solution of cycloadduct 119 
at 220C and a pressure of 4 bar lead to the formation of a product spot on tlc 
with a RF close to the original cycloadduct. However, despite running the 
reaction over prolonged periods, up to 2.5 hours, the reaction only proceeded 
to about 50-60%, although the kinetic tricycle was easily collected and recycled. 
Nevertheless, both components were readily separated by column 
chromatography and NMR analysis of the newly formed compound indicated it 
was the desired 6,6-spiroadduct.  
 
Analysis of the 1H-NMR spectrum shows clear distinctions between the 6,5-
cycloadduct and the 6,6-cycloadduct.  The main change being the -proton to 
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the oxygen, where in the 6,5-cycloadduct there are two peaks integrating to 
these protons, there is now only one.  Evidence from the DEPT 135 also confirms 
that C8 is a methine, rather than a methylene carbon.  
 
Figure 18.  1H-NMR spectrum of the [6,6,5]-cycloadduct 165 product. 
 
With quantities of the 6,6-cycloadduct 198 in hand, conversion to the nitrone 
derivative 231 was performed, applying our previously developed oxidative ring 
opening methodology (scheme 44). The reaction proceeded without much 
difficulty, utilising slow addition of a mCPBA solution followed by flash column 
chromatography using eluent 9.5:0.5, CH2Cl2:MeOH as eluent gave a 6,6-
spironitrone in a 60% yield.   
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Scheme 44. Conversion of [6,6,5]-cycloadduct 198 to spironitrone 231. 
 
Analysis of the 1H-NMR spectrum and comparison between the 6,5-spironitrone 
again shows a difference in integration for the -proton to the hydroxyl group 
at 3.85 ppm, the distinctive nitrone triplet can also be seen at 7.1 ppm.  
 
Figure 19.  1H-NMR spectrum of the 6,6-spironitrone 231. 
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5.2 Cycloadditions to the 6,6-Spironitrone 
We envisioned that cycloadditions to the 6,6-spironitrone 231, could be carried 
out in the same manner as the 6,5-spironitrone,63 without great difficulty.  It 
was planned to conduct a small number of cycloadditions using various 
substrates with terminal alkenes, both electron rich and electron poor 
substituents.  A list of substrates attempted are tabulated below.   
 
Table 4.  Cycloadditions onto spirocyclic nitrone 231. 
 
 
Entry R1 R2 Solvent Temp (C) Cycloadduct Yield 
(%) 
1 Ph H PhMe 110 232 25 
2 COCH3 H EtOH 40 233 41 
3 COCH3 H PhMe 110 233 0 
4 H CO2CH3 PhMe 110 234 46 
5 CO2CH3 CO2CH3 PhMe 110 235 0 
6 CN H CH2Cl2 25 236 0 
7 CN H EtOH 40 236 0 
8 CN H PhMe 110 236 0 
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These cycloadditions proved more challenging than originally perceived.  Whilst 
monitoring the reactions by tlc, the loss of starting material was seen, with the 
appearance of numerous new spots.  The general work up for these 
cycloadditions involved removal of the solvent before purification by flash 
column chromatography.  This was difficult, and analysis of the different 
fractions collected by 1H-HMR suggests the formation of diastereoisomers.  
A number of these cycloadditions (entries 3, 5-8) resulted in the formation of 
very complex product mixtures, especially the addition of acrylonitrile, which, 
after trying various reaction conditions didn’t produce the desired results.  
However, three of these (entries 1, 2 and 4) were successful.  The formation of 
the desired cycloadduct could be readily discerned by analysis of the relevant 
1H NMR spectra. Spectra of cycloadduct 232 exhibited a key absorbance at 5.06 
ppm assigned to the proton as C3 along with aromatic signals between 7.19 and 
7.37 while the 1H NMR spectrum of cycloadduct 233 possesses key signals 
between 5.11-5.39 assigned to C2’ and additionally, a singlet at 3.70 ppm,  
arising from the presence of the newly introduced methyl group associated with 
the acetate at C3”.  The spectrum of the cycloadduct arising from addition of 
methyl acrylate, 234, was complicated possibly due to the presence of 
inseperable diastereoisomers as a number of peaks are doubled up. 
Nevertheless, mass spectral analysis of this product indicated that the reaction 
produced the desired product. 
Unfortunately, NMR studies have been unable to definitively assign relative 
stereochemistry, as key protons overlap in the 1H-NMR spectra.  Diagnostic 
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NOESY spectrum cross peaks can be predicted by examination of cycloadduct 
conformers, which are more complex for the cycloadditions than those in 
section 4.2.1.  
Figure 20 displays the possible conformers arising from cycloaddition from the 
“top” face, the same side as the hydroxyl group.  Each conformer arises by 
flipping of the chair conformations of each 6-membered ring in turn. 
Conformers a and b are expected to be minor conformers due to steric 
hindrance between C3 and C3’ on conformer a and C2 and C2’ on conformer b, 
while conformers c and d are thus major conformers expected, and thus, upon 
analysis of the NOESY, you should find correlations between protons on C2 and 
C11.  
 
Figure 20.  The possible conformers of a cycloaddition if attack occurs from the top face. 
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Alternatively, attack from the bottom, opposite to the hydroxyl group gives 
conformers a and b major conformers, where correlations should be observed 
between C2 and C4’, figure 21.  Conformers c and d would be minor conformers, 
again, due to steric hindrance between the 5-membered ring on the isolazidine 
and the hydroxycyclohexane ring. 
 
Figure 21.  The possible conformers of a cycloaddition if attack occurs from the bottom face. 
 
Unfortunately, upon analysis of the 1H-NMR and NOESY spectra, it was 
discovered that protons on both C2 and C4’ reside under the same multiplet, 
and therefore we cannot use NOESY to unambiguously determine 
stereochemistry for these structures at the present time.  Upon referring to 
previous cycloadditions to the 6,5-spironitrone, we can reasonably assume that 
the exo isomer would result but we are unable to determine relative 
stereochemistry at C3’ at present, figure 22. 
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Figure 22.  Shows the expected stereochemistry for the series of cycloadditions, with the 
unassigned conformation of C2”. 
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5.3 Grignard Additions to the 6,6-Spironitrone 
With small quantities of the 6,6-spironitrone in hand, the next aim was to 
produce a small library of alkyl derivatives through the addition of Grignard 
reagents to spironitrone 231.   
 
Scheme 45.  Addition of Grignard reagents onto spironitrone 231. 
 
It was envisioned that the reactions would proceed in a similar fashion, with 
comparable levels of success, to the previous nucleophilic additions to the 6,5-
spironitrone (section 4.2), unfortunately this was not the case.   The only 
previous example of the synthesis of mono, C -2 functionalised derivatives of 
histrionicotoxin  (Section 2.3.3) reveals that an alkyl chain, in this case a 
pentenyl chain, has been previously added.62 
The reactions conditions were as previous, under inert conditions throughout, 
trialling both diethyl ether and tetrahydrofuran as solvents.  TLC analysis 
showed a number of product spots, but upon purification by flash column 
chromatography, entries 1, 3-6 (table 5) formed complex mixtures.  During 
attempted addition of a propyl group (Entry 1), analysis of both 1H and 13C NMR 
spectra indicated a reduced spirocycle had formed, with no alkyl chain present.  
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This may have arose from reduction of the spirocyclic nitrone, indicating that 
no addition of Grignard reagent took place. 
Unfortunately, we were only successful in attaching the hexyl group onto the 
6,6-spironitrone.  This may have been partially due to the small scale these 
reactions were conducted on (approximately 60 mg).  
The 1H NMR spectrum did closely match that obtained by Gessner and co-
workers for pentenyl-substituted azaspirocycle 146b, (figure 23). The proton 
spectrum for this compound exhibited peaks at 3.98 ppm for H-8 and at 2.85 
ppm for H-2. While the 1H-NMR spectrum for 240 exhibits peaks at 3.70 ppm 
assigned to   H-8 and 2.88 ppm assigned to H-2.  Mass spectral analysis also 
confirmed a product with the desired molecular mass had been isolated. 
 
Figure 23. The pentyl adduct 146b synthesised by the Brossi group.62 
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Table 5.  Shows the reaction conditions for the attempted nucleophilic additions onto the 6,6-
spironitrone 231. 
 
 
Entry R group Solvent Cycloadduct Yield1 (%) 
1 Propyl Diethyl ether 236 0 
2 Butyl Diethyl ether 237 0 
3 Pentyl Diethyl ether 238 0 
4 Pentyl THF 239 0 
5 Hexyl Diethyl ether 240 23 
6 Hexyl THF 241 0 
1 Yield over two steps. 
 
We can try and predict the stereochemistry of these cycloadducts by 
investigating the possible conformers of the nitrone and hence the presence of 
any exposed faces to cycloaddition.  The nitrone has four possible conformers, 
as it has two rings and each of these rings can be flipped. It is therefore easy to 
ascertain that there are four possible product conformations.  Inspection of 
these conformers, should provide an indication of expected relative 
stereochemistry of addition (figure 24). 
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Figure 24.  The possible conformers of spirocyclic nitrone 231. 
 
Unfortunately, there are no obvious candidates for high or low energy 
conformers amongst A-D and hence it is difficult to predict the diastereofacial 
preferences of dipolarophiles or Grignard reagents by simple inspection of 
these conformers. 
 
Furthermore, due to the low amounts obtained, we were unable to obtain an 
adequate NOESY spectrum to confirm stereochemistry.  Due to the likeness of 
the 1H- NMR spectrum, we could reasonably assume the same stereochemistry 
has been obtained. 
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Chapter 6 Alternative Routes to Access Spirocyclic Structures 
Functionalisation of 6,5-spironitrone 147 provides excellent access to a range 
of C2-analogues of halichlorine/pinnaic acid. However, the relative 
stereochemistry of products obtained is not that observed in the natural 
products and this strategy is less than flexible as nitrone 147 must be 
functionalised directly only providing access to hydroxymethyl-substituted 
products. Owing to problems encountered in the stereoselectivity of addition 
of alkenes and Grignard reagents to hydroxymethylnitrone 147 we became 
interested in attempting preparation of O-protected nitrone 242 and 243, 
(figure 25).  
 
Figure 25. The bulky silyl protection groups of interest. 
 
The presence of a bulky silylether may cause adoption of an alternate nitrone 
conformer where the “bottom” face is occluded leading to formation of 
products with relative stereochemistry matching that of the natural products 
(figure 26). 
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Figure 26.  The expected conformer of a silyl-protected 6,5-spironitrone. 
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6.1 Alternative Methods to Ring Open the Isoxazolidine  
It was envisaged that the 6,5-spironitrone could be accessed by reductive 
cleavage of 119 followed by O-protection followed by direct oxidation of the 
amine to the nitrone (scheme 46). 
 
Scheme 46.  Shows the proposed route to accessing an O-protected spironitrone. 
 
The tricycle 119 was reductively ring opened using zinc and acetic acid, 
producing 244 in a good yield.  Unfortunately, it was later discovered that like 
the allyl reductions, the zinc/ acetic acid method seemed to, on occasion add 
an acetate group onto the nitrogen (section 4.2).  Reductive ring opening of 119 
using indium powder was tried, although this was unsuccessful. 
The next step in our synthetic route required protection of the free OH as a silyl 
ether, (table 6).  Silylation as either a TBDMS or TBDPS ether was trialled under 
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a variety of conditions.  Protection of the hydroxyl group occurred without 
issue, and were purified without much difficulty. 
 
Table 6. Protection of the C1-hydroxy group as a silyl ether. 
 
 
Entry Protecting group Base Product Yield 
1 TBDPSCl Imidazole 242 54 
2 TBDPSCl TEA 242 59 
3 TBDMSCl Imidazole 243 63 
4 TBDMSCl TEA 243 52 
 
With quantities of 242 and 243, studies to oxidise these to the corresponding 
nitrone were investigated.  A literature study on similar oxidations of amines to 
nitrones (reviewed in section 3.2) provided a number of possible methods to 
access the key nitrone intermediate.  Table 7 shows the numerous oxidation 
reagents used, as well as changes in the reaction conditions to help aid the 
oxidation, these included using sodium tungstate/ H2O2;79, 96 oxone97 and 
titanium isopropoxide.80  The peroxide/ sodium tungstate system has been used 
with success in the oxidation of spiro-amines close in structure to 242/243 
(scheme 47).98 
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Scheme 47. A successful oxidation using hydrogen peroxide and sodium tungstate.98 
 
Oxone has also been used with success to oxidise relatively complex alkaloid 
skeletal, such as 249 to the corresponding nitrones 250a/250b, (scheme 48).80 
 
Scheme 48. A successful oxidation using oxone and EDTA. 
 
Unfortunately, both the tungstate-mediated oxidation and the oxone-based 
methodology proceeded without success.  The most promising of these 
oxidations was the sodium tungstate and hydrogen peroxide method.  The TLC’s 
during the monitoring of this reaction displayed the UV active bright spot you 
would expect from the nitrone.  Although this was performed on a 100 mg scale, 
so this may have contributed to the difficulties experienced in getting the 
desired product from this reaction.  
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Table 7.  Reagents screened for oxidation of spirocyclic amines, with the hydroxyl group both 
TBDPS protected 242, and deprotected 244 to nitrones. 
 
 
Entry Amine Oxidant  Catalyst Solvent Temp. 
(C) 
Nitrone1 
1 244 Oxone EDTA MeCN 5 147 
2 244 H2O2 Na2WO42H2O MeOH 0 147 
3 242 Oxone EDTA MeCN 5 251 
4 242 Cumene 
H2O2 
Ti(O-Pr)4 CHCl3 0 251 
5 242 H2O2 Na2WO42H2O MeOH 0 251 
6 242 H2O2 Na2WO42H2O Acetone 25 251 
7 242 H2O2 Na2WO42H2O/ 
TBAB/ K2CO3 
CH2Cl2 0 251 
8 242 H2O2 Na2WO42H2O/ 
Et4NCl/ K2CO3 
CH2Cl2 0 251 
1 0% yield. 
 
After unsuccessfully attempting to directly oxidation to the spironitrone 147 
from 119 or 242 alternative methods were required.  The group of O’Neil have 
developed a strategy to access N-hydroxy amines by Cope elimination of the N-
oxides of -cyanoethyl tertiary amines. Thus, cyanoethylamine 252 was 
oxidised with mCPBA to give the N-oxide 253 which underwent Cope-
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elimination in situ to the hydroxylamine 254. The latter process involves the 
thermal decomposition of an amine oxide, via a five-membered cyclic transition 
state (scheme 49).99   
 
Scheme 49.  The cope elimination method to access N-oxide intermediates.99 
 
The theory being that nucleophilic addition of a nitrile onto the free amine 
followed by oxidation would displace the nitrile group yielding the desired 
nitrone, (scheme 50).  Unfortunately, attempted additions of acrylonitrile to 
spiro-amine 242 were unsuccessful, which may have been due to steric reasons, 
with such a bulky protecting group attached. 
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Scheme 50. Synthesis of Spironitrones by Cope Rearrangement of N-oxo- -cyanoethylamines 
 
Alternatively, attention was moved to the studying the chemistry of the C1-
hydroxy group.  This functionalised pendant is a potentially useful tool to 
synthesise a range of C1-substituted pinnaic acid/halichlorine analogues.  
Theoretically, oxidation of the hydroxyl group to an aldehyde will then allow, 
through the use of Wittig reagents, a range of alkene derivatives (scheme 51).   
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Scheme 51.  Proposed synthetic route towards extending the pendant chain. 
 
The amine on 242 was protected with trifloroacetic acid (TFAA) 258, before the 
removal of the silyl protecting group.  Unfortunately, this was far more 
challenging than theoretically predicted.  The removal of the silylether was tried 
with both hydrofluoric acid and pyridinium p-toluenesulfonate (PPTS) without 
success, this was possibly due to steric factors hindering the release of the bulky 
protecting group.  We therefore opted to attempt TFA-protection of the more 
labile TBS-ether 243 followed by deprotection. Unfortunately, this was 
unsuccessful (table 8). 
 
 
 
Table 8.  Reagents screened for deprotection of the silylethers on 207/208 to the free hydroxyl. 
 
 
Entry Silylether Reagent Equiv. Solvent Temp. (C) 
1 242 TEA-HF 10 MeCN 0 then 25 
2 242 PPTS 10 CH2Cl2 30 
3 242 PPTS 30 CH2Cl2 25 
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4 243 TEA-HF 10 MeCN 0 then 25 
5 243 PPTS 10 CH2Cl2 30 
6 243 PPTS 30 CH2Cl2 25 
 
 
 
  
 111 
6.2 Di-alkenyl Additions to Access a Spirocyclic Core 
We also became interested in synthesising unsubstituted spirocycles of general 
structure 264 which we postulated could be accessed by RCM of a bis-alkenyl 
precursors 265. These compounds would allow investigation into the effects of 
C7-substitution on bioactivity without interfering effects from C1 functionality, 
(figure 27). 
 
Figure 27. Retroanalysis of the intended RCM route. 
 
It was envisioned that utilising the previous method of a Grignard addition onto 
nitrone 117, the hydroxylamine product 266, could be synthesised by iterative 
Grignard addition/nitrone generation. Oxidation using mercury oxide could 
then provide the target nitrone systems 267. This route could also provide 
convenient access to spirocycles 268, in a variety of ring sizes including that seen 
in the HTX family of compounds (scheme 52). 
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Scheme 52. RCM-based synthetic route to various ring size spirocycles.  
 
Firstly, a small range of Gringard additions to 116 were investigated.  The 
product obtained from addition of a vinyl group was extremely difficult to 
purify, although mass spectral analysis indicated the correct compound was 
formed. Additions of allyl and butenyl groups proceeded with more success  
(table 9).  
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Table 9. Series of mono-additions to nitrone 116. 
 
 
Entry R1MgBr Solvent Product Yield (%) 
1 Vinyl Diethyl 
ether1 
269 0 
2 Vinyl THF 269 182 
3 Allyl Diethyl 
ether2 
270 0 
4 Allyl THF 270 232 
5 Butenyl THF 271 372 
6 Pentenyl THF 117 552 
1Solubility issues ; 2Contained impurities. 
 
Next, the mono-adducts were converted back to a nitrone using the HgO-based 
method employed previously.  This reaction was monitored by TLC, and when 
the spot had moved to the baseline, the reaction mixture was filtered through 
a pad of sodium sulphate and Celite and concentrated under reduced pressure. 
No attempt to purify these mono-substituted nitrones was made at this stage, 
owing to potential problems arising from degradation of these unstable 
molecules.  Further functionalisation by addition of a second set of unsaturated 
Grignard reagents was then attempted.  These included additions of vinyl- or 
allylmagnesium halides groups, (table 10). 
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Table 10. Series of Grignard additions onto mono-additions 101, 231. 
 
 
Entry Starting 
material 
R2MgBr Temp. Product Yield (%) 
1 271 Allyl -78 272 211 
2 271 Vinyl 0 then 25 273 301 
3 117 Vinyl 0 then 25 274 411 
4 117 Allyl 0 then 25 275 0 
1NMR spectra contained impurities. 
 
 NMR spectral analysis of these reactions did indicate complex mixtures and 
thus purification of these di-additions was difficult, and we were unfortunately 
unsuccessful in isolating products with very high levels of purity. Nevertheless, 
accurate mass data did indicate successful formation of the target dienes.  This 
would also explain the complexity of the NMR analysis.  RCM was attempted on 
274 (scheme 53), which did display formation of a  new compound on TLC, 
although comparison of 1H- and 13C NMR between 274 and spirocycle 276, 
revealed few visible differences. Once again accurate mass analysis did indicate 
that the desired spirocycle has formed.  
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Scheme 53.  Attempted RCM of diene 274 to spirocycle 276. 
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Chapter 7.  Biological Studies 
The aim of this section of work was to identify any biological activity for the 
easily accessible halichlorine analogues discussed in chapters 4-6.  Two 
biological assays were conducted to determine if these molecules potentially 
possess any bioactivity.   
A variety of 19 compounds were selected from the derivatives produced, 
summarised in scheme 54. The names have been abbreviated to reflect the 
structure of the anlaogue  (for instance EthylAc signifies ethyl substitution at C-
7 and presence of an N-acetyl group, i.e compound 206).  Stock solutions of 
each compound were prepared at 10-3 M, made up in DMSO.  Serial dilutions in 
cell culture media from the stock gave working solutions of 10-4 M and 10-5 M 
that were tested in two biological in vitro assays to determine their effect on 
cell growth/viability and nitric oxide (NO) production. 
Both assays were independently performed on both undifferentitated U937 
cells and LPS activated U937 cells. 
The findings were statistically analysed on SPSS, using an ANOVA test. 
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Scheme 54. A summary of the compounds tested in the biological assays, with the abbreviations 
used in the graphs. 
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7.1  Cell Culture 
U937 cells were cultured using RPMI-1640 medium containing 25mM HEPES 
and L-glutamine supplemented with foetal bovine serum (FBS), and 1% 
penicillin.  Cells were incubated in a humidified atmosphere of 5% CO2 at 37°C, 
and all cell culture techniques were performed under adequate aseptic 
conditions to prevent contamination.  The cell concentration was maintained 
below 1.5 x 106 viable cells/ ml, by centrifugation and re-suspension in fresh 
medium every 2-3 days.  
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7.2 Growth and Viability Assays 
This assay was conducted in order to determine if the growth or viability is 
affected upon coming into contact with the compounds.  Using 96 well plates, 
six replicates of each molecule at both concentrations (10-4 M and 10-5 M), as 
well as six replicates of DMSO (vehicle) controls at the same concentrations as 
negative controls were performed, with the final cell concentration set to 
0.5x106 viable cells/ ml. 
Cell viability was assessed using trypan blue solution (0.4%), which stains dead 
cells blue.  The viable cell counts were obtained using a Bio Rad TC20TM 
automated cell counter.  Viable cell counts were taken from each of the six 
replicates, using an equal volume of cell suspension to trypan blue solution. The 
average replicate reading was compared to the average viable cell count taken 
from untreated cells.   
The findings suggested that the ethyl adduct at 10-4 M and the benzyl at 10-4 M 
showed significant difference (P<0.05) compared to the untreated cell growth, 
(Figure 28). 
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Figure 28. Effect of the molecules at 10-4 M and 10-5 M on undifferentiated U937 cells.               * 
indicates a significant difference compared to the untreated cells (P<0.05), calculated from 12 
repeats. 
* 
 * 
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After testing on undifferentiated cells, the same experiment was performed, 
but this time the cells were exposed to lipopolysaccharide (LPS) for 24 hours 
prior to the treatment with the compounds, which activated the cells and 
initiated an inflammatory type response.  After 24 hours, the same derivatives 
were tested, again using a 96 well plate, with six replicates in all cases.  The LPS 
activated final cell concentration was 0.5x106 viable cells/ml, (figure 29).  Trypan 
blue solution and the same automated cell counter was used to collect the 
results. 
Interestingly, these results exhibited different compound treatments to have a 
significant effect on cell growth/viability.  The effective compounds included the 
N-acetylated ethyl-substituted analogue 206 at 10-4 M, the N-acetylated 
phenyl-substituted analogue 172, at both concentrations, the allyl substituted 
adduct at 10-5 M 182, the N-hydroxy pentenyl-substituted adduct at 10-4 M 236 
and the pentyl-substituted adduct 178 at 10-4 M.  
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Figure 29. Average viable cell counts for LPS activated cells and treated cells at 10-4 M and 10-5 
M.  * Signifies a significant difference compared to the untreated cells (P<0.05). 
 
 * 
 *    *  
   *    * 
   * 
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7.3 Nitric Oxide Assay 
A nitric oxide (NO) assay was conducted on both undifferentiated U937 cells 
and LPS activated U937 cells.  A Griess reagent was used to assess the 
production of NO.  The Griess test is a colourmetric assay, which detects the 
presence of nitrite ions within a solution, the solution was prepared by addition 
of ultrapure water (10M, which is considered nitrite free).  The experiment 
was standardised using serial dilutions of sodium nitrite, from which, a standard 
curve was used to determine the concentrations of NO within the samples.   
The assay was conducted on 96 well plates.  The undifferentiated cells were 
treated with the same range of compounds used in the growth and viability 
assay, with a total cell concentration of 0.5x106 viable cells/ ml, and were 
incubated for 24 hours before the addition of the Griess reagent, followed by 
incubation for a further 15 minutes.  The LPS-activated cells underwent the 
same procedure, after activation of the cells for 24 hours, and resuspension to 
the total cell concentration of 0.5x106 viable cells/ ml.  The absorbance was read 
at 540 nm on a synergy HT plate reader after the 15 minute incubation. 
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7.3.1 Results of the NO assay 
Analysis of the absorbances obtained from the assay followed.  Firstly, the 
readings were blanked, using the average value obtained from the absorbance 
of just cell culture media.  Next the absorbances were blanked again, this time 
for the negative control, which was the DMSO solutions at the corresponding 
concentrations (10-4 M and 10-5 M).   The resulting values were then converted 
into concentrations, using the standard curve.  Graphs were produced for the 
average concentrations, one for undifferentiated cells (figure 30), and one for 
LPs activated cells (figure 32). 
Using the average viable cell counts from the growth and viability assay, the 
assay was standardised to determine NO production per million viable cells. 
Standardisation of these results gave a more robust interpretation of the anti-
inflammatory capabilities of the compounds (figure 31 and 33).   
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Figure 30.  Average NO concentrations (M) calculated for undifferentiated cells compared to 
the treated cells at 10-4 M and 10-5 M concentrations.  * signifies a significant difference 
compared to the untreated cells (P<0.05), calculated from 12 repeats. 
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Figure 31.  Average NO concentrations (M) per million viable undifferentiated cells compared 
to the treated cells following treatment with molecules at 10-4 M and 10-5 M concentrations. 
 127 
 
Figure 32.  Average NO concentrations (M LPS activated cells compared to the treated cells 
following treatments with molecules at 10-4 M and 10-5 M concentrations.  * signifies a 
significant difference compared to the untreated cells (P<0.05).  
 * 
  * 
  *  
 *  
   *  
   *  
 * 
 * 
 * 
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Figure 33.  Average NO concentrations (M) per million viable LPS activated cells compared to 
the treated cells following treatment with molecules at 10-4 M and 10-5 M concentrations.  
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7.4 Discussion 
The results for the NO assays suggests that little NO activity occurs in the 
undifferentiated monocyte U937 cells, (figure 30), compared to the LPS 
activated NO assay, where a large proportion of the molecules used in the 
treatments expressed activity, especially at the higher concentration (figure 32). 
Analysis of the 10-5 M concentration suggested that the more potent NO 
inhibitors seem to be the compounds containing the larger alkyl and aryl 
adducts attached to C7, in particular the allyl substituted adduct, the pentyl 
substituted adduct, the hexyl substituted adduct and the benzyl substituted 
adduct (figure 34).  Further studies at a lower concentration would help to 
identify which of the molecules has the highest potency towards inhibition of 
nitric oxide.    
The series of mono- and di-protections all displayed a significant difference to 
untreated cells at both concentrations, suggesting that the silyl ethers may 
possess some NO inhibition properties on their own. 
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Figure 34.  The molecules which shown a significant difference at both concentration in the NO 
assay with LPS activated cells, suggesting a higher potency.  
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Chapter 8. Summary and Future Work 
8.1 Summary 
The aims of the project were met, with a library of halichlorine derivatives 
synthesised, followed by biological studies on a range of these isolated 
compounds.  The concise synthetic route towards the common key 
intermediate 147 was challenged by synthetic studies into alternate oxidative 
methods to gain access to 147 through a more convenient route determined 
alternative oxidants to be inadequate. 
Many synthetic obstacles have been identified, including interferences from the 
hydroxyl group; reduction of the hydroxylamine to amines using zinc dust and 
acetic acid and selective deprotection. 
The biological assays have provided evidence to suggest that this range of 
derivatives could possess anti-inflammatory properties.  Further assays would 
help to provide a detailed description of the bioactivity, and contribute to 
determining which of the derivatives possess the highest potency. 
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8.2 Future Work 
There are many avenues for furthering this project and developing a deeper 
knowledge of the chemistry and biological activity of halichlorine core structure 
derivatives.  Gaining an in-depth insight into the biological capabilities of 
simplified analogues would be very beneficial and informative for developing a 
library of specific bioactive compounds. The activities determined in this thesis 
do provide an indication for the structure of future libraries based on this 
scaffold, for example, the larger alkyl chains attached at C7 displayed in figure 
35.  This would give the further synthetic investigations a direction, working on 
expansion of the most potent molecules.  Comparison against a second 
screening would identify any effects these changes have had on the potency.  
It would also be beneficial to explore the alternative methods for oxidising the 
free hydroxyl group of azaspirodecanes in an effort to explore how bioactivity 
is related to the structure of C1-side chains: 
 
Figure 35.  Alternate methods to oxidise the free hydroxyl group. 
Furthermore, the RCM-based route to the core structure of both halichlorine 
and pinnaic acid described in schemes 52 and 53 warrants investigation once a 
strategy for separating diasteromeric allyl adducts has been devised.  
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The strategy towards 6,6-spirosystems related to the HTX family of alkaloids 
demonstrates that a range of analogues should be accessed with some ease via 
cycloaddition and a thorough exploration of the scope of this process needs to 
be undertaken. The analogues obtained are all novel derivatives of HTX and 
should be tested for cholinergic activity. Given the structural similarity between 
halichlorine/pinnaic acid and HTX’s it is also proposed to test the compounds 
investigated herein in likewise manner.  
As stated in the Introduction NFB regulates genes encoding cyclooxygenase 2 
(COX2) in addition to iNOS, thus some future efforts should be directed towards 
determining the COX activity of the active compounds highlighted in this thesis. 
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Chapter 9. Experimental 
All reactions were performed using oven dry glassware.  All air sensitive 
reactions were performed with a Schlenk line under Ar.  Dry solvents were 
collected from an Innovative Technology Pure Solv solvent drying system.  All 
chemicals were purchased from either Sigma Aldrich or Alfa Aesar.  Thin layer 
chromatography were performed using Sigma Aldrich silica gel 60Å F254 plates, 
a basic potassium permanganate solution was used as a stain.  Flash column 
chromatography was performed using Sigma Aldrich silica gel pore size 60, 230-
400 mesh as the solid support with indicated eluent.  NMR spectra were 
recorded using a Joel ECS 400 NMR spectrometer, operating at 400 MHz for 1H 
nuclei and 100 MHz for 13C nuclei. Chemical shifts are reported relative to TMS 
(1H 0.00 ppm) and CDCl3 (1H 7.26 ppm, 13C 77.0 ppm) and are reported in parts 
per million (ppm) on the scale. Multiplicities are described as sinlget (s), 
doublet (d), doublet of doublet (dd), triplet (t), doublet of triplets (dt), multiplet 
(m), broad (b). The symbols * is used to differentiate between two isomers 
present in a mixed sample, a and b protons refer to different germinal protons.  
Infared spectra were recorded using a Thermo Nicolet 380 FT-IR. Mass spectra 
and accurate mass data were obtained on a Aligent Technologies 6540 UHD 
Accurate-Mass Q-TOF LC/MS.  Melting points were checked on Stuart SMP10 
apparatus. 
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General procedure for Grignard Reagents in THF  
Grignard reagents were prepared to approximately 1.5M concentration. 
Organohalide (4 mmol) was added to a stirred solution of Mg (15 mmol, 0.36g) 
in tetrahydrofuran (4 ml) with a crystal of iodine.  Upon initiation, the remaining 
organohalide (11 mmol) was added as a solution in tetrahydrofuran (6 ml).  The 
mixture was stirred under reflux for 30 minutes.  The resulting reagent was used 
directly after preparation. 
General procedure for Grignard reagents in diethyl ether 
Grignard reagents were prepared to approximately 1.5M concentration. 
Organohalide (4 mmol) was added to a stirred solution of Mg (15 mmol, 0.36g) 
in diethyl ether (4 ml) with a crystal of iodine.  Upon initiation, the remaining 
organohalide (11 mmol) was added as a solution in ether (6 ml).  The mixture 
was stirred under reflux for 30 minutes.  The resulting reagent was used directly 
after preparation. 
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Piperidin-1-ol   (115) 
 
The synthesis was performed according to the literature procedure.60 1,5 
dibromopentane 196 (0.13 mol, 30.00g) was added to a suspension of 
hydroxylamine hydrochloride (0.325 mol, 22.84g) in triethylamine (230 ml), 
before heating under reflux for 4 h.  The mixture was filtered through a pad of 
sodium sulphate and Celite® and the residue washed with diethyl ether  (3x 20 
ml).  The filtrate was concentrated under reduced pressure to give a pale yellow 
oil.  Purification by flash column chromatography on silica gel using ethyl 
acetate: methanol (9.5:0.5) as the eluent gave the title compound (9.23g, 70%) 
as a colourless oil.  Rf value 0.76; δH (400 MHz; CDCl3) 1.07-1.13 (1H, m, 4a-H), 
1.49-1.56 (3H, m, 3a-H, 4b-H, 5a-H), 1.69-1.71 (2H, dd J = 3.2 and 10.4 Hz, 3b-H, 
5b-H), 2.38-2.44 (2H, dt J = 2 and 10.8 Hz, 2a-H, 6a-H), 3.19-3.29 (2-H, d J = 10 
Hz, 2b-H, 6b-H);  δc (100 MHz; CDCl3) 22.9 (CH2, C-4) 25.4 (CH2, C-3)59.0 (CH2, C-
2).  IR/ cm-1 3160 (O-H br), 2973 (C-H), 2833 (C-H), 1476 (C-H).  HRMS calcd for 
C5H11NO 101.0841: found [M+H] 102.0895.  
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2,3,4,5-Tetrahyrdopyridine 1-oxide (116) 
 
The synthesis was performed according to the literature procedure.60 To a 
solution of 115 (86 mmol, 8.82g) in dichloromethane (20 ml) at 0°C, a 
suspension of mercuric oxide (195 mmol, 42.26g) in dichloromethane (60 ml) 
was added.  The mixture was warmed to r.t. and stirred for 3 h.  The slurry was 
filtered through sodium sulphate and a pad of Celite®.  The filtrate was 
concentrated under reduced pressure to give the title compound as a yellow/ 
orange oil.  Rf value 0.05, the crude product was used for further synthesis 
without purification.  
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2-Allylpiperidin-1-ol (270) 
 
The synthesis was performed according to the literature procedure.60 N-oxide 
116 (2 g, 21 mmol) in tetrahydrofuran (20 ml) was cooled to 0°C under Ar.  
Commercially prepared allylmagnesium chloride (2M, 25 mmol, 0.7 ml) was 
added drop-wise.  The resulting mixture was warmed to r.t. and gently warmed 
for 30 minutes to aid solubility, before leaving to stir for 10 hours.  Water (3 ml) 
was added to quench the reaction before separation between saturated 
aqueous ammonium chloride (10 ml) and dichloromethane.  The aqueous phase 
was extracted further with dichloromethane (3x 15 ml).  The combined organic 
layers were dried with anhydrous sodium sulphate and concentrated under 
reduced pressure.  The residue was purified by flash column chromatography 
using ethyl acetate: hexane as the eluent to give the title compound (0.7240g, 
23%) as an orange oil, Rf value 0.69.  δH (400 MHz; CDCl3) 1.01-1.19 (2H, m, 4a-
H, 5a-H); 1.46-1.70 (3H,m, 3a,b-H, 4b-H); 1.80 (1H, dd J = 2.4 and 7.2 Hz, 5b-H); 
2.01 (1H, m, 1’a-H); 2.28 (1H, m, 2-H); 2.47 (1H, m, 6a-H); 2.78 (1H, m, 1’b-H); 
3.24 (1H, d J = 11.2 Hz, 6b-H); 4.96-5.00 (2H, m, 3’a,b-H); 5.70-5.75 (1H, m, 2‘-
H).  δc (100 MHz; CDCl3) 23.7 (CH2, C-4); 25.9 (CH2, C-3); 30.8 (CH2, C-5); 38.0 
(CH2, C-‘1); 59.8 (CH2, C-6); 67.0 (CH, C-2); 117.1 (CH2, C-‘3); 136.4 (CH, C-‘2). 
IR/cm-1 3363 (O-H br), 2935 (C-H), 1639 (C=C), 1450 (C-H2).  HRMS calcd for 
C8H15NO 141.1154: found [M+H] 142.1227.  
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2-(But-3-en-1-yl)piperidin-1-ol (271) 
 
A solution of nitrone 116 (2.8 g, 27.7 mmol) in tetrahydrofuran (40 ml) was 
cooled to 0°C under Ar.  But-3-en-1-ylmagnesium bromide (42 mmol) prepared 
in tetrahydrofuran (30 ml) according to the general procedure, was added to 
the nitrone via cannula addition, which was then warmed to r.t. and left to stir 
overnight.  Water (10 ml) was added to quench the reaction before the removal 
of the tetrahydrofuran and water under reduced pressure, this was followed by 
separation between saturated aqueous ammonium chloride (30 ml) and diethyl 
ether, followed by further extraction with diethyl ether (3x 20 ml).  The 
combined organic layers were dried with anhydrous sodium sulphate and 
concentrated under reduced pressure.  The residue was purified by flash 
column chromatography using ethyl acetate: hexane (1:1) as the eluent to give 
the title compound (1.55 g, 37%*) as a colourless oil, Rf value 0.69.  δH (400 MHz; 
CDCl3) 1.05-2.03 (9H, m, 2x 3-H, 2x 4-H, 2x 5-H, 2x 1’-H, 2’a-H); 2.36 (1H, m, 2’b-
H); 3.14 (1H, m, 6a); 3.36-3.57 (2H, m, 2-H, 6b-H), 4.81-4.90 (2H, m, 2x 4’-H); 
5.66-5.73 (1H, m, 3’-H).  δc (100 MHz; CDCl3) 21.8, 22.5, 26.4, 27.5, 29.8 (C1’, 
C2’, C3, C4, C5); 60.9 (C6); 76.1 (C2), 113.9 (C4’); 139.1 (C3’).  IR/cm-1 3267 (O-H 
br), 2933 (C-H), 1639 (C=C), 1455 (C-H2), 728 (C-H2).  HRMS calcd for C9H17NO 
155.1310: found [M+H] 156.1370.  
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2-Pent-4-enylpiperidinol (117) 
 
The synthesis was performed according to the literature procedure.60 A solution 
of nitrone 116 (86 mmol, 8.82g) in tetrahydrofuran (40 ml) was cooled to 0°C, 
and a solution of pent-4-enylmagnesium bromide, prepared according to the 
general procedure, in tetrahydrofuran, was added via cannula addition.  The 
resulting reaction mixture was warmed to r.t. and left to stir for 15 h.  The 
mixture was quenched with water (20 ml) followed by the removal of 
tetrahydrofuran and water under reduced pressure.   Saturated aqueous 
ammonium chloride (30 ml) was added to the slurry and extracted with diethyl 
ether (3 x 20 ml).  The combined organic extracts were dried with anhydrous 
sodium sulphate and concentrated under reduced pressure to a yellow/brown 
oil.  This was purified by flash column chromatography using ethyl acetate: 
hexane (1:1) as the eluent to give the title compound (7.96g, 55%) as a pale 
yellow oil, Rf value 0.77.  δH (400 MHz; CDCl3) 1.05-1.67 (9H, m, 2x 1’a-H, 2x 2’-
H, 3-a, 2x 4-H, 2x 5-H); 1.79-1.82 (1H, m, 3H-b); 2.00-2.12 (3H, m, 1’H-b, 2x 3’-
H); 2.19-2.21 (1H, m, 2-H); 2.43-2.50 (1H, dt J = 2.8 and 10.4 Hz, 6H-a); 3.23-3.26 
(1H, d J = 10.4 Hz, 6H-a); 4.84-4.97 (2H, m, 2x 5’-H); 5.71-5.82 (1H, m, 4’-H); δC 
(100 MHz; CDCl3) 23.8 (C4), 25.3 (C1’), 25.9 (C5), 31.1 (C3), 32.9 (C2’), 34.2 (C3’), 
59.7 (C6), 67.6 (C2), 114.4 (C5’), 138.8 (C4’).  IR/cm-1 3076 (O-H br), 2932 (C-H), 
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2857 (C-H), 1641 (C=C), 1442 (C-H).  HRMS calcd for C10H19NO 169.1467: found 
[M+H] 170.1505.  
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6-(Pent-4-en-1-yl)-2,3,4,5-tetrahydropyridine 1-oxide (118) 
 
The synthesis was performed according to the literature procedure.60 A solution 
of 116 (6.66g, 39 mmol) in dichloromethane (20 ml) was cooled to 0°C.  
Mercuric oxide (89 mmol, 19.2g) was added as a suspension in dichloromethane 
(70 ml) and the reaction mixture was warmed to r.t. and stirred for 3 h.  The 
mixture was filtered through a pad of anhydrous sodium sulphate and Celite® 
and concentrated under reduced pressure to give the title compound, Rf value 
0.05.  This product was used without purification. 
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2-(But-3-en-1-yl)-2-vinylpiperidin-1-ol (273) 
 
271 (3.2 mmol, 0.5g) was cooled to 0°C in dichloromethane (5 ml), before 
mercuric oxide (8.0 mmol, 1.74g) was added as a suspension in 
dichloromethane (15 ml), the reaction mixture was warmed to r.t. and stirred 
for 3 h.  The mixture was filtered through a pad of anhydrous sodium sulphate 
and Celite® and concentrated under reduced pressure to give the title 
compound.  This product was used without purification.   
A mixture of the crude nitrone was cooled to 0°C in tetrahydrofuran (15 ml) 
under argon.   Commercially prepared vinylmagnesium bromide (1M, 4.8 mmol, 
0.65 ml) was added drop-wise over 5 minutes. The reaction mixture to warm to 
r.t. and stirring for 4 h, then reaction mixture was quenched with saturated 
aqueous ammonium chloride before concentrating under reduced pressure.  
This mixture was extracted with diethyl ether (3 x 10 ml).  The combined organic 
layers were dried with anhydrous sodium sulphate and concentrated under 
reduced pressure to give a yellow oil.  This was purified by flash column 
chromatography on silica gel using ethyl acetate: hexane (1:1) gave the title 
compound as a pale yellow oil, Rf value 0.5. (0.19 g, 30%*) δH (400 MHz; CDCl3) 
1.22-2.38 (10H, m, 3-H, 4-H, 5-H, 1’-H, 2’-H); 3.60 (2H, m, 6-H); 4.92-5.03 (4H, 
m, 2”-H, 4’-H); 5.54-5.81 (2H, m, 1”-H, 3’-H).  δC (100 MHz; CDCl3) 11.0, 14.1, 
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23.8, 30.4, 38.8 (C3, C4, C5, C1’, C2’); 68.2 (C6); 128.5, 130.9 (C2”, C4’); 132.5, 
167.8 (C1’, C3’).  HRMS calcd for C11H19NO 181.1467: found [M+H] 182.1530.  
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2-(Pent-4-en-1-yl)-2-vinylpiperidin-1-ol (274) 
 
116 (0.5 g, 2.96 mmol) was cooled to 0°C in dichloromethane (5 ml), before 
mercuric oxide (6.66 mmol, 1.44 g) was added as a suspension in 
dichloromethane (15 ml), the reaction mixture was warmed to r.t. and stirred 
for 3 h.  The mixture was filtered through a pad of anhydrous sodium sulphate 
and Celite® and concentrated under reduced pressure to give the title 
compound, Rf value 0.05.  This product was used without purification.   
A mixture of the crude intermediate was cooled to 0°C in tetrahydrofuran (15 
ml) under argon.   Commercially prepared vinylmagnesium bromide (1M, 4.4 
mmol, 0.59 ml) was added drop-wise over 5 minutes, before allowing the 
reaction mixture to warm to r.t. and stirring for 4 h.  Upon completion, the 
reaction mixture was quenched with saturated aqueous ammonium chloride 
before concentrating under reduced pressure to remove most of the 
tetrahydrofuran.  This was then extracted with diethyl ether (3 x 10 ml).  The 
combined organic layers were dried with anhydrous sodium sulphate and 
concentrated under reduced pressure to give a yellow oil.   This was purified by 
flash column chromatography on silica gel using ethyl acetate: hexane (1:1) to 
give the title compound, Rf value 0.56, (0.24 g, 41%*).  δH (400 MHz; CDCl3) 1.06-
2.09 (12H, m, 2x 1’-H, 2x 2’-H, 2x 3-H, 2x 3’-H, 2x 4-H, 2x 5-H); 2.82-3.08 (2H, m, 
2x 6-H); 4.88-5.33 (4H, m, 2x 2”-H, 2x 5’-H); 5.73-5.89 (2-H, m, 1”-H, 4’-H).  HRMS 
calcd for C12H21NO 195.1623: found [M+H] 196.1650.  
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2-allyl-2-(but-3-en-1-yl)-piperidin-1-ol (272) 
 
271 (3.3 mmol, 0.5 g) was cooled to 0°C in dichloromethane (5 ml), before 
mercuric oxide (7.45 mmol, 1.61 g) was added as a suspension in 
dichloromethane (15 ml), the reaction mixture was warmed to r.t. and stirred 
for 3 h.  The mixture was filtered through a pad of anhydrous sodium sulphate 
and celite® and concentrated under reduced pressure to give the title 
compound, Rf value 0.05.  This product was used without purification.   
A mixture of the crude intermediate was cooled to -78°C in tetrahydrofuran (15 
ml) under argon.   Commercially prepared allylmagnesium chloride (2M, 6.6 
mmol, 0.34 ml) was added drop-wise over 5 minutes.  The mixture was stirred 
at -78°C for 2 h, before quenching with saturated aqueous ammonium chloride.  
The reaction mixture was concentrated under reduced pressure to remove 
most of the tetrahyrofuran, before extracting with diethyl ether (3 x 10 ml).  The 
combined organic layers were dried with anhydrous sodium sulphate and 
concentrated under reduced pressure to give an orange oil.  This was purified 
by flash column chromatography on silica gel using ethyl acetate: hexane (1:1) 
to give the title compound as an orange oil, Rf value 0.49. (0.07g, 21%*).  δH (400 
MHz; CDCl3) 1.21-2.49 (12H, m, 2x 1’-H, 2x 1”-H, 2x 2’-H, 2x 3-H, 2x 4-H, 2x 5-H); 
3.57-3.65 (2H, m, 2x 6-H); 4.91-5.04 (4H, m, 2x 3”-H, 2x 4’-H); 5.76-5.82 (2H, m, 
2”-H, 3’-H).  HRMS calcd for C12H21NO 195.1623: found [M+H] 196.1692. 
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(3aS*,10aS*)-Octahydro-1H-cyclopenta[3.4]isoxazolo[2,3-a]pyridine (119) 
 
The synthesis was performed according to the literature procedure.60 A solution 
of crude compound 118 in toluene (50 ml) was heated under reflux for 24 h.  
The mixture was cooled to r.t. and concentrated under reduced pressure to 
obtain a dark brown oil.  This was purified by flash column chromatography on 
silica gel using diethyl ether: hexane (1:1) as the eluent to give the title 
compound (3.50g, 53%) as a yellow oil, Rf value 0.5.  δH (400 MHz; CDCl3) 1.29-
1.53 (4H, m, 2x 2-H, 8a-H, 10a-H); 1.54-1.93 (8H, m, 2x 1-H, 2x 3-H, 8H-b, 2x 9-
H, 10b-H); 2.55-2.63 (1H, m, 3a-H); 2.77-2.89 (1H, m, 7a-H); 2.99-3.10 (1H, m, 
7b-H); 3.39-3.48 (1H, dd J = 3.2 and 8.4 Hz, 4a-H); 4.20-4.31 (1H, t J = 8 Hz, 4b-
H).  δC (400 MHz, CDCl3) 21.6 (C1), 22.8 (C10), 24.1 (C9), 31.4 (C2), 33.2 (C3), 
39.2 (C8), 49.9 (C3a), 50.4 (C7), 72.2 (C4), 75.2 (C10a). IR/cm-1 2933 (C-H), 2856 
(C-H), 1444 (C-H), 850 (C-H).  HRMS calcd for C10H17NO 167.1310: found [M+H] 
168.1352. 
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(1S*,5S*)-6-Azaspiro[4.5]decan-1-ylmethanol (244) 
 
The synthesis was performed according to the literature procedure.63 A solution 
of 119 (3.80g, 22.5 mmol) in acetic acid: water (1:1, 60 ml) with zinc dust (179.9 
mmol, 11.76g) was heated under reflux for 4 h.  The reaction mixture was then 
cooled to r.t., before quenching with saturated aqueous sodium bicarbonate 
(40 ml) and extracting with chloroform (3 x 30 ml).  The organic layers were 
combined, dried with anhydrous sodium sulphate and concentrated under 
reduced pressure to a give a crude yellow oil.  This was purified by flash column 
chromatography on silica gel using dichloromethane: methanol (9:1) as the 
eluent to give the title compound (3.53g, 93%) as a pale yellow oil, Rf value 0.15.  
δH (400 MHz; CDCl3) 1.46-2.03 (13H, m, 2x 3-H, 2x 4-H, 2x 5-H, 6-H, 2x 7-H, 2x 8-
H, 2x 9-H; 2.78-2.85 (1H, m, 2b-H), 3.18-3.21 (1H, d J = 13.2 Hz, 2a-H), 3.72-3.81 
(2H, m, 2x 1’-H). δc (100 MHz; CDCl3) 20.5, 22.0, 23.0, 26.9, 32.8, 34.8 (C3, C4, 
C5, C6, C7, C8); 41.7 (C2); 50.1 (C9); 61.7 (C10); 65.8 (C5a).  IR/cm-1 3277 (O-H 
br), 2944 (C-H), 2869 (C-H), 1558 (N-H), 1401 (C-H).  HRMS calcd for C10H19NO 
169.1467: found [M+H] 170.1529. 
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(1R*- 8S*)-7-Oxa-6-aza-tricyclo[6.3.1.01,6]dodecane (198) 
 
A solution of 119 (2.0g, 11.4 mmol) in toluene (10 ml) was heated by microwave 
irradiation at 220°C for 2.5 h.  The resulting black solution was concentrated 
under reduced pressure.  Purification by column chromatography using diethyl 
ether: hexane (1:1), gave the title compound (1.27g, 76%) as a pale yellow oil, 
Rf value 0.26.  The remaining starting material was recovered for further use.  
δH (400 MHz; CDCl3) 0.89-1.48 (11H, m, 4a-H, 2x 2-H, 2x 3-H, 9a-H, 2x 10-H, 2x 
11-H, 12a-H); 1.64-1.67 (2H, m, 4b-H, 9b-H); 2.14-2.40 (2H, m, 12b-H, 5a-H); 
3.00 (1H, m, 5b-H); 4.26 (1H, m, 8-H).  δc (100 MHz; CDCl3) 18.8, 19.7, 24.7, 31.5 
(C2, C3, C10, C11), 33.2 (C4), 38.3 (C12), 40.0 (C9), 55.3 (C5), 62.4 (C1), 75.4 (C8).  
IR/cm-1 2928 (C-H), 1447 (c-H2), 872 (C-H).  HRMS calcd for C10H17NO 167.1310: 
found [M+H] 168.1387. 
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(6R*,8S*)-8-hydroxy-1-azaspiro[5.5]undecane (280) 
 
231 (0.1 g, 0.55 mmol) was cooled to 0°C in tetrahydrofuran (10 ml) under 
argon.   Propylmagnesium bromide (0.5 ml), prepared according to the general 
procedure in tetrahydrofuran (10 ml) was added drop-wise over 5 minutes, 
before warming to r.t. and allowing to stir for 10 h.  The reaction mixture was 
quenched with saturated aqueous ammonium chloride and extracted with 
diethyl ether (3 x 10 ml).  The combined organic layers were dried with 
anhydrous sodium sulphate and concentrated under reduced pressure to give 
a crude oil, which was used without purification.  
 The crude nitrone in acetic acid: water (1:1, 10 ml) and zinc dust (4.4 mmol, 
0.29g) was heated under reflux for 4 h.  Upon cooling, the reaction mixture was 
quenched using saturated aqueous sodium bicarbonate and extracted using 
dichloromethane (3 x 15 ml).  The combined organic extracts were dried using 
anhydrous sodium sulphate and concentrated under reduced pressure.   The 
crude product was purified by flash column chromatography on silica gel using 
chloroform: methanol (9:1) as the eluent to give the title compound, Rf value 
0.15 (33 mg, 35%).  δH (400 MHz; CDCl3) 1.14-1.73 (11 H, m, 2x  3-H, 2x 4-H, 2x 
5-H, 9a-H, 2x 10-H, 2x 11-H); 1.89-2.01 (2H, m, 7a-H, 9b-H); 2.45-2.53 (2H, m, 2a-
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H, 7b-H); 3.24 (1H, t J = 6.8 Hz, 2b-H); 4.54 (1H, t J = 5.6 Hz, 8-H).  δc (100 MHz; 
CDCl3) 19.0, 19.9, 25.0, 31.6 (C4, C5, C10, C11), 33.4 (C3), 38.6 (C9), 40.2 (C7), 
55.6 (C2), 62.7 (C8), 75.7 (C6).  IR/ cm-1 3363 (O-H br), 2931 (C-H), 1481 (C-H2), 
871 (C-H).  HRMS calcd for C10H19NO 169.1467: found [M-H] 168.1381.   
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(1S*,5S*)-1-(hydroxymethyl)-6-azaspiro[4.5]-dec-6-ene 6-oxide (147) 
 
The synthesis was performed according to literature procedure.63  A solution of 
isoxazolidine 119 (30.8 mmol, 5.2 g) in dichloromethane (200 ml) was cooled to 
0°C under argon. mCPBA (1.5 equiv. at ~77%, 46.2  mmol, 7.96 g) in 
dichloromethane (150 ml) was added drop wise over 7 hours.  On completion 
of the addition, the mixture was warmed to r.t. and left to stir for 20 hours.  The 
reaction mixture was quenched with a solution of saturated aqueous sodium 
thiosulfate: saturated aqueous sodium bicarbonate (1:1)  (160 ml) and 
extracted with dichloromethane (3 x 40 ml).  The organic layers were combined, 
dried with anhydrous sodium sulphate and concentrated under reduced 
pressure to give an orange oil.  Purification was performed by flash column 
chromatography on silica gel using dichloromethane: methanol (9.5: 0.5) as the 
eluent gave the title compound, Rf value 0.44 (2.78 g, 49%) as an orange solid.  
δH (400 MHz; CDCl3) 1.41-2.05 (9H, m, 2a-H, 2x 3-H, 2x 4-H, 2x 9-H, 2x 10-H), 
2.09-2.21 (1H, m, 2a-H), 2.39-2.44, (2H, m, 2x 8-H), 2.69-2.73 (1H, m, 1-H), 3.61-
3.72 (2H, m, 2x 1’-H) 7.29 (1H, t J = 4.4 Hz, 7-H).  δc (100 MHz; CDCl3) 15.6, 24.2 
(C4, C10), 26.5 (C8), 28.4 (C3), 37.2 (C9), 38.7 (C2), 52.9 (C1), 61.2 (C’1), 77.6 
(C5), 141.9 (C7).  IR/ cm-1 3272 (O-H br), 2936 (C-H), 1448 (C-H) 1114 (C-O), 791 
(C-H).  HRMS calcd for C10H17NO2 183.1259: found [M+H] 184.1331. 
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(6R*,8S*)-8-hydroxy-1-azaspiro[5.5]undec-1-ene 1-oxide (231) 
  
To a cooled solution of isoxazolidine 198 (2.2 g, 13 mmol) in dichloromethane 
(90 ml) under argon, a solution of mCPBA (1.5 equiv. at ~77%, 20 mmol, 3.37g) 
in dichloromethane (70 ml) was added drop-wise over 7 hours.  The mixture 
was then warmed to r.t. and left to stir overnight.  Upon completion the 
reaction was quenched with a mixture of saturated aqueous sodium thiosulfate: 
saturated aqueous sodium bicarbonate (1:1, 50 ml), and washed with 
dichloromethane (3x 20 ml).  The combined organic layers were dried with 
anhydrous sodium sulphate and concentrated under reduced pressure.  
Purification by flash column chromatography on silica gel using 
dichloromethane: methanol (9.5: 0.5) as the eluent gave the title compound 
(1.43 g, 60%) as an orange oil, Rf value 0.37  δH (400 MHz; CDCl3) 1.39-1.83 (9H, 
m, 3a-H, 2x 4-H, 2x 5-H, 2x 10-H, 2x 11-H); 2.06-2.49 (5H, m, 3b-H, 2x 7-H, 2x 9-
H); 3.83 (1H, m, 8-H); 7.18 (1H, t J = 4 Hz, 2-H).  δc (100 MHz; CDCl3) 14.4, 18.5, 
26.2, 33.4 (C4, C5, C10, C11); 37.1, 35.4 (C3, C9); 42.3 (C7); 68.1 (C6); 64.6 (C8); 
138.2 (C2).  HRMS calcd for C10H17NO2 183.1259: found [M+H] 184.1329.  
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(1S*,5S*,7R*)-1-(hydroxymethyl)-6-acetyl-7-methyl-6-azaspiro[4.5]decane 
(205) 
 
A solution of spironitrone 147 (0.13 g, 0.71 mmol) was cooled to 0°C in THF (5 
ml) under Ar.  Commercially prepared methylmagnesium bromide (3M, 4.3 
mmol, 0.16 ml) was added drop-wise before warming to r.t. and leaving to stir 
for 10 hours.  The reaction mixture was quenched with saturated aqueous 
ammonium chloride (10 ml) and extracted with diethyl ether (3x 10 ml).  The 
combined organic layers were dried with anhydrous sodium sulphate and 
concentrated under reduced pressure.  The crude orange residue obtained was 
reduced without purification. 
A mixture of the crude hydroxylamine (0.085 g, 0.42 mmol) and zinc dust (3.4 
mmol, 0.22g) in acetic acid: water (1:1, 10 ml) was heated under reflux for 4 h.  
Upon completion, the mixture was cooled to r.t. and quenched with saturated 
aqueous sodium bicarbonate (10 ml) and extracted with dichloromethane (4 x 
15 ml).  The combined organic layers were dried using anhydrous sodium 
sulphate and concentrated under reduced pressure.  Purification by flash 
column chromatography using dichloromethane: methanol (9: 1) as the eluent 
gave the title compound (70 mg, 44%) as a pale yellow oil, Rf value 0.17  δH (400 
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MHz; CDCl3) 1.21 (3H, d J = 6.4 Hz, 3x 1”-H); 1.39-1.81 (10H, m, 2x 2-H, 2x 3-H, 
2x 4-H, 2x 9-H, 2x 10-H); 1.90 (3H, s, 2”’-H); 2.01-2.15 (1H, m, 8a-H); 2.37 (1H, 
m, 1-H); 3.55 (2H, m, 7-H, 1’-H); 3.70-3.78 (1H, m, 1’-H).  δc (100 MHz; CDCl3) 
19.1, 26.1, 31.1, 33.5, 36.3 (C2, C3, C4, C9, C10); 19.8 (C1”); 20.0 (C2”’-H); 36.3 
(C8); 41.5 (C1); 51.1 (C7); 63.7 (C1’); 66.4 (C5); 178.5 (C1’”).  IR/ cm-1 3245 (O-H 
br), 2926 (C-H), 1735 (C=O), 1302 (C-H), 731 (C-H).  HRMS calcd for C13H23NO2 
225.1729: found [M+H] 226.1797.  
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(1S*,5S*,7R*)-1-(hydroxymethyl)-6-acetyl-7-ethyl-6-azaspiro[4.5]decane 
(206) 
 
A solution of spironitrone 147 (0.10 g, 0.55 mmol) in tetrahydrofuran (5 ml) was 
cooled to 0°C under Ar.  Ethylmagnesium bromide (1.0 ml), prepared according 
to the general procedure in tetrahydrofuran (10 ml), was added drop-wise 
before warming to r.t. and leaving to stir for 10 h.  The reaction mixture was 
quenched with saturated aqueous ammonium chloride (10 ml) and extracted 
with diethyl ether (3 x 10 ml).  The combined organic layers were dried with 
anhydrous sodium sulphate and concentrated under reduced pressure.  The 
crude orange residue obtained was reduced without purification. 
A mixture of the crude hydroxylamine (57 mg, 0.23 mmol) and zinc dust (1.9 
mmol, 0.12 g) in acetic acid: water (1:1, 8 ml) was heated under reflux for 4 h.  
Upon completion, the mixture was cooled and quenched with saturated 
aqueous sodium bicarbonate (10 ml) before extracting with dichloromethane 
(4 x 15 ml).  The combined organic layers were dried using anhydrous sodium 
sulphate and concentrated under reduced pressure.  Purification by flash 
column chromatography using dichloromethane: methanol (9: 1) as the eluent 
gave the title compound (50 mg, 38%) as a pale yellow oil, Rf value 0.17  δH (400 
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MHz; CDCl3) 0.87 (3H, t J = 7.6 Hz, 3x 2”-H); 1.26-1.89 (13H, m, 2x 1’-H, 2x 2-H, 
2x 3-H, 2x 4-H, 8a-H, 2x 9-H, 2x 10-H); 1.93 (3H, s, 3x 1’”-H); 2.22 (1H, m, 8b-H); 
2.43 (1H, m, 1-H); 3.38 (1H, m, 7-H), 3.55 (1H, m, 1’a-H); 3.81-3.87 (1H, m, 1’b-
H).  δc (100 MHz; CDCl3) 18.8, 19.5, 25.6, 26.6, 27.7, 33.4, 35.3 (C1’, C2, C3, C4, 
C8, C9, C10); 23.8 (C2’”); 41.5 (C1); 57.0 (C7); 63.2 (C1’); 67.0 (C5); 177.9 (C1’”).  
IR/ cm-1 3210 (O-H br), 2931 (C-H), 2562 (C-H), 1747 (C=O), 1264 (C-H), 1101 (O-
H).  HRMS calcd for C14H25NO2 239.1885: found [M+H] 240.1955. 
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(1S*,5S*,7R*)-1-(hydroxymethyl)-6-acetyl-7-propyl-6-azaspiro[4.5]decane 
(207) 
 
A solution of spironitrone 147 (0.10 g, 0.55 mmol) was cooled to 0°C in 
tetrahydrofuran (5 ml) under Ar.  Propylmagnesium bromide (1.0 ml), prepared 
according to the general procedure in tetrahydrofuran (10 ml),  was added 
drop-wise before warming to r.t. and leaving to stir for 10 h.  The reaction 
mixture was quenched with saturated aqueous ammonium chloride (10 ml) and 
extracted with diethyl ether (3x 10 ml).  The combined organic layers were dried 
with anhydrous sodium sulphate and concentrated under reduced pressure.  
The crude orange residue obtained was reduced without purification. 
A mixture of the crude hydroxylamine (0.04 g, 0.15 mmol) and zinc dust (1.2 
mmol, 80 mg) in acetic acid: water (1:1, 8 ml) was heated under reflux for 4 h.  
Upon completion, the mixture was cooled and quenched with saturated 
aqueous sodium bicarbonate (10 ml) before extracting with dichloromethane 
(4 x 15 ml).  The combined organic layers were dried using anhydrous sodium 
sulphate and concentrated under reduced pressure.  Purification by flash 
column chromatography using dichloromethane: methanol (9: 1) as the eluent 
gave the title compound (32 mg, 28%) as a pale yellow oil, Rf value 0.33  δH (400 
 160 
MHz; CDCl3) 0.87 (3H, t J = 6.8 Hz, 3x 3”-H); 1.19-1.82 (15H, m, 2x 1”-H, 2x 2”-H, 
2x 2-H, 2x 3-H, 2x 4-H, 8a-H, 2x 9-H, 2x 10-H); 1.96 (3H, t, 3x 1’”-H); 1.96-2.05 
(1H, m, 8b-H); 2.29 (1H, m, 1-H); 3.12-3.15 (1H, m, 7-H); 3.60 (1H, m, 1’a-H); 
3.73 (1H, m, 1’b-H).  δc (100 MHz; CDCl3) 14.2 (C3”); 18.9, 19.6, 20.2, 26.6, 30.3, 
35.2, 37.7, 38.0 (C1”, C2”, C2, C3, C4, C8a, C9, C10); 24.4 (C2”’); 41.5 (C1); 54.6 
(C7); 64.5 (C1’); 65.8 (C5); 178.1 (C1’”).  IR/ cm-1 3220 (O-H br), 2943 (C-H), 1736 
(C=O), 1124 (C-H).  HRMS calcd for C15H27NO2 253.2042 (211.194 –COCH3): 
found [M+H] 212.201 –COCH3 observed.  
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(1S*,5S*,7R*)-1-(hydroxymethyl)-6-acetyl-7-pentyl-6-azaspiro[4.5]decane 
(208) 
 
A solution of spironitrone 147 (0.10 g, 0.55 mmol) was cooled to 0°C in 
tetrahydrofuran (5 ml) under Ar.  Pentylmagnesium bromide (1.0 ml), prepared 
according to the general procedure, was added drop-wise before warming to 
r.t. and leaving to stir for 10 h.  The reaction mixture was quenched with 
saturated aqueous ammonium chloride (10 ml) and extracted with diethyl ether 
(3x 10 ml).  The combined organic layers were dried with anhydrous sodium 
sulphate and concentrated under reduced pressure.  The crude orange residue 
obtained was reduced without purification. 
A mixture of the crude hydroxylamine (60 mg, 0.33 mmol) and zinc dust (1.9 
mmol, 0.12 g) in acetic acid: water (1:1, 8 ml) was heated under reflux for 4 h.  
Upon completion, the mixture was cooled and quenched with saturated 
aqueous sodium bicarbonate (6 ml) before extracting with dichloromethane (4 
x 15 ml).  The combined organic layers were dried using anhydrous sodium 
sulphate and concentrated under reduced pressure.  Purification by flash 
column chromatography using dichloromethane: methanol (9: 1) as the eluent 
gave the title compound (43 mg, 33%) as a pale yellow oil.  Rf value 0.45 δH (400 
 162 
MHz; CDCl3) 0.81 (3H, t J = 6.8 Hz, 3x 5”-H); 1.20-1.94 (19H, m, 2x 1”-H, 2x 2”-H, 
2x 3”-H, 2x 4”-H, 2x 2-H, 2x 3-H, 2x 4-H, 8a-H, 2x 9-H, 2x 10-H); 1.94 (3H, s, 3x 
1’”-H); 2.22 (1H, m, 8b-H); 2.45 (1H, m, 1-H); 2.86-2.91 (1H, m, 7-H); 3.50-3.54 
(1H, m, 1’-H); 3.80-3.88 (1H, m, 8b-H).  δc (100 MHz; CDCl3) 14.2 (C5”); 20.5, 
21.0, 25.6, 27.8, 32.1, 33.0, 37.7, 37.9, 41.1 (C1”, C2”, C2, C3”, C3, C4”, C4, C8, 
C8, C9, C10); 41.7 (C1); 53.5 (C7); 64.2 (C1’); 65.8 (C5), 178.1 (C1”’).  IR/ cm-1 
3201 (O-H br), 2931 (C-H), 1754 (C=O), 921 (C-H), 727 (C-H).  HRMS calcd for 
C17H31NO2 281.2355 (239.225 –COCH3): found [M+H] 240.2318. 
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(1S*,5S*,7R*)-1-(hydroxymethyl)-6-acetyl-7-phenyl-6-azaspiro[4.5]decane 
(209) 
 
A solution of nitrone 147 (0.2 g, 0.1 mmol) in tetrahydrofuran (10 ml) was 
cooled to 0°C under Ar.  Phenylmagnesium bromide in tetrahydrofuran (1.8 ml), 
prepared according to the general procedure, was added drop-wise, before 
warming to r.t and leaving to stir for 2 hours. Upon completion, the reaction 
mixture was quenched with water (3 ml) and saturated aqueous ammonium 
chloride and extracted with diethyl ether (3 x 10 ml).  The combined organic 
extracts were dried with anhydrous sodium sulphate and concentrated under 
reduced pressure.  The crude orange residue obtained was reduced without 
purification.  
The crude starting material (0.15 mmol, 40 mg) in glacial acetic acid: water (1:1, 
10 ml) with zinc dust (1.2 mmol, 79 mg) was heated under reflux for 4 h.  Once 
cooled the reaction mixture was quenched with saturated aqueous sodium 
bicarbonate (10 ml) before extracting with dichloromethane (3 x 15 ml).  The 
combined organic layers were dried with anhydrous sodium sulphate and 
concentrated under reduced pressure.  Purification by flash column 
chromatography on silica gel using dichloromethane: methanol (9.5: 0.5) as the 
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eluent gave the title compound (0.008g, 6%) as a colourless oil, Rf value 0.69  δH 
(400 MHz; CDCl3) 1.42-2.0 (12H, m, 2x 2-H, 2x 3-H, 2x 4-H, 2x 8-H, 2x 9-H, 2x 10-
H); 2.45 (1H, m, 1-H); 2.98 (1H, t J = 26.8 Hz, 1’a-H); 3.30 (1H, dd J = 6.8 and 12 
Hz, 1’b-H); 4.33-4.37 (1H, m, 7-H); 7.2-7.3 (3H, m, 3”-H, 4”-H, 5”-H); 7.4 (2H, m, 
2”-H, 6”-H).  δC (100MHz; CDCl3) 18.8, 20.5, 25.4, 31.1, 33.6, 36.0 (C-2, C-3, C-4, 
C-8, C-9, C-10); 23.6 (C-2”’); 40.6 (C-1); 59.1 (C-7); 63.3 (C-1’); 67.2 (C-5); 127.9 
(C-2”, C6”); 128.4 (C4”); 128.8 (C3”, C5”).  IR/cm-1 3220 (O-H br), 2950 (C-H), 
1717 (C=O), 1491 (C-H2), 852 (=C-H).  HRMS calcd for C18H25NO2 287.1885 (-
COCH3 245.178): found [M+H] 246.1853 – COCH3 observed. 
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(1S*,5S*,7R*)-1-(hydroxymethyl)-6-acetyl-7-benzyl-6-azaspiro[4.5]decane 
(209) 
 
A solution of spironitrone 147 (0.10 g, 0.55 mmol) was cooled to 0°C in 
tetrahydrofuran (5 ml) under Ar.  Benzylmagnesium bromide (0.4 ml), prepared 
according to the general procedure in tetrahydrofuran, was added drop-wise 
before warming to r.t. and leaving to stir for 10 h.  The reaction mixture was 
quenched with saturated aqueous ammonium chloride (10 ml) and extracted 
with diethyl ether (3 x 10 ml).  The combined organic layers were dried with 
anhydrous sodium sulphate and concentrated under reduced pressure.  The 
crude orange residue obtained was reduced without purification. 
A mixture of the crude intermediate (60 mg, 0.33 mmol) and zinc dust (1.9 
mmol, 0.12 g) in acetic acid: water (1:1, 8 ml) was heated under reflux for 4 h.  
Upon completion, the mixture was cooled and quenched with saturated 
aqueous sodium bicarbonate (10 ml) before extracting with dichloromethane 
(4 x 15 ml).  The combined organic layers were dried using anhydrous sodium 
sulphate and concentrated under reduced pressure.  Purification by flash 
column chromatography using dichloromethane: methanol (9: 1) as the eluent 
gave the title compound (69 mg, 42%) as a white solid, Rf value 0.69  δH (400 
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MHz; CDCl3) 1.19-1.67 (12H, m, 2x 2-H, 2x 3-H, 2x 4-H, 2x 8-H, 2x 9-H, 2x 10-H); 
1.78-1.88 (2H, m, 2x 1”-H); 1.98-2.12 (4H, m, 2x 1-H, 2x 2’”-H); 3.69-3.72 (1H, d 
J = 11.6 Hz, C7); 4.09 (1H, dd J = 3.2 and 11.2 Hz, 1’a-H); 4.35-4.39 (1H, dd J = 4.8 
and 11.2 Hz, 1’b-H), 7.20-7.31 (4H, m, 2”-H, 4”-H, 5”-H, 6”-H); 7.37-7.38 (2H, m, 
3”-H, 7”-H).  δC (100MHz; CDCl3) 21.3 (C2’”); 21.8, 23.1, 28.2, 34.6, 35.5, 35.8 
(C2, C3, C4, C8, C9, C10); 49.3 (C1); 56.7 (C7); 63.5 (C5); 65.7 (C1’); 127.0 (C3”, 
C7”); 128.4 (C4”, C6”); 146.5 (C5”); 171.5 (C1’”).  IR/cm-1 3210 (O-H br), 2926 (C-
H), 1731 (C=O), 1590 (C=C), 1397 (C-H), 984 (C-H), 802 (C-H2), m.p. 63-64°C.  
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(1S*,5S*,7R*)-1-(hydroxymethyl)-7-methyl-6-azaspiro[4.5]decane (211) 
 
A solution of spironitrone 147 (0.18 g, 0.98 mmol) was cooled to 0°C in 
tetrahydrofuran (10 ml) under Ar.  Commercially prepared methylmagnesium 
bromide (3M, 2.9 mmol, 0.11 ml) was added drop-wise before warming to r.t. 
and leaving to stir for 10 hours.  The reaction mixture was quenched with 
ethanol: saturated aqueous ammonium chloride (2:1, 10 ml) and indium 
powder (0.55 mmol, 0.06 g) was added before heated under reflux for 4 h.  
Upon cooling, diethyl ether and saturated aqueous ammonium chloride were 
added and the aqueous layer further extracted with diethyl ether (3 x 10 ml).  
The combined organic extracts were dried using anhydrous sodium sulphate 
and concentrated under reduced pressure.   This was purified by flash column 
chromatography on silica gel using dichloromethane: methanol (9:1) as the 
eluent gave the title compound (76 mg, 42%) as a pale white solid, Rf value 0.48  
δH (400 MHz; CDCl3) 144-1.46 (3H, d J = 6.4 Hz, 1”-H); 1.56-1.83 (11H, m, 2x 2-H, 
2x 3-H, 2x 4-H, 8a-H, 2x 9-H, 2x 10-H); 2.29-2.38 (1H, m, 8b-H); 2.49 (1H, m, 1-
H); 3.54-3.58 (1H, m, 1’a-H); 3.70 (1H, m, 7-H); 4.00-4.06 (1H, m, 1’b-H).  δC 
(100MHz; CDCl3) 19.4 (C1”); 18.6, 19.6, 25.2, 27.6, 30.3, 32.4 (C2, C3, C4, C8, C9, 
C10); 41.0 (C1); 52.7 (C7); 63.1 (C1’); 67.7 (C5).  IR/cm-1 3310 (O-H br), 2940, (C-
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H), 1448 (C-H2), 7.26 (C-H2), m.p. 161-163°C.  HRMS calcd for C11H21NO 
183.1623: found [M+H] 184.1696.     
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(1S*,5S*,7R*)-1-(hydroxymethyl)-7-ethyl-6-azaspiro[4.5]decane (212) 
 
A solution of spirnitrone 147 (0.17 g, 0.93 mmol) was cooled to 0°C in 
tetrahydrofuran (10 ml) under Ar.  Ethylmagnesium bromide (1.5 ml), prepared 
according to the general procedure in tetrahydrofuran, was added drop-wise 
before warming to r.t. and leaving to stir for 10 hours.  The reaction mixture 
was quenched with ethanol: saturated aqueous ammonium chloride (2:1, 10 
ml) and indium powder (0.55 mmol, 0.06 g) was added before heated under 
reflux for 4 h.  Upon cooling, diethyl ether and saturated aqueous ammonium 
chloride were added and the aqueous layer further extracted with diethyl ether 
(3 x 10 ml).  The combined organic extracts were dried using anhydrous sodium 
sulphate and concentrated under reduced pressure.   This was purified by flash 
column chromatography on silica gel using dichloromethane: methanol (9:1) as 
the eluent gave the title compound (49 mg, 27%) as a pale yellow oil, Rf value 
0.47  δH (400 MHz; CDCl3) 0.83-0.87 (3H, t J = 7.6 Hz, 3x 2”-H); 1.41-1.90 (14H, 
m, 2x 2”-H, 2x 2-H, 2x 3-H, 2x 4-H, 2x 8-H, 2x 9-H, 2x 10-H); 2.43 (1H, m, 1-H); 
3.38 (1H, m, 7-H); 3.60 (1H, m, 1’a-H); 3.78 (1H, m, 1’b-H).  δC (100MHz; CDCl3) 
10.4 (C2”); 18.7, 19.4, 23.2, 25.0, 26.7, 28.6, 35.1 (C1”, C2, C3, C4, C8, C9, C10); 
42.3 (C1); 50.3 (C7); 62.4 (C1).  IR/cm-1 3268 (O-H br), 2937 (C-H), 1458 (C-H2), 
725 (C-H2). HRMS calcd for C12H23NO 197.1780: found [M+H] 198.1849. 
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(1S*,5S*,7R*)-1-(hydroxymethyl)-7-propyl-6-azaspiro[4.5]decane (213) 
 
A solution of spironitrone 147 (0.18 g, 0.98 mmol) was cooled to 0°C in 
tetrahydrofuran (10 ml) under Ar.  Propylmagnesium bromide (1.6 ml), 
prepared according to the general procedure in tetrahydrofuran, was added 
drop-wise before warming to r.t. and leaving to stir for 10 hours.  The reaction 
mixture was quenched with ethanol: saturated aqueous ammonium chloride 
(2:1, 10 ml) and indium powder (0.55 mmol, 0.06g) was added before heated 
under reflux for 4 h.  Upon cooling, diethyl ether and saturated aqueous 
ammonium chloride were added and the aqueous layer further extracted with 
diethyl ether (3 x 10 ml).  The combined organic extracts were dried using 
anhydrous sodium sulphate and concentrated under reduced pressure.   This 
was purified by flash column chromatography on silica gel using chloroform: 
methanol (9:1) as the eluent to give the title compound (60 mg, 29%) as a white 
solid.  δH (400 MHz; CDCl3) 0.83-0.87 (3H, t J = 7.6 Hz, 3x 3”-H);  1.24-2.07 (15H, 
m, 2x 2”-H, 2x 2-H, 2x 3”-H, 2x 3-H, 2x 4-H, 8a-H, 2x 9-H, 2x 10-H); 2.34-2.46 (2H, 
m, 1-H, 8b-H); 3.50-3.54 (2H, dd J = 3.2 and 11.6 Hz, 1’-H, 7-H); 3.99-4.05 (1H, t 
J = 11.6 Hz, 1’-H).  δC (100MHz; CDCl3) 13.8 (C3”); 18.5, 18.7, 19.4, 25.1, 27.6, 
32.7, 34.8, 35.4 (C1”,C2”, C2, C3, C4, C8, C9, C10); 41.0 (C1); 56.6 (C7); 62.3 (C1’); 
68.0 (C5).  IR/cm-1 3161 (O-H br), 2934 (C-H), 1616 (N-H), 1466 (O-H), 1064 (C-
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C), 739 (C-H2), m.p. 167-169°C, HRMS calcd for C13H25NO 211.1936: found [M+H] 
212.2008. 
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(1S*,5S*,7R*)-1-(hydroxymethyl)-7-butyl-6-azaspiro[4.5]decane (214)  
 
A solution of spironitrone 147 (0.15 g, 0.82 mmol) was cooled to 0°C in 
tetrahydrofuran (10 ml) under Ar.  Butylmagnesium bromide (1.5 ml), prepared 
according to the general procedure in tetrahydrofuran, was added drop-wise 
before warming to r.t. and leaving to stir for 10 hours.  The reaction mixture 
was quenched with ethanol: saturated aqueous ammonium chloride (2:1, 10 
ml) and indium powder (0.55 mmol, 0.06 g) was added before heated under 
reflux for 4 h.  Upon cooling, diethyl ether and saturated aqueous ammonium 
chloride were added and the aqueous layer further extracted with diethyl ether 
(3 x 10 ml).  The combined organic extracts were dried using anhydrous sodium 
sulphate and concentrated under reduced pressure.   This was purified by flash 
column chromatography on silica gel using dichloromethane: methanol (9:1) as 
the eluent gave the title compound (79 mg, 43%) as a yellow oil, Rf value 0.51  
δH (400 MHz; CDCl3) 0.84-0.90 (3H, t J = 7.6 Hz, 3x 4”-H); 1.21-2.03 (17H, m, 2x 
1”-H, 2x 2”-H, 2x 2-H, 2x 3”-H, 2x 3-H, 2x 4-H, 8a-H, 2x 9-H, 2x 10-H); 2.34-2.48 
(2H, m, 1-H, 8b-H); 3.53-3.56 (2H, m, 1’-H, 7-H); 4.01-4.07 (1H, t J = 11.6 Hz, 1’-
H).  δC (100MHz; CDCl3) 14.0 (C4”); 18.5, 19.5, 22.4, 22.6, 25.1, 27.6, 32.8, 33.3, 
34.9 (C1”, C2”, C2, C3”, C3, C4, C8, C9, C10); 41.0 (C1); 56.7 (C7); 63.1 (C1’); 67.8 
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(C5).  IR/cm-1 3354 (O-H br), 2926 (C-H), 1440 (C-H2).HRMS calcd for C14H27NO 
225.2093: found [M+H] 226.2165. 
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(1S*,5S*,7R*)-1-(hydroxymethyl)-7-pentyl-6-azaspiro[4.5]decane (215) 
 
A solution of spironitrone 147 (0.15 g, 0.82 mmol) was cooled to 0°C in 
tetrahydrofuran (10 ml) under Ar.  Pentylmagnesium bromide (1.5 ml), 
prepared according to the general procedure in tetrahydrofuran (10 ml), was 
added drop-wise before warming to r.t. and leaving to stir for 10 hours.  The 
reaction mixture was quenched with ethanol: saturated aqueous ammonium 
chloride (2:1, 10 ml) and indium powder (0.55 mmol, 0.06 g) was added before 
heated under reflux for 4 h.  Upon cooling, diethyl ether and saturated aqueous 
ammonium chloride were added and the aqueous layer further extracted with 
diethyl ether (3 x 10 ml). The combined organic extracts were dried using 
anhydrous sodium sulphate and concentrated under reduced pressure.   This 
was purified by flash column chromatography on silica gel using 
dichloromethane: methanol (9:1) as the eluent gave the title compound (79 mg, 
43%) as a yellow oil, Rf value 0.47  δH (400 MHz; CDCl3) 0.69-0.91 (5H, m, 3x 5”-
H, 2x 4”-H); 1.21-2.19 (18H, m, 2x 1”-H, 2x 2”-H, 2x 2-H, 2x 3”-H, 2x 3-H, 2x 4-H, 
2x 8-H, 2x 9-H, 2x 10-H); 2.43-2.52 (1H, m, 1-H); 3.51-3.56 (1H, m, 7-H); 3.82-
4.03 (2H, m, 2x 1’-H). δC (100MHz; CDCl3) 14.1 (C5”); 18.5, 19.4, 22.7, 25.1, 27.5, 
31.5, 32.6, 32.7, 33.2, 34.7 (C1”, C2”, C2, C3”, C3, C4”, C4, C8, C9, C10); 40.9 
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(C1); 56.8 (C7); 63.1 (C1’); 68.0 (C5).  IR/cm-1 3362 (O-H br), 2954 (C-H), 1458 (C-
H2).  HRMS calcd for C15H29NO 239.2249: found [M+H] 240.2322. 
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(1S*,5S*,7R*)-1-(hydroxymethyl)-7-hexyl-6-azaspiro[4.5]decane (216) 
 
A solution of spironitrone 147 (0.2 g, 1.0 mmol) was cooled to 0°C in dithyl ether 
(12 ml) under Ar.  Hexylmagnesium bromide (0.4 ml), prepared according to the 
general procedure in diethyl ether (10 ml), was added drop-wise before 
warming to r.t. and leaving to stir for 10 hours.  The reaction mixture was 
quenched with ethanol: saturated aqueous ammonium chloride (2:1, 12 ml) and 
indium powder (0.55 mmol, 0.06g) was added before heated under reflux for 4 
h.  Upon cooling, diethyl ether and saturated aqueous ammonium chloride were 
added and the aqueous layer further extracted with diethyl ether (3 x 10 ml).  
The combined organic extracts were dried using anhydrous sodium sulphate 
and concentrated under reduced pressure.   This was purified by flash column 
chromatography on silica gel using dichloromethane: methanol (9:1) as the 
eluent to give the title compound (87 mg, 34%) as a pale yellow oil, Rf value 0.32  
δH (400 MHz; CDCl3)  0.82-0.84 (3H, t J = 6.8 Hz, 3x 6”-H); 1.23-1.39 (8H, m, 2x 
3”-H, 2x 4”-H, 2x 5”-H); 1.58-2.04 (15H, 2x 1”-H, 2x 2”-H, 2x 2-H, 2x 3-H, 2x 4-H, 
8a-H, 2x 9-H, 2x 10-H); 2.36-2.51 (2H, m, 1-H, 8b-H); 3.47-3.57 (2H, dd J = 3.2 
and 11.6 Hz, 1’-H, 7-H); 4.03-4.09 (1H, t J = 11.6 Hz, 1’-H).  δC (100MHz; CDCl3) 
14.3 (C6”); 18.5, 19.6, 22.6, 25.0, 25.6, 27.6, 29.1, 31.8, 33.4, 34.7, 35.0 (C1”, 
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C2”, C2, C3”, C3, C4”, C4, C5”, C8, C9, C10); 41.0 (C1); 57.0 (C7); 63.1 (C1’); 67.9 
(C5).  HRMS calcd for C16H31NO 253.2406: found [M+H] 254.2478. 
  
 179 
(1S*,5S*,7R*)-1-(hydroxymethyl)-7-phenyl-6-azaspiro[4.5]decane (217)  
 
A solution of spironitrone 147 (0.2 g, 1.0 mmol) was cooled to 0°C in 
tetrahydrofuran (10 ml) under Ar.  Commercially prepared phenylmagnesium 
bromide (3M, 3 mmol, 0.2 ml) was added drop-wise before warming to r.t. and 
leaving to stir for 10 hours.  The reaction mixture was quenched with ethanol: 
saturated aqueous ammonium chloride (2:1, 12 ml) and indium powder (1.0 
mmol, 0.11 g) was added before heated under reflux for 4 h.  Upon cooling, 
diethyl ether and saturated aqueous ammonium chloride were added and the 
aqueous layer further extracted with diethyl ether (3 x 15 ml).  The combined 
organic extracts were dried using anhydrous sodium sulphate and concentrated 
under reduced pressure.   This was purified by flash column chromatography on 
silica gel using dichloromethane: methanol (9:1) as the eluent to give the title 
compound (165 mg, 67%) as a white solid, Rf value 0.48  δH (400 MHz; CDCl3) 
1.23-1.90 (12H, m, 2x 2-H, 2x 3-H, 2x 4-H, 2x 8-H, 2x 9-H, 2x 10-H); 2.36 (1H, m, 
1-H); 3.64 (2H, m, 2x 1’-H); 4.07 (1H, m, 7-H); 7.22-7.41 (5H, m, 2”-H, 3”-H, 4”-
H, 5”-H, 6”-H).  δC (100MHz; CDCl3) 20.2, 21.5, 27.6, 32.8, 36.7, 40.9 (C2, C3, C4, 
C8, C9, C10); 41.7 (C1); 57.8 (C7); 64.9 (C5); 65.5 (C1’); 126.7 (C3”, C5”); 127.4 
(C4”); 128.4 (C2”, C6”).  IR/cm-1 3284 (O-H br), 2931 (C-H), 1440 (C=C), 1068 (C-
 180 
C), 698 (C=C); m.p. 161-163°C.  HRMS calcd for C16H23NO 245.1780: found [M+H] 
246.1851. 
  
 181 
(1S*,5S*,7R*)-1-(hydroxymethyl)-7-benzyl-6-azaspiro[4.5]decane (218)  
 
A solution of spironitrone 147 (0.2 g, 1 mmol) was cooled to 0°C in diethyl ether 
(10 ml) under Ar.  Benzylmagnesium bromide (1.8 ml), prepared according to 
the general procedure in diethyl ether (10 ml), was added drop-wise before 
warming to r.t. and leaving to stir for 10 hours.  The reaction mixture was 
quenched with ethanol: saturated aqueous ammonium chloride (2:1, 12 ml) and 
indium powder (1.0 mmol, 0.11 g) was added before heated under reflux for 4 
h.  Upon cooling, diethyl ether and saturated aqueous ammonium chloride were 
added and the aqueous layer further extracted with diethyl ether (3 x 15 ml).  
The combined organic extracts were dried using anhydrous sodium sulphate 
and concentrated under reduced pressure.   This was purified by flash column 
chromatography on silica gel using dichloromethane: methanol (9:1) as the 
eluent gave the title compound (89 mg, 34%) as a pale yellow solid, Rf value 0.62  
δH (400 MHz; CDCl3)  1.23-2.09 (14H, m, 2x 1”-H, 2x 2-H, 2x 3-H, 2x 4-H, 2x 8-H, 
2x 9-H, 2x 10-H); 2.49 (1H, m, 1-H); 3.54 (1H, dd J = 3.2 and 11.6 Hz, 7-H); 3.73 
(1H, t J = 11.6 Hz, 1’a-H); 4.34 (1H, d J = 12 Hz, 1’b-H); 7.24-7.33 (4H, m, 3”-H, 
4”-H, 6”-H, 7”-H); 7.55 (1H, m, 5”-H).  δC (100MHz; CDCl3) 128.3, 128.4, 128.7 
(C3”, C4”, C5”, C6”, C7”). IR/cm-1 3290 (O-H br), 2930 (C-H), 1449 (C=C), 1070 
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(C-C), 698 (C=C); m.p. 165-168°C.  HRMS calcd for C17H25NO 259.1936: found 
[M+H] 260.1654. 
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(1S*,5S*,7R*)-7-allyl-(hydroxymethyl)-6-azaspiro[4.5]decan-6-ol (281) 
  
A solution of spironitrone 147 (0.10 g, 0.55 mmol) was cooled to 0°C in THF (10 
ml) under Ar.  Commercially prepared allylmagnesium chloride (2M, 1.65 mmol, 
0.2 ml) was added drop-wise over 5 minutes.  The resulting mixture was 
warmed to r.t., before leaving to stir for 10 hours.  Water (2 ml) was added to 
quench the reaction before separation between saturated aqueous ammonium 
chloride (10 ml) and dichloromethane (10 ml), followed by further extraction 
with dichloromethane (3x 15 ml).  The combined organic layers were dried with 
anhydrous sodium sulphate and concentrated under reduced pressure.  The 
residue was purified by flash column chromatography gave the title compound 
(0.7240g, 28%*, 25.5 mg, 3%) as an orange oil, Rf value 0.63  δH (400 MHz; CDCl3)  
1.23-2.33 (14H, m, 1”-H, 2-H, 3-H, 4-H, 8-H, 9-H, 10-H); 3.08 (1H, m, 7-H); 3.42-
3.60 (2H, m, 1’-H); 5.00-5.02 (2H, m, 3”-H); 5.81 (1H, m, 2”-H).   δC (100MHz; 
CDCl3) 20.0, 20.4, 24.1, 27.7, 28.6, 37.6 (C2, C3, C4, C8, C9, C10); 38.3 (C1”); 43.4 
(C1); 61.6 (C7); 65.4 (C1’); 73.0 (C5); 116.7 (2”-H); 136.3 (3”-H).  IR/cm-1 3272 
(O-H br), 2938 (C-H), 1495 (C=C), 1038 (C-C).  HRMS calcd for C13H23NO2 
225.1729: found [M+H] 226.1813. 
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(1S*,5S*,7R*)-1-(hydroxymethyl)-7-allyl-6-azaspiro[4.5]decane (219)  
 
A solution of 281 (0.1g, 0.55 mmol) in acetic acid: water (1:1, 10 ml) with zinc 
dust (4.4 mmol, 0.29 g) was heated under reflux for 4 h.  The reaction mixture 
was then cooled to r.t., before quenching with saturated aqueous sodium 
carbonate (10 ml), before extracting with chloroform (3 x 30 ml).  The organic 
layers were combined, dried with anhydrous sodium sulphate and concentrated 
under reduced pressure to a give a crude yellow oil.  This was purified by flash 
column chromatography on silica gel using dichloromethane: methanol (9:1) as 
the eluent gave the title compound (64 mg, 55%) as a yellow oil, Rf value 0.30  
δH (400 MHz; CDCl3) 1.42-2.16 (13H, m, 1’’a-H, 2x 2-H, 2x 3-H, 2x 4-H, 2x  8-H, 
2x 9-H, 2x 10-H); 2.51-2.54 (1’’b-H); 2.87 (1H, m, 1-H); 3.06 (1H, m, 7-H); 3.93-
4.02 (2H, m, 2x 1’-H); 5.16-5.24 (2H, m, 2x 3”-H); 5.64-5.72 (1H, m, 2”-H).  δC 
(100MHz; CDCl3) 20.4, 23.0, 27.4, 28.0, 33.4, 34.7 (C2, C3, C4, C8, C9, C10); 37.9 
(C1”); 50.2 (C1); 54.0 (C7); 61.5 (C1’); 68.2 (C5); 120.4 (C2”); 132.0 (C3”).  IR/cm-
1 3268 (O-H br), 2938 (C-H), 1458 (C=C), 1054 (C-C).  HRMS calcd for C13H23NO 
209.1780: found [M+H] 210.1850. 
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(1S*,5S*,7R*)-1-(hydroxymethyl)-7-pentyl-6-azaspiro[4.5]decan-6-ol (282) 
 
A solution of spironitrone 147 (0.10 g, 0.55 mmol) was cooled to 0°C in 
tetrahydrofuran (10 mL) under Ar.  Freshly prepared pentenylmagnesium 
bromide (1.0 ml) was added drop-wise before warming to r.t. and leaving to stir 
for 10 h.  The mixture was quenched with water (5 ml) followed by the removal 
of tetrahydrofuran and water under reduced pressure.   Saturated aqueous 
ammonium chloride (10 ml) was added to the slurry and extracted with diethyl 
ether (3 x 10 ml).  The combined extracts were dried with anhydrous sodium 
sulphate and concentrated under reduced pressure to a yellow oil.  This was 
purified by flash column chromatography using ethyl acetate: hexane (1:1) as 
the eluent to give the title compound (23 mg, 17%) as a clear oil, Rf value 0.54  
δH (400 MHz; CDCl3) 1.16-2.23 (19H, m, 1-H, 2x 1”-H, 2x 2”-H, 2x 2-H, 2x 3”-H, 
2x 3-H, 2x 4-H, 2x 8-H, 2x 9-H, 2x 10-H); 2.91 (1H, m, 7-H); 3.58 (2H, m, 2x 1’-H); 
4.75-4.98 (2H, m, 2x 4”-H); 5.76 (1H, m, 5”-H).  δC (100MHz; CDCl3) 20.6, 21.1, 
25.3, 27.9, 33.1, 34.0, 37.4, 41.3, 41.7 (C1’, C2’, C2, C3’, C3, C4, C8, C9, C10); 
50.3 (C1); 53.3 (C7); 63.6 (C1’); 65.9 (C5); 114.7 (C4’); 138.8 (C5’).  IR/cm-1 3279 
(O-H br), 2926 (C-H), 1456 (C=C), 907 (C-C).  HRMS  calcd for C15H27NO2 
253.2042: found [M+H] 254.2125. 
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1-((1S*, 5S*)-1-(((tert-butyldiphenylsilyl)oxy)methyl)-6-azaspiro[4.5]decane 
(242) 
 
Method 1 
244 (2.7 g, 15.9 mmol) was dissolved in minimal amounts of dimethylformamide 
(8 ml) with 4-dimethylaminopyridine (3.2 mmol, 0.39 g) and imidazole (47.7 
mmol, 3.25 g) before the drop-wise addition of tert-butyldiphenylsilyl chloride 
(31.8 mmol, 8.2 ml) over 10 minutes, before stirring at r.t. for 48 h.  The thick 
white solution was separated between dichloromethane and brine, before 
extraction with dichloromethane (3 x 20 ml).  The combined organic layers were 
dried using anhydrous sodium sulphate and concentrated under reduced 
pressure.   This was purified by flash column chromatography using a 
dichloromethane: methanol gradient elution 100% dichloromethane to 9:1 
dichloromethane: methanol to give the title compound (0.45 g, 54%) as a yellow 
oil. 
Method 2 
Spiroamine 244 (2.0 g, 12.1 mmol) in dichloromethane (20 ml) was cooled to 
0°C with 4-dimethylaminopyridine (0.6 mmol, 0.73 g), and triethylamine (74.9 
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mmol, 10.5 ml) before the drop-wise addition of tert-butyldiphenylsilyl chloride 
(24.2 mmol, 6.2 ml).  The mixture was warmed to r.t. and stirred overnight.  
Upon completion, the reaction mixture was separated between 
dichloromethane and brine, before extraction with dichloromethane (3 x 20 
ml).  The combined organic layers were dried using anhydrous sodium sulphate 
and concentrated under reduced pressure.   This was purified by flash column 
chromatography using a dichloromethane: methanol gradient elution 100% 
dichloromethane to 9:1 dichloromethane: methanol to give the title compound 
(2.84 g, 59%) as a yellow oil, Rf value 0.68  δH (400 MHz; CDCl3) 1.03 (9H, s, tBu); 
1.46-2.01 (12H, m, 2x 2-H, 2x 3-H, 2x 4-H, 2x 8-H, 2x 9-H, 2x 10-H); 2.21 (1H, m, 
7a-H); 2.30 (1H, m, 7b-H); 2.88-2.99 (1H, m, 1’a-H); 3.39-3.47 (1H, m, 1’b-H); 
7.38-7.59 (10H, m, Ph-H).   δC (100MHz; CDCl3) 18.7, 19.2, 21.3, 24.3, 25.7, 34.8 
(C2, C3, C4, C8, C9, C10); 27.0 (3C-tBu); 43.6 (C7); 48.9 (C1); 62.9 (C1’); 70.9 (C5); 
127.9, 130.5, 132.9, 135.1, 135.9 (C-Ph); IR/cm-1 2856 (C-H), 2732 (C-H), 1428 
(C-H3), 1109 (C-H); 706 (C-C); m.p.92-93°C.  HRMS calcd for C26H37NOSi 
407.2643: found [M+H] 408.2717. 
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1-((1S, 5S)-1-(((tert-butyldiphenylsilyl)oxy)methyl)-6-azaspiro[4.5]decan-6-
yl)-2,2,2-trifluoroethanone (258) 
 
Silyl ether 242 (0.9 g, 2.2 mmol) with triethylamine (4.9 mmol, 0.7 ml) in 
dichloromethane (15 ml) was cooled to 0°C, before the cautious drop-wise of 
trifloroacetic anhydride (4.4 mmol, 0.6 ml).  The reaction mixture was stirred 
for 30 minutes at 0°C, before warming to r.t. and stirring for 6 h.  When 
complete, the solution was quenched with a PH7 aqueous buffer and extracted 
with dichloromethane (3 x 20 ml).  The combined organic layers were dried 
using anhydrous sodium sulphate and concentrated under reduced pressure.   
This was purified by flash column chromatography using a ethyl acetate: hexane 
as the eluent to give the title compound (0.74 g, 68%) as a pale orange oil, Rf 
value 0.91  δH (400 MHz; CDCl3) 1.03 (9H, s, tBu); 1.53-2.06 (12H, m, 2x 2-H, 2x 
3-H, 2x 4-H, 2x 8-H, 2x 9-H, 2x 10-H); 2.21 (1H, m, 7a-H); 2.33 (1H, m, 7b-H); 
2.92-2.98 (1H, m, 1’a-H); 3.47-3.49 (1H, m, 1’b-H); 7.35-7.6 (10H, m, Ph-H).   δC 
(100MHz; CDCl3) 18.4, 19.3, 21.6, 24.7, 25.9, 34.9 (C2, C3, C4, C8, C9, C10); 27.0 
(3C-tBu); 43.6 (C7); 48.7 (C1); 63.7 (C1’); 70.3 (C5); 127.8, 129.8, 133.5, 135.6, 
135.7 (C-Ph); 133.8 (C-F3); 157.0 (C=O). IR/cm-1 2931 (C-H), 2744 (C-H), 1741 
(C=O), 1446 (C-H3), 1127 (C-H); 703 (C-C).  HRMS calcd for C28H36F3NO2Si 
503.2466: found [M+H].  
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1-((1S, 5S)-1-(((tert-butyldimethylsilyl)oxy)methyl)-6-azaspiro[4.5]decane 
(243) 
 
Method 1 
244 (1.6 g, 9.5 mmol) was dissolved in minimal amounts of dimethylformamide 
(6 ml) with 4-dimethylaminopyridine (4.7 mmol, 0.58 g) and imidazole (28.3 
mmol, 1.93) before the portion-wise addition of tert-butyldimethylsilyl chloride 
(18.9 mmol, 2.6 g) over 10 minutes.  The mixture was heated at 120°C for 5 h.  
When complete, the mixture was separated between dichloromethane and 
brine, before extraction with dichloromethane (3 x 20 ml).  The combined 
organic layers were dried using anhydrous sodium sulphate and concentrated 
under reduced pressure.   This was purified by flash column chromatography 
using a dichloromethane: methanol gradient elution 100% dichloromethane to 
9:1 dichloromethane: methanol to give the title compound (1.38 g, 52%) as a 
pale yellow oil. 
 
 
 
 190 
Method 2 
Spiroamine 244 (2.0 g, 11.8 mmol) in dichloromethane (20 ml) with 4-
dimethylaminopyridine (0.6 mmol, 0.73 g), and imidazole (29.5 mmol, 2.0 g) 
before the portion-wise addition of tert-butyldimethylsilyl chloride (24.2 mmol, 
63.5 g).  The mixture was warmed to r.t. and stirred for 48 h.  Upon completion, 
the reaction mixture was separated between dichloromethane and brine, 
before extraction with dichloromethane (3 x 20 ml).  The combined organic 
layers were dried using anhydrous sodium sulphate and concentrated under 
reduced pressure.   This was purified by flash column chromatography using a 
dichloromethane: methanol gradient elution 100% dichloromethane to 9:1 
dichloromethane: methanol to give the title compound (2.11 g, 63%) as a pale 
yellow oil, Rf value 0.33  δH (400 MHz; CDCl3) 0.10-0.15 (6H, d J = 3.6 Hz, (CH3)2); 
0.89 (9H, s, tBu); 1.41-2.10 (12H, m, 2x 2-H, 2x 3-H, 2x 4-H, 2x 8-H, 2x 9-H, 10-
H); 2.17-2.25 (1H, m, 7a-H); 2.97 (1H, m, 1-H); 3.35-3.38 (1H, m, 7b-H); 3.96 (1H, 
m, 1’a-H); 4.14 (1H, m, 1’b-H).  δC (100MHz; CDCl3) -5.3 (CH3)2); 20.4, 22.8, 24.1, 
28.1, 33.8, 36.0 (C2, C3, C4, C8, C9, C10); 41.5 (C7); 51.0 (C1); 63.6 (C1’); 66.8 
(C5).  IR/cm-1 2928 (C-H), 1461 (C-H3), 1079 (C-H); 835 (C-C).  HRMS calcd for 
C16H33NOSi 283.2331: found [M+H] 284.2373. 
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1-((1S*, 5S*)-1-(((tert-butyldimethylsilyl)oxy)methyl)-6-azaspiro[4.5]decan-6-
yl)-2,2,2-trifluoroethanone (242) 
 
Silyl ether 243 (0.9 g, 3.1 mmol) with triethylamine (6.7 mmol, 1.0 ml) in CH2Cl2 
(10 ml) was cooled to 0°C, before the cautious drop-wise of trifloroacetic 
anhydride (6.2 mmol, 0.9 ml).  The reaction mixture was stirred for 30 minutes 
at 0°C, before warming to r.t. and stirring overnight.  When complete, the 
solution was quenched with a PH7 aqueous buffer and extracted with 
dichloromethane (3 x 20 ml).  The combined organic layers were dried using 
anhydrous sodium sulphate and concentrated under reduced pressure.   This 
was purified by flash column chromatography using a ethyl acetate: hexane as 
the eluent to give the title compound (0.87 g, 86%) as a pale yellow solid.  Rf 
value 0.65 δH (400 MHz; CDCl3) 0.05 (6H, d J = 3.6 Hz, (CH3)2); 0.85 (9H, s, tBu); 
1.44-1.97 (12H, m, 2x 2-H, 2x 3-H, 2x 4-H, 2x 8-H, 2x 9-H, 2x 10-H); 2.21-2.26 
(1H, m, 7a-H); 2.47 (1H, m, 1-H); 3.21-3.22 (1H, m, 7b-H); 3.43-3.48 (2H, m, 2x 
1’-H).  δC (100MHz; CDCl3) -3.3 (CH3)2); 19.3, 20.8, 22.9, 28.1, 33.8, 36.0 (C2, C3, 
C4, C8, C9, C10); 40.9 (C7); 51.3 (C1); 64.2 (C1’); 66.9 (C5); 134.2 (C-F3); 154.3 
(C=O).  IR/cm-1 2942 (C-H), 1734 (C=O), 1453 (C-H3), 1058 (C-H), 830 (C-C); m.p. 
46-49°C.  HRMS calcd for C18H32F3NO2Si 379.2154: found [M+H].  
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(6R*, 8S*)-2-hexyl-1-azaspiro[5.5]undecan-8-ol (240) 
 
A solution of spironitrone 231 (0.06 g, 0.33 mmol) was cooled to 0°C in diethyl 
ether (10 ml) under Ar.  Freshly prepared hexylmagnesium bromide (0.2 ml) was 
added drop-wise before warming to r.t. and leaving to stir for 10 hours.  The 
reaction mixture was quenched with ethanol: saturated aqueous ammonium 
chloride (2:1, 10 ml) and indium powder (0.33 mmol, 0.04 g) was added before 
heated under reflux for 4 h.  Upon cooling, the reaction mixture was separated 
using diethyl ether and saturated aqueous ammonium chloride and washed 
with diethyl ether (3 x 10 ml).  The combined organic extracts were dried using 
anhydrous sodium sulphate and concentrated under reduced pressure.   This 
was purified by flash column chromatography on silica gel using chloroform: 
methanol (9:1) as the eluent to give the title compound (19 mg, 23%) as a clear 
oil.  Rf value 0.65; δH (400 MHz; CDCl3) 0.85 (3H, t J = 7.6 Hz, 6’-H); 1.23-1.94 
(22H, m, 2x 1’-H, 2x 2’-H, 2x 3’-H, 2x 3-H, 2x 4’-H, 2x 4-H, 2x 5’-H, 2x 5-H, 2x 9-
H, 2x 10-H, 2x 11-H); 2.19-2.2 (1H, m, 7a-H); 2.5 (1H, m, 7b-H); 2.88 (1H, m, 2-
H); 3.6-3.8 (1H, m, 8-H).  δC (100MHz; CDCl3) 14.2, 20.2, 20.7, 22.7, 25.9, 26.7, 
27.4, 29.4, 31.8, 36.6, 37.1, 41.6 (C1’, C2’, C3’, C3, C4’, C4, C5’, C5, C9, C10, C11); 
46.9 (C7); 54.0 (C2); 64.8 (C8); 65.4 (C6).  IR/cm-1 3362 (O-H br), 2936 (C-H), 1457 
(C-C), 1069 (C-H2).  HRMS calcd for C16H31NO 253.2406: found [M+H] 254.2480. 
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(1R*, 2’R*, 3S*)-2’-phenylhexyhydrospiro[cyclohexane-1,7’-isoxazolo[2,3-
a]pyridine]-3-ol (232) 
 
Spironitrone 231 (0.02 g, 0.1 mmol) and styrene (0.7 mmol, 0.08 ml) in toluene 
(6 ml) was heated under reflux for 4 h.  When complete the toluene was 
removed under reduced pressure.  This was purified by flash column 
chromatography using ethyl acetate: hexane (1: 1) as the eluent to give the title 
compound (0.87 g, 86%) as a clear oil, Rf value 0.63; δH (400 MHz; CDCl3) 1.42-
1.9 (12H, m, 2x 4-H, 2x 4’-H, 2x 5-H, 2x 5’-H, 2x 6-H, 2x 6’-H); 2.17-2.47 (4H, m, 
2x 2-H, 2x 3’-H); 3.67 (2H, m, 2’-H, 3a’-H); 5.06 (1H, m, 3-H); 7.19-7.37 (5H, m, 
Ph-H).  δC (100MHz; CDCl3) 19.3, 21.5, 26.1, 27.6, 38.0, 44.6, 45.7, 65.6 (C2, C3’, 
C4, C4’, C5, C5’, C6, C6’); 58.6 (C3a’); 69.9 (C1); 76.5 (C3); 86.7 (C2’); 125.5, 
127.2, 128.6 (C-Ph); IR/cm-1 3347 (O-H br), 2913 (C-H), 1446 (C-C), 975 (C-H).  
HRMS calcd for C18H25NO2 287.1885: found [M+H] 469.3051. 
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1-((1R*,3S*)-3-hydroxyhexahydrospiro[cyclohexane-1,7’-isoxazolo[2,3-
a]pyridine]-3’-yl)ethanone (233) 
 
Spironitrone 231 (0.06 g, 0.3 mmol) and methyl vinyl ketone (2.0 mmol, 0.16 
ml) in ethanol (5 ml) was stirred at r.t..  When complete the ethanol was 
removed under reduced pressure.  This was purified by flash column 
chromatography using ethyl acetate: hexane (1: 1) as the eluent to give the title 
compound (0.87 g, 86%) as a clear oil.  Rf value 0.26; δH (400 MHz; CDCl3) 1.01-
2.34 (19H, 2x 2-H, 2’-H, 2x 2”-H, 2x 4-H, 2x 4’-H, 2x 5-H, 2x 5’-H, 2x 6-H, 2x 6’-
H); 3.62-3.65 (1H, m, 3a’-H); 3.97 (1H, m, 3-H); 4.28-4.33 (1H, m, 3’-H).  δC 
(100MHz; CDCl3) 15.6, 18.4, 25.7, 31.0, 33.4, 36.6, 38.4, 39.1 (C2, C2’ C4, C4’, 
C5, C5’, C6, C6’); 25.5 (C2”); 55.0 (C3a); 59.2 (C1); 67.0 (C3); 79.3 (C2’); 211.4 
(C1”).  IR/cm-1 3346 (O-H br), 2968 (C-H), 1725 (C=O), 1455 (C-C) 1048 (C-H2).  
HRMS calcd for C14H23NO3 253.1678: found [M+H] 254.1746. 
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(1R*, 2’R*, 3S*)-2’-methyl 3-hexyhydrospiro[cyclohexane-1,7’-isoxazolo[2,3-
a]pyridine]-2’-carboxylate (234) 
 
Spironitrone 231 (0.10 g, 0.5 mmol) and methyl acrylate (3.3 mmol, 0.3 ml) in 
toluene (10 ml) was heated under reflux for 4 h.  When complete the toluene 
was removed under reduced pressure.  This was purified by flash column 
chromatography using ethyl acetate: hexane (1: 1) as the eluent to give the title 
compound (0.68 g, 39%*) as a clear oil.  Rf value 0.34; δH (400 MHz; CDCl3) 1.03-
2.53 (16H, 2.71-3.07 (2x 2-H, 2x 2*-H, 2x 3’-H, 2x 3’*-H, 2x 4-H, 2x 4*-H, 2x 4’-
H, 2x 4’*-H, 2x 5-H, 2x 5*-H, 2x 5’-H, 2x 5’*-H, 2x 6-H, 2x 6*-H, 2x 6’-H, 2x 6’*-
H); (1H, m, 3a-H, 3a*-H); 3.43-4.11 (3H, m, 3’’-H, 3’’*-H); 4.12-4.56 (1H, m, 3-H, 
3*-H); 5.11-5.39 (1H, m, 2’-H, 2’*-H).  δC (100MHz; CDCl3) 15.0, 15.3, 18.3, 25.9, 
26.2, 31.3, 31.4, 32.1, 33.6, 36.8, 37.1, 38.8, 39.0, 39.6, 52.2, 52.4, 53.5, 54.3, 
58.3, 58.7, 66.7, 67.0, 67.4, 67.8 (C2, C2*, C3, C3*, C3’, C3’*, C3”, C3”*, C3a’, 
C3a’*, C4, C4*, C4’, C4’*, C5, C5*, C5’, C5*, C6, C6*, C6’, C6’*); 65.9 (C1); 72.5 
(C2’); 173.2, 173.5 (C1”, C1”*).  IR/cm-1 3353 (O-H br), 2936 (C-H), 1734 (C=O), 
1436 (C-C) 1058 (C-H2). HRMS calcd for C14H23NO4 269.1628: found [M+H] 
270.1699. 
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Chapter 10 Appendix  
10.1 Statistical data 
Statistical data obtained from the ANOVA test calculated using SPSS stats 
package, showing the untreated cells against the treated cells. 
Growth and viability data for undifferentiated U937 cells. 
Untreated cells     
  VS   
ALL treatments 
Mean 
Difference  Std. Error 
Sig. 
(P) 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
Propyl 10-4 M .20383 .09972 .990 -.1889 .5966 
Propyl 10-5 M .17250 .09972 1.000 -.2202 .5652 
Phenyl 10-4 M .10667 .09972 1.000 -.2861 .4994 
Phenyl 10-5 M .21900 .09972 .972 -.1737 .6117 
Ethyl Ac 10-4 M -.27983 .09972 .669 -.6726 .1129 
Ethyl Ac 10-5 M -.12217 .09972 1.000 -.5149 .2706 
Phenyl Ac 10-4 M -.32483 .09972 .318 -.7176 .0679 
Phenyl Ac 10-5 M -.24467 .09972 .895 -.6374 .1481 
Ethyl 10-4 M -.47833* .09972 .002 -.8711 -.0856 
Ethyl 10-5 M -.28917 .09972 .594 -.6819 .1036 
Allyl 10-4 M -.39167 .09972 .052 -.7844 .0011 
Allyl 10-5 M -.13300 .09972 1.000 -.5257 .2597 
Pentenyl OH 10-4 
M 
-.28667 .09972 .614 -.6794 .1061 
Pentenyl OH 10-5 
M 
-.10900 .09972 1.000 -.5017 .2837 
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Allyl OR 10-4 M .75950* .09972 .000 .3668 1.1522 
Allyl OR 10-5 M 
Methyl Ac 10-4 M 
.06967 
.11383 
.09972 
.09972 
1.000 
1.000 
-.3231 
-.2789 
.4624 
.5066 
Methyl Ac 10-5 M .22600 .09972 .958 -.1667 .6187 
Methyl 10-4 M 
Methyl 10-5 M 
Butyl 10-4 M 
-.40167* 
-.32083 
.05750 
.09972 
.09972 
.09972 
.037 
.345 
1.000 
-.7944 
-.7136 
-.3352 
-.0089 
.0719 
.4502 
Butyl 10-5 M .13050 .09972 1.000 -.2622 .5232 
Hexyl 10-4 M -.32083 .09972 .345 -.7136 .0719 
Hexyl 10-5 M -.05183 .09972 1.000 -.4446 .3409 
Benzyl Ac 10-4 M .19717 .09972 .994 -.1956 .5899 
Benzyl Ac 10-5 M .33300 .09972 .265 -.0597 .7257 
Benzyl 10-4 M -.52583* .09972 .000 -.9186 -.1331 
Benzyl 10-5 M -.43667* .09972 .011 -.8294 -.0439 
Pentyl 10-4 M -.19050 .09972 .997 -.5832 .2022 
Pentyl 10-5 M -.35167 .09972 .168 -.7444 .0411 
TBDMS 10-4 M .26267 .09972 .795 -.1301 .6554 
TBDMS 10-5 M .17667 .09972 .999 -.2161 .5694 
TBDPS 10-4 M .16783 .09972 1.000 -.2249 .5606 
TBDPS 10-5 M -.12367 .09972 1.000 -.5164 .2691 
N-Ac OH 10-4 M -.40500* .09972 .033 -.7977 -.0123 
N-Ac OH 10-5 M -.19367 .09972 .996 -.5864 .1991 
TFA-PS 10-4 M .18117 .09972 .999 -.2116 .5739 
TFA-PS 10-5 M .21617 .09972 .977 -.1766 .6089 
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Growth and viability data for LPS activated U937 cells. 
 
Untreated cells 
VS 
ALL Treatments 
Mean 
Difference Std. Error 
Sig. 
(P) 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
 Propyl 10-4 M -.02100 .08395 1.000 -.3516 .3096 
Propyl 10-5 M -.09733 .08395 1.000 -.4280 .2333 
Phenyl 10-4 M -.07467 .08395 1.000 -.4053 .2560 
Phenyl 10-5 M .08933 .08395 1.000 -.2413 .4200 
Ethyl Ac 10-4 M -.39083* .08395 .004 -.7215 -.0602 
Ethyl Ac 10-5 M -.34917* .08395 .024 -.6798 -.0185 
Phenyl Ac 10-4 M -.49117* .08395 .000 -.8218 -.1605 
Phenyl Ac 10-5 M -.46617* .08395 .000 -.7968 -.1355 
Ethyl 10-4 M -.23683 .08395 .658 -.5675 .0938 
Ethyl 10-5 M -.17000 .08395 .992 -.5006 .1606 
Allyl 10-4 M -.35017* .08395 .023 -.6808 -.0195 
Allyl 10-5 M -.45850* .08395 .000 -.7891 -.1279 
Pentenyl OH 10-4 M -.49200* .08395 .000 -.8226 -.1614 
Pentenyl OH 10-5 M -.36683* .08395 .011 -.6975 -.0362 
Allyl OR 10-4 M .46633* .08395 .000 .1357 .7970 
Allyl OR 10-5 M -.03033 .08395 1.000 -.3610 .3003 
Methyl Ac 10-4 M -.04700 .08395 1.000 -.3776 .2836 
Methyl Ac 10-5 M .01483 .08395 1.000 -.3158 .3455 
Methyl 10-4 M -.19217 .08395 .953 -.5228 .1385 
Methyl 10-5 M .06100 .08395 1.000 -.2696 .3916 
Butyl 10-4 M -.12917 .08395 1.000 -.4598 .2015 
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Butyl 10-5 M -.11317 .08395 1.000 -.4438 .2175 
Hexyl 10-4 M .13883 .08395 1.000 -.1918 .4695 
Hexyl 10-5 M .17750 .08395 .984 -.1531 .5081 
Benzyl Ac 10-4 M .31417 .08395 .092 -.0165 .6448 
Benzyl Ac 10-5 M .14850 .08395 .999 -.1821 .4791 
Benzyl 10-4 M -.34433* .08395 .029 -.6750 -.0137 
Benzyl 10-5 M -.36100* .08395 .014 -.6916 -.0304 
Pentyl 10-4 M -.48450* .08395 .000 -.8151 -.1539 
Pentyl 10-5 M -.28583 .08395 .228 -.6165 .0448 
TBDMS 10-4 M -.18133 .08395 .978 -.5120 .1493 
TBDMS 10-5 M -.24500 .08395 .579 -.5756 .0856 
TBDPS 10-4 M -.19433 .08395 .946 -.5250 .1363 
TBDPS 10-5 M -.29150 .08395 .193 -.6221 .0391 
N-Ac OH 10-4 M .11117 .08395 1.000 -.2195 .4418 
N-Ac OH 10-5 M -.09717 .08395 1.000 -.4278 .2335 
TFA-PS 10-4 M -.08267 .08395 1.000 -.4133 .2480 
TFA-PS 10-5 M -.16500 .08395 .995 -.4956 .1656 
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NO data for undifferentiated U937 cells. 
Untreated cells 
Vs 
ALL Treatments 
Mean 
Difference  Std. Error 
Sig. 
(P) 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Propyl 10-4 M 128.91667* 30.76323 .018 8.8038 249.0295 
Propyl 10-5 M 72.22250 30.76323 .939 -47.8903 192.3353 
Phenyl 10-4 M 110.00000 30.76323 .139 -10.1128 230.1128 
Phenyl 10-5 M 64.16750 30.76323 .988 -55.9453 184.2803 
Ethyl Ac 10-4 M 85.55667 30.76323 .691 -34.5562 205.6695 
Ethyl Ac 10-5 M 31.11333 30.76323 1.000 -88.9995 151.2262 
Phenyl Ac 10-4 M 64.44583 30.76323 .988 -55.6670 184.5587 
Phenyl Ac 10-5 M -28.33250 30.76323 1.000 -148.4453 91.7803 
Ethyl 10-4 M 56.94583 30.76323 .999 -63.1670 177.0587 
Ethyl 10-5 M 7.50167 30.76323 1.000 -112.6112 127.6145 
Allyl 10-4 M 55.02750 30.76323 .999 -65.0853 175.1403 
Allyl 10-5 M -36.08167 30.76323 1.000 -156.1945 84.0312 
Pentenyl OH 10-4 M 92.22333 30.76323 .511 -27.8895 212.3362 
Pentenyl OH 10-5 M 72.77750 30.76323 .934 -47.3353 192.8903 
Allyl OR 10-4 M 91.38917 30.76323 .534 -28.7237 211.5020 
Allyl OR 10-5 M 56.39000 30.76323 .999 -63.7228 176.5028 
Methyl Ac 10-4 M 115.00083 30.76323 .086 -5.1120 235.1137 
Methyl Ac 10-5 M 72.77833 30.76323 .934 -47.3345 192.8912 
Methyl 10-4 M 108.61250 30.76323 .158 -11.5003 228.7253 
Methyl 10-5 M 76.39000 30.76323 .886 -43.7228 196.5028 
Butyl 10-4 M 102.27326 31.45462 .314 -20.5391 225.0856 
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Butyl 10-5 M 73.33417 30.76323 .927 -46.7787 193.4470 
Hexyl 10-4 M 105.00167 30.76323 .215 -15.1112 225.1145 
Hexyl 10-5 M 66.39000 30.76323 .981 -53.7228 186.5028 
Benzyl Ac 10-4 M 104.39508 31.45462 .270 -18.4173 227.2074 
Benzyl Ac 10-5 M 70.00083 30.76323 .959 -50.1120 190.1137 
Benzyl 10-4M 120.00083 30.76323 .051 -.1120 240.1137 
Benzyl 10-5 M 78.05583 30.76323 .858 -42.0570 198.1687 
Pentyl 10-4 M 107.33317 32.26475 .265 -18.6422 233.3086 
Pentyl 10-5 M 76.11250 30.76323 .890 -44.0003 196.2253 
TBDMS 10-4 M 50.00083 30.76323 1.000 -70.1120 170.1137 
TBDMS 10-5 M .27917 30.76323 1.000 -119.8337 120.3920 
TBDPS 10-4 M 33.61167 30.76323 1.000 -86.5012 153.7245 
TBDPS 10-5 M -8.05500 30.76323 1.000 -128.1678 112.0578 
N-Ac OH 10-4 M 29.72250 30.76323 1.000 -90.3903 149.8353 
N-Ac OH 10-5 M 10.00000 30.76323 1.000 -110.1128 130.1128 
TFA-PS 10-4 M 48.88833 30.76323 1.000 -71.2245 169.0012 
TFA-PS 10-5 M -15.27667 30.76323 1.000 -135.3895 104.8362 
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NO data for LPS activated U937 cells. 
Untreated cells 
VS 
ALL Treatments 
Mean 
Difference  Std. Error 
Sig. 
(P) 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Propyl 10-4 M 152.22333* 20.55686 .000 71.9297 232.5170 
Propyl 10-5 M 87.77667* 20.55686 .013 7.4830 168.0703 
Phenyl 10-4 M 129.24182* 20.97729 .000 47.3060 211.1776 
Phenyl 10-5 M 72.88000 20.97729 .184 -9.0558 154.8158 
Ethyl Ac 10-4 M 114.72333* 20.55686 .000 34.4297 195.0170 
Ethyl Ac 10-5 M 34.72250 20.55686 1.000 -45.5711 115.0161 
Phenyl Ac 10-4 M 124.99917* 20.55686 .000 44.7055 205.2928 
Phenyl Ac 10-5 M 71.38833 20.55686 .184 -8.9053 151.6820 
Ethyl 10-4 M 163.00000* 21.47094 .000 79.1360 246.8640 
Ethyl 10-5 M 77.33300 21.47094 .129 -6.5310 161.1970 
Allyl 10-4 M 203.33300* 21.47094 .000 119.4690 287.1970 
Allyl 10-5 M 122.27273* 20.97729 .000 40.3369 204.2085 
Pentenyl OH 10-4 M 206.33300* 21.47094 .000 122.4690 290.1970 
Pentenyl OH 10-5 M 68.61083 20.55686 .259 -11.6828 148.9045 
Allyl OR 10-4 M 205.63500* 21.47094 .000 121.7710 289.4990 
Allyl OR 10-5 M 74.16667 20.55686 .127 -6.1270 154.4603 
Methyl Ac 10-4 M 147.49917* 20.55686 .000 67.2055 227.7928 
Methyl Ac 10-5 M 56.66667 20.55686 .710 -23.6270 136.9603 
Methyl 10-4 M 118.05667* 20.55686 .000 37.7630 198.3503 
Methyl 10-5 M 50.27667 20.55686 .903 -30.0170 130.5703 
Butyl 10-4 M  111.66583* 20.55686 .000 31.3722 191.9595 
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Butyl 10-5 M 81.66667* 20.55686 .040 1.3730 161.9603 
Hexyl 10-4 M 131.11083* 20.55686 .000 50.8172 211.4045 
Hexyl 10-5 M 95.27833* 20.55686 .003 14.9847 175.5720 
Benzyl Ac 10-4 M 133.05500* 20.55686 .000 52.7614 213.3486 
Benzyl Ac 10-5 M 53.66900 21.47094 .877 -30.1950 137.5330 
Benzyl 10-4 M 223.52000* 22.05930 .000 137.3580 309.6820 
Benzyl 10-5 M 177.33400* 21.47094 .000 93.4700 261.1980 
Pentyl 10-4 M 188.88917* 20.55686 .000 108.5955 269.1828 
Pentyl 10-5 M 180.27833* 20.55686 .000 99.9847 260.5720 
TBDMS 10-4 M 121.94500* 20.55686 .000 41.6514 202.2386 
TBDMS 10-5 M 163.88833* 20.55686 .000 83.5947 244.1820 
TBDPS 10-4 M 113.61167* 20.55686 .000 33.3180 193.9053 
TBDPS 10-5 M 144.00100* 21.47094 .000 60.1370 227.8650 
N-Ac OH 10-4 M 131.66583* 20.55686 .000 51.3722 211.9595 
N-Ac OH 10-5 M 131.66583* 20.55686 .000 51.3722 211.9595 
TFA-PS 10-4 M 175.60636* 20.97729 .000 93.6706 257.5422 
TFA-PS 10-5 M 106.38917* 20.55686 .000 26.0955 186.6828 
 
 
